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A mio figlio,  
 
Fai dei figli.  
Non sono un ostacolo,  
come qualcuno proverà a farti credere.  
I figli vengono a salvarti la vita 
 e a dare un significato 
 a tutto ciò che hai fatto e farai.  
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 ABSTRACT 
 
Alzheimer’s disease (AD) is characterized by severe, progressive decline of cognition due to 
neuronal loss in brain regions involved in learning and memory. Two main 
pathophysiological hallmarks of AD are well characterized: amyloid beta (Aβ) plaques and 
neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein. Significant evidence 
obtained over the last decade has shown that neuroinflammation is also associated with AD 
pathology. Furthermore, vascular leakage and endothelial activation were reported in AD 
brains, suggesting a role for vascular inflammation and leukocyte trafficking in the 
pathogenesis of AD. However, the inflammation mechanisms involved in AD pathogenesis 
remain largely unknown and a better understanding of the role of inflammation in AD may 
help to develop new therapeutic approaches to slow the progression of this disorder. Blood-
derived leukocyte subpopulations, including lymphocytes, monocytes, and neutrophils, have 
been identified in the brains of patients with AD and in corresponding animal models, but 
their role in disease pathogenesis is unclear. We have recently reported an active 
inflammatory process taking place during AD, which includes up-regulation of adhesion 
molecules on cerebrovascular endothelium and leukocyte trans-endothelial migration into 
the brain of AD-like disease mice. Notably, neutrophil depletion during the early phase of 
disease led to an amelioration of cognitive deficits and neuropathological condition in 
mouse models of AD, suggesting their contribution to the pathology. Indeed, the inhibition 
of neutrophil function strongly reduced microglial activation and Aβ deposition, suggesting 
that neutrophils play a key role in disease progression.  
The GOAL of the present study was to investigate the role of LFA-1 and VLA-4 integrins in 
the pathogenesis of AD-like disease. LFA-1, the predominant β2-integrin expressed on 
leukocytes, is known to play a key role in leukocyte adhesion on inflamed endothelium. 
Instead VLA-4, the predominant α4-integrin expressed on the surface of lymphocytes, is 
expressed only by approximately 3% of circulating neutrophils, but several studies 
demonstrated it represents an alternative pathway for neutrophil migration to inflammatory 
sites. Interestingly, in addition to neutrophil infiltration we found T cells infiltrating the 
brain in mouse models of AD at different time points of disease. Therefore, different 
leukocyte subpopulations migrate into the brain of 3xTg-AD mice, suggesting that 
neutrophils and T cells may play a role in disease evolution. We performed our experiments 
in 3xTg-AD mice, which reproduces AD-like cerebral amyloidosis and tangle pathology, 
and closely resemble the cognitive and behavioral alterations reported in human disease.  
We first evaluated by two-photon microscopy the effect of monoclonal antibodies known to 
block the integrin LFA-1 on neutrophil thus affecting adhesion and extravasation in the 
central nervous system (CNS). Our results showed that LFA-1 integrin blockade prevents 
neutrophil adhesion, extravasation, and inhibits intraparenchymal motility in the brain of 
3xTg-AD mice. In addition, we demonstrate that both oligomeric and fibrillary Aβ are able 
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to trigger rapid LFA-1- dependent neutrophil adhesion to its counterligand ICAM-1, with 
oligomeric Aβ preparation being more effective. Subsequently, we assessed the blockade of 
neutrophil trafficking by an anti-LFA–1 integrin antibody treatment in 3xTg-AD mice at 
early stages of the disease confirming that the integrin LFA-1 is fundamental for brain 
infiltration of neutrophils in AD-like mice. We next studied the effects of LFA-1 ablation on 
3xTg-ADxItgal-/- mice lacking LFA-1 integrin. We found that they show improved memory 
in cognitive tests compared to wild-type animals. Our results demonstrated a reduced of 
cognitive dysfunctions in 3xTg-ADxItgal-/-  compared to age-matched 3xTg-AD mice. 
These findings were supported by neuropathological data showing a lower density and 
activation state of microglia in the CA1 and DG and a reduction of Aβ deposition and tau 
hyperphosphorylation in 3xTg-ADxItgal-/-  compared to 3xTg-AD aged-matched controls. 
Taken together, these results suggest that the inhibition of neutrophil trafficking through the 
blockade of LFA-1 integrin may represent a new therapeutic strategy for AD. 
In  addition, our results showed that treated 3xTg-AD mice with an anti-α4 integrin antibody 
improved memory function compared to control treated mice in behavioral tests. Notably, 
restoration of cognitve function in mice that received anti-α4 treatment during early stages 
of disease was also maintained at late time points in aged animals, suggesting that 
therapeutic blockade of leukocyte adhesion during the early stages of disease has a long-
term beneficial effect on cognition in older mice. In support of the results obtained in 
cognitive tests, neuropathological studies showed a reduction of amyloid beta deposition, tau 
hyperphosphorylated and microglial activation. Therefore, VLA-4 integrin may also play a 
key role in the induction of cognitive deficit and progression of AD-like disease.  
In summary, the results obtained in the present study show that LFA-1 and VLA-4 integrins 
contribute to disease pathogenesis and may represent novel therapeutic targets in AD. 
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ABBREVIATIONS 
3xTg-AD  Triple transgenic Alzheimer’s disease mouse with mutations in 
APPSWE, PS1M146V and TauP301L 
AD    Alzheimer’s disease 
ADAM   A disintegrin metalloproteinase 
ADDLs   Amyloid derived diffusible ligands 
AICD    Amyloid precursor protein intracellular domain  
APC    Antigen-presenting cell 
APOE    Alipoprotein 
 APP    Amyloid precursor protein 
Aβ   Beta amyloid 
BACE1   β-Site APP cleaving enzyme 1 
BACE2   Beta-site amyloid precursor protein-cleaving enzyme 2  
BBB    Blood brain barrier 
C99 or βCTF   99-residue carboxy-terminal fragment  
CAA    Cerebral amyloid angiopathy 
CBF    Cerebral blood flow 
CDK-5   Cyclin-dependent kinase-5 
CFC    Contextual fear conditioning  
CNS    Central Nervous System 
CSF    Cerebro- spinal fluid 
CTF    C-terminal fragment 
CTFα    83-residue carboxy-terminal fragment  
DAG    Diacylglycerol  
EAE    Experimental autoimmune encephalomyelitis  
ECM    Extracellular matrix 
EOFAD   Early onset familial Alzheimer’s disease  
ER    Endoplasmatic reticulum 
FAK    Focal adhesion kinase  
fMLP    N-formylmethionyl-leucyl-phenylalanine  
GEFs    Guanine-nucleotide-exchange factors 
GPCRs   G-protein-coupled receptors 
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HEVs    Venular endothelial cells 
HPK1    Hematopoietic progenitor kinase 1  
I.P.    Intraperitoneal 
ICAM-1   Intercellular adhesion molecule-1 
IL    Interleukin 
InsP3   Inositol 1-4-5 triphosphate  
LDL    Low-density lipoprotein 
LFA-1   Lymphocyte function-associated antigen-1  
LOAD   Late onset Alzheimer’s disease 
LRP-1-1   LDL receptor related protein-1 
LTP    Long-term potentiation 
MAPK   Mitogen-activated protein kinase 
MAPs    Microtubule-associated proteins family  
MCI    Mild cognitive impairment 
MHC    Major histocompatibility complex 
MIDAS   Metal- ion-dependent adhesion site  
MRI    Magnetic resonance scans 
MS    Multiple sclerosis 
MVB    Mutivescicules body 
NFTs    Neurofibrillary tangles 
PAMPs   Patterns associated molecules pathogens 
PBS    Phosphate buffered saline 
PDL1    Phospholipase D1  
PET    Positron emission tomography 
PFA    Paraformaldehyde 
PHF    Paired helical filament 
PiB    Pittsburgh compound-B 
PIP5KC   Phosphatidylinositol-4-phosfate 5-kinase isoform 1γ  
PLC    Phospholipase C 
PRRs    Patterns recognition receptors 
PSEN-1/2   Presenilin-1/2 
PSGL-1   P-selectin glycoprotein ligand-1 
PtdIns (4,5)P2  Phosphatidylinositol 4-5-bisphosphate 
PTx    Pertussin toxin  
Pyk2   Proline-rich tyrosine kinase-2  
RAGE   Receptor for advanced glycation end products  
ROS    Reactive oxigen species 
sAPPα   Soluble N-terminal fragment  
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SORL1   Sortilin-related receptor 1  
SP    Senile plaques  
TCA    T cell Analysis program  
TIM    T cell immunoglobulin and mucin domain  
TJs    Tight junctions 
TMD    Transmembrane domain  
TNFα    Tumor necrotic factor α 
TPM    Two photon microscopy  
VCAM-1   Vascular cell adhesion molecule-1 
VLA-4   Very-late antigen-4 
VLDLs   Very-low-density lipoproteins 
vWFA   Von Willebrand Factor  
α2-M    α2-macroglobulin 
βAPPs   Smaller ectodomain derivative 
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OVERVIEW OF THESIS SECTIONS 
 
Sections 1 to 8 cover Alzheimer’s disease definitions and features. Particularly, in Section 8, 
we give a description of inflammation and the molecular mechanisms controlling leukocyte 
recruitment under inflammatory conditions. Section 8.2 provides important information for 
the thesis, covering the structure, modulation and functions mediated by LFA-1 and VLA-4 
integrins. In section 9, we describe neuroinflammation events that may represent a potential 
driving force in AD.  
 
In Section 11, Material and Methods, we describe the methods and technologies used 
throughout this thesis, such as mice typization, isolation of brain leukocytes, flow cytometry 
analysis, two-photon microscopy, mouse treatment and behavioural assessments. A brief 
introduction to AD animal models is given in section 11.12.  Figure 12 provides the strategy 
of our in vivo studies in mouse models of AD. 
Section 12 shows  the results obtained in all our experiments. The main data of the thesis 
can be summarized as follows: 
 
• we observed that blocking monoclonal antibodies to LFA-1 integrin significantly inhibit 
neutrophil adhesion in brain vessels and extravasation into the CNS, suggesting a key role 
for this integrin in neutrophil recruitment in AD; 
• we demonstrated that LFA-1 integrin has a key role in the induction of cognitive deficits and 
reduces microglia activation in mice with AD-like disease.  
• we give a description of 3xTg-ADxItgal-/- mice that we generated to better evaluate the 
effect of LFA-1 integrin blockade on disease. We reported that 3xTg-ADxItgal-/- restores 
cognition at early and late stages of disease and it induces neuropathological changes. 
• we demonstrate that the VLA-4 integrin antibody treatment could inhibit early pathogenesis 
and progression of AD in 3xTg-AD mice.  
 
Finally, the Discussion (section 12) contains the main conclusions drawn from this project 
and possible directions for future research. The emerging role for leukocyte recruitments in 
CNS diseases provides insight into the mechanisms of brain damage during AD and may 
contribute to the development of novel therapeutic strategies. Our study suggests that LFA-1 
and VLA-4 integrins mediate leukocyte trafficking into the SNC in AD models and may 
represent novel attractive therapeutic targets in AD. Section 13 contains all references cited 
in this thesis.  
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 INTRODUCTION 
 
 
1. ALZHEIMER’S DISEASE 
 
In 1906 Dr. Alois Alzheimer, a German neurologist and psychiatrist, described the case of a 
51-year-old woman, Auguste D., who had been admitted to a hospital 5 years earlier with a 
cluster of unusual symptoms, including problems with comprehension and memory, an 
inability to speak, disorientation, behavioral problems, and hallucinations. After her death, 
Dr. Alzheimer examined her brain tissue and described specific features: i.e. numerous globs 
of sticky proteins in the spaces between neurons called beta-amyloid (Aβ) plaques, and a 
tangled bundle of fibrils within neurons called neurofibrillary tangles (NFTs). That moment 
was crucial to establish the hallmarks of a new pathology, which nowadays is the most 
diffuse neurodegenerative disorder affecting more that affects only in the U.S. more than 48 
million people and this number is set to increase in the future due to an increase in the life 
expectancy. It is expected that by 2050 approximately 88 million people in the U.S. will 
have AD, thus the number of people affected will double (Alzheimer’s disease Facts and 
Figures, 2017). There are also indications that the incidence of illness double every 5 years 
after 65 years old (Querfurth H.W. & Laferla F.M., 2010). Because of the growing number 
of AD patients, the disease represents a category with high impact on social economy. In 
fact, the costs associated with the disease also put a heavy economic burden on society. It is 
estimated that total costs of care for individuals with AD by all payers in US were from 
$172 billion in 2010 to more than $1 trillion in 2050, with Medicare costs increasing more 
than 600 percent, from $88 billion today to $627 billion in 2050 (Washington, 2010). Taken 
together these data strongly suggest that AD is an urgent research priority, and the early 
identification of the disease and the possible intervention to slow its unrestrainable 
progression will be a benefit for individuals, families and Nations. 
 
 
1.1  SIGNS AND SYMPTOMS OF AD 
  
AD can affect different people in different ways, but the most common symptom pattern 
begins with gradually worsening difficulty in remembering new information. This 
phenomenon is due to the disruption of brain cells by Aβ and NFTs, in regions involved in 
forming new memories. The rate of progression varies greatly. On average, people with AD 
live 8 years, but some people may survive up to 20 years. The progression of the disease 
depends on both the age of the diagnosis and other health concurrent issues. Although the 
course of the disease is not the same in every AD patient, symptoms seem to develop over 
the same general stages. Brains of individuals with AD manifest a severe atrophy linked to 
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massive neuronal and synaptic loss, due to formation of Aβ plaques between nerve cells, but 
also of intracellular deposits of tau protein, called tangles. 
 
 
1.2 DIAGNOSIS 
 
Although AD apparently is different from other types of dementia, it is very difficult to 
differentiate between the onset of AD and other types of age-related cognitive decline from 
the early stages. Therefore, clinicians use a range of methods to diagnose what it is called 
“possible AD” (dementia that could be due to another condition) or “probable AD” (no other 
cause of dementia can be found).  
Braak et al. guided an important study examining 83 brains coming from nondemented and 
demented individual autopsies, leding to the hallmark identification of six-stages of AD 
development (Braak H. and Braak E., 1991) (Fig. 1). The first two stages were characterized 
by an either mild or severe alteration of the transentorhinal layer Pre-α (transentorhinal 
stages I-II). The two forms of limbic stages (stages III- IV) were marked by a conspicuous 
affection of layer Pre-α in both transentorhinal region and proper entorhinal cortex. In 
addition, there was mild involvement of the first Ammon's horn sector. The hallmark of the 
isocortical stages (stages V-VI) was the virtual destruction of all isocortical association areas 
(Fig. 1). The cerebral cortex, inparticular the isocortex, is the predilection site for the 
deposition of Aβ. Then, the authors observed patient specific variation in size, shape and 
distribution pattern of the Aβ deposits and NFTs from and within architectonic units.    
 
 
 
Figure 1. Neuropathological staging of AD-related changes.  
H. Braak and E. Braak, 1991. 
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Additionally, in the Nun Study, a longitudinal study of aging and AD patients some authors 
have used the Braak method of staging AD's pathology in 130 women aging between 76-102 
years. All the collected autopsy data showed a strong relationship between Braak stage and 
cognitive state (Riley K.P. et al., 2002). Much research is being done to identify the early 
changes, which may be useful in predicting dementia or AD. In 2011, the National Institute 
on Aging and the Alzheimer’s Association recommended new diagnostic criteria and 
guidelines for AD. The new criteria and guideless update refine and broaden guideless 
published in 1984 by Alzheimer’s Association and National Istitute of Neurological 
Disorders and Stroke (Scheltens P. et al., 2016). The 1984 criteria were based chiefly on a 
doctor’s clinical judgment about the cause of a patient’s symptoms, considering reports from 
the patient, family members and friends; results of cognitive testing; and general 
neurological assessment. The new criteria and guideless identify the three stages of AD: 
preclinical AD, mild cognitive impairment (MCI) and dementia. An early diagnosis results 
to be important because allow starting treatments in the first stages of AD and can help to 
preserve brain function. 
 
 
1.2.1 PRECLINICAL AD  
 
In the preclinical stage, AD develops in the entorhinal cortex, a brain region that is near the 
hippocampus and has direct connections to it. Healthy neurons in this region begin to work 
less efficiently, losing their ability to communicate, and ultimately die. This process 
gradually spreads to the hippocampus, the brain region that plays a major role in learning 
and is involved in converting short-term memories to long-term memories. Affected regions 
begin to atrophy. Ventricles, the cerebrospinal fluid (CSF) filled spaces inside the brain, 
begin to enlarge as the process continues. These brain changes may begin 10 to 20 years 
before any clinically detectable signs or symptoms of forgetfulness appear. A deeper 
knowledge of these early stages of the disease leads to more chances to develop new drugs 
or treatments that will slow or stop the disease triggering before significant impairment 
occurs. 
 
 
1.2.2   MILD TO MODERATE AD  
 
As AD spreads through the brain, there is an increase in Aβ and NFTs in the regions 
involved in memory, thinking and planning develop more. Hence, memory loss continues 
and changes in other cognitive abilities begin to emerge. AD patients develop problems with 
memory or thinking serious enough to interfere with work or social life. It’s only when Aβ 
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and NFTs diffusion affects areas involved in speaking, understanding and sensing the body 
with respect to other surrounding objects, that people are first diagnosed with AD.  
 
 
 1.2.3 SEVERE AD  
 
As severe stage is reached, Aβ and NFTs are widespread throughout the brain. Most areas of 
the brain have shrunk further, and ventricles have enlarged even more (Fig. 2). People 
become not self-sufficient in daily activities and start showing changes in personality and 
behavior, with efforts in recognizing friends and family members. At this stage of disease, 
patients are completely dependent on others for care. 
 
 
 
Figure 2. Differences in healthy and AD brain. [www.alz.org] 
 
 
1.3  BIOMARKERS IN AD 
 
A biomarker is a characteristic measurable and evaluable as an indicator of the disease 
progress. The CSF is considered the ideal source of biomarkers for AD because it is in 
contact with the cerebral tissue and it reflects its pathological changes. Besides, the sampling 
is simple and non-invasive and the measurement is precise. Indeed, the concentrations of 
several proteins in CSF reflect with good diagnostic accuracy the pathophysiological 
features of the disease. In particular, several studies have found that patients with AD have a 
reduction in CSF levels of the concentration of Aβ and a marked increase of total and 
phosphorylated tau (Forlenza O.V. et al., 2010). Magnetic Resonance Scans (MRI) and 
Positron Emission tomography (PET) are sophisticated imaging systems that may help 
measure earliest changes in brain function or structure to identify patients in the very first 
stages of AD (Scheltens P. et al., 2009). Structural MRI in AD can assess brain atrophy and 
changes in tissue characteristics through alterations in the radiofrequency signal emitted 
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(Figure 4). The earliest site of atrophy is the entorhinal cortex, followed by hippocampus, 
amygdala and parahippocampus. The distribution and the amount of cerebral atrophy are 
strictly correlated with cognitive deficits (Johnson K.A., et al., 2012). Instead, Positron 
Emission Tomography (PET) is used to detect Aβ plaques in the brain using the 
radiolabelled Pittsburgh Compound-B (PiB) that marks Aβ plaques (Johnson K.A., et al., 
2013). A radiolabelled compound called PiB binds to Aβ plaques in the brain and it can be 
imaged using PET scans. Initial studies showed that people with AD take up more PiB in 
their brains than do cognitively healthy older people. However, high levels of PiB are found 
in some cognitively healthy people, suggesting that the damage from Aβ may already be 
underway. Data support the principle that the presence of Aβ plaques deposition alone, even 
in substantial quantities, is not sufficient to produce dementia, and abnormalities in Aβ 
deposition biomarkers precede clinical/cognitive symptoms (Stomrud E. et al., 2007). This 
principle is clearly illustrated by data from the individual (Fig. 3), who was cognitively 
normal with no evidence of atrophy on MRI, but had a highly abnormal PiB study. 
Furthermore, several tau pathology PET tracers have been recently developed and used in 
clinical studies for the diagnosis of AD (James O.G., et al., 2015). Tau-PET imaging 
represents a significant new advance for the field and it is hoped that the combination of tau 
positive and amyloid positive PET scans, along with the clinical presentation, may in the 
future move us closer to an affirmative diagnosis of AD. 
 
 
Figure 3. Illustration of biomarker Alzheimer’s disease staging. [Jack C.R, Lancet 
Neurol, 2010] 
Three elderly individuals are placed in order from left to right with a proposed biomarker 
staging scheme. (A) A cognitively normal individual with no evidence of Aβ on PET 
amyloid imaging with Pittsburgh Compound B (PiB) and no evidence of atrophy on MRI. 
(B) A cognitively normal individual who has no evidences of neurodegenerative atrophy on 
MRI, but has significant Aβ deposition on PET amyloid imaging. (C) An individual who has 
dementia and a clinical diagnosis of AD, a positive PET amyloid imaging study, and 
neurodegenerative atrophy on MRI. 
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2. PATHOGENESIS 
 
AD can be classified in two different forms: early-onset familial (EOFAD) and late-onset 
AD (LOAD). EOFAD is an uncommon form of AD, accounting for less than 5% of total 
cases. It is diagnosed before age 65 with an autosomal dominant pattern of 19 inheritance, 
which means that one copy of the altered gene is sufficient to cause the disorder. Most cases 
of EOFAD are caused by gene mutations, found in one of three genes: amyloid precursor 
protein (APP), presenilin-1 (PSEN1) or presenilin-1 (PSEN2). When these genes are altered, 
large quantities of Aβ toxic protein fragments are produced in the brain and accumulate 
forming “clumps” called senile plaques (SP), which are characteristic of AD. LOAD is also 
known as “sporadic AD” because appears to be no genetic factor or family link involved. It 
is the most common form of the illness, affecting about 90% of sufferers. Neuropathologic 
hallmarks of AD are characterized by initial amyloidosis, due to extracellular deposition of 
Aβ toxic protein fragments (Aβ1-40 and Aβ1-42) and fibrils in SP; tauopathy, developed by 
abnormal intracellular accumulation of hyperphosphorylated tau proteins in NFTs and 
vascular deposition of Aβ resulting in cerebral amyloid angiopathy (CAA).  
 
 
2.1 APP  
The principal constituent of the plaques is Aβ, a 39±43 amino acids long peptide, which 
derived by proteolytic cleavage of the ubiquitous transmembrane APP (Kang J. et al., 1987). 
 
2.1.1 APP gene 
The APP gene is located on the long arm of chromosome 21 at position 21.2, from base pair 
27,252,860 to base pair 27,543,445 (bp 290,585). 
 
APP is a single-transmembrane, receptor-like protein that is ubiquitously expressed in neural 
and non-neural cells (Haass C. & Selkoe D.J., 2007,). It is synthesized in the endoplasmatic 
reticulum, post-transcriptionally modified in the Golgi and transported to the cell surface via 
the secretory pathway (Sastre M. et al., 2008). Moreover, APP might also be endocytosed 
from the cell surface and processed in the endosomal-lysosomal pathway (Benzinger T.L., et 
al., 2000). Additionally, APP is cut by proteases to create smaller peptides, some of which 
are released outside the cell. More than 25 different mutations in the APP gene can cause 
EOFAD. These mutations are responsible for 10% to 15% of all early-onset cases of the 
disorder, which show between 45 and 65 years. The most common mutation is the 
replacement of the amino acid valine with the amino acid isoleucine at protein position 717 
in the APP. Mutations in the APP gene increase the amount of Aβ peptide.  
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APP is coded on chromosome 21 and this explains why Down syndrome patients have an 
increased risk of developing AD and start suffering from AD symptoms in their late 30s 
(Farfara D., et al., 2008). In fact, Down syndrome patients have three copies of genes on 
chromosome 21 in each cell, including the APP gene, instead of the usual two copies. 
Although the connection between Down syndrome and AD is unclear, the production of 
excess Aβ peptide in cells may account for the increased risk. 
 
2.1.2 APP PROCESSING 
 
APP processing is considered a key event in the pathological cascade leading to AD (Hardy 
J., 1997). APP undergoes post-translational proteolytic processing, distinct in 
nonamyloidogenic and amyloidogenic pathway, where several sequential enzymes are 
involved. Normally about 90% of APP enters the non- amyloidogenic pathway, and 10% the 
amyloidogenic one, but these ratios can change due to mutations, environmental factors, as 
well as the age of the individual. In non-plaque-forming pathway α-secretase generates 
soluble amyloid protein, while β- and γ-secretases generate APP components with 
amyloidogenic features. The intermediates of Aβ aggregation from low molecular weight to 
higher molecular weight are respectively monomers, oligomers, protofibrils and fibrils. 
Fibril formation is a complex and nucleation-dependent process. The Aβ monomeric state 
does not appear to be neurotoxic; in contrast, oligomeric and profibril species are considered 
the cause of the cognitive impairment (LaFerla F.M., et al, 2007). 
 
The non-amyloidogenic pathway  
In the non-amyloidogenic pathway, APP is cleaved by α-secretase. This constitutive 
cleavage occurs in the interior of the Aβ peptide sequence, thereby precluding formation and 
deposition of the Aβ (Esch F.S., et al., 1990). A large soluble N-terminal fragment (sAPPα) 
is released into the lumen/extracellular space, leaving an 83-residue carboxy-terminal 
fragment (CTFα) in the membrane. CTFα is then digested by γ-secretase to yield a soluble 
N-terminal fragment (p3) and a membrane-bound C-terminal fragment (AICD, or APP 
intracellular domain). AICD is a short tail (approximately 50 amino acids) released into the 
cytoplasm after progressive e to γ cleavages by γ-secretase. AICD is targeted to the nucleus 
and is involved in activation signalling of transcription. Three related metalloproteases of 
ADAM (a disintegrin and metalloprotease) family, ADAM-9, ADAM-10 and ADAM-17, 
appear to exert α–secretase activity. A confirmation that ADAM-10 is involved in α–
secretase activity came from studies in transgenic mice for human APP, where an over- 
expression of ADAM-10 showed increased secretion of the neurotrophic α- APPs, reduced 
formation of Aβ and prevention of their deposition in Aβ plaques (Postina R., et al., 2004). 
Another candidate with α–secretase activity is beta-site amyloid precursor protein-cleaving 
enzyme 2 (BACE2), which likewise cleaves within the Aβ domain and abrogates Aβ 
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formation (Tanzi R.E. & Bertram L., 2005). Therefore, ADAM-10 and BACE2 may become 
a promising therapeutic target to AD. 
 
The amyloidogenic pathway  
Some APP molecules that are not subjected to α–secretase proteolysis can be cleaved by β-
secretase, also called beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1), 
essential for initiating amyloidogenic processing. BACE1 cleaves APP at the N-terminal 
position of Aβ, leading to secretion of a smaller ectodomain derivative (βAPPs). This 
generates a 99-residue carboxy-terminal fragment (C99 or βCTF), which is inserted in the 
membrane. The membrane- associated stub C99, can then undergo an intra-membrane 
division that is mediated by the γ-secretase complex, a special type of aspartyl-protease with 
a unique active site and cleavage mechanism (Wolfe M.S., et al., 1999, Steiner H., et al., 
2000) (Fig. 4). This complex is composed of PSEN1 or PSEN2, nicastrin, APH1 and PEN2 
(Kimberly et al., 2003). It has been proved that all four proteins are necessary and sufficient 
to reconstitute γ-secretase activity in yeast, which lacks these enzymes (Edbauer D., et al., 
2003). γ-secretase can carry out multiple intra-membrane cleavages. Current evidence 
indicates that the “presenilin–γ-secretase complex” can cleave at different sites (referred to 
as γ, ε and ζ) in the transmembrane domain (TMD). The ε-cleavage close to the cytoplasmic 
border of the TMD releases the free intracellular domain into the cytosol (Sastre M., et al., 
2001). It seems that the remaining membrane-anchored fragment undergoes an intermediate 
scission of about 3 N-terminal residues to the ε-cut at the so-called ζ-site (Zhao G., et al., 
2005). Thereafter, Aβ is released into biological fluids by the final cuts at the γ-site. The γ-
cut is variable and occurs after Aβ amino acids 38, 40 or 42. Most secreted Aβ peptides are 
40 amino acids in length (Aβ1-40), although the longer fraction of 42 amino acid species 
(Aβ1-42) have received greater attention due to the propensity of these peptides and other 
derivatives of the APP to nucleate and drive production of Aβ fibrils. These γ-cleavages 
have an important influence on the self-aggregating potential and resulting pathogenicity of 
Aβ, where only the Aβ1-42 peptide has a strong propensity to oligomerize in vivo. 
 
 
 
Figure 4. Neural activity controls formation of APP cleavage derivatives.  
[Kamenetz, Neuron, 2003] Biochemical pathways leading to the formation of Aβ from APP. 
α and β cleavage of APP result in the production of a large, soluble ectodomain (APPs) and 
a membrane associated carboxy-terminal fragment (CTF). Cleavage of APP by α-secretase 
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precludes production of Aβ. γ-secretase cleavage of CTFs produce small peptides (Aβ and 
p3), which can be secreted and a truncated CTF (γ-CTF). 
 
 
2.2. PRESENILIN GENES 
 
There are 2 presenilin genes that encode two different forms of proteins: PSEN1 and 
PSEN2. 
The PSEN1 gene is located on the long arm of chromosome 14 at position 24.3, from base 
pair 73,603,142 to base pair 73,690,398 (bp 87,256). 
PSEN1 is a protein involved in the activity of γ-secretase. γ-secretase is associated in protein 
complex at high molecular weight, where PSEN1 exerts its action. More than 150 PSEN1 
mutations have been identified. These mutations are the most common cause of EOFAD, 
accounting for up to 70% of cases. Disease shows between 28 and 50 years. 
Almost all PSEN1 mutations change single nucleotide of DNA in a specific segment of the 
gene. These mutations result in the production of an abnormal PSEN1 protein. Defective 
PSEN1 disrupts the processing of APP, leading to the overproduction of Aβ peptide.  
 
The PSEN2 gene is located on the long arm of chromosome 1 between positions 31 and 42, 
from base pair 227,058,272 to base pair 227,083,803 (bp 25,531). PSEN2 is a protein 
homologous to PSEN1. Several studies suppose that PSEN2 may act in synergy with 
PSEN1, in the function of γ-secretase. Mutations in PSEN2 gene account for less than 5% of 
all EOFAD cases of AD and the onset of the disease is later in age, between 40 and 55 years. 
Two of the most common PSEN2 mutations that cause EOFAD are due by a change of 
single amino acids. One mutation replaces the amino acid asparagine with isoleucine at 
position 141. The other mutation changes the amino acid methionine to valine at position 
239. These mutations appear to disrupt the processing of APP, leading to the overproduction 
of Aβ peptide. The causes of LOAD are less clear. The late-onset form is probably related to 
variations in one or more genes in combination with lifestyle and environmental factors. 
Although a specific gene has not been identified as the cause of late-onset AD, the most 
influential genetic risk factor for LOAD is allelic variation in the apolipo-protein E (APOE) 
gene (Querfurth H.W. & Laferla F.M., 2010). 
 
 
2.3. APOE4 GENE 
 
The APOE gene is located on chromosome 19 at position 13.2, from base pair 45,409,038 to 
base pair 45,412,649 (bp 3611). 
ApoE acts normally to scaffold the formation of high-density lipoprotein (HDL) particles, 
which promote the proteolytic degradation of soluble forms of Aβ. It is synthesized and 
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secreted primarily by astrocytes and is involved in brain development and repair (Fagan 
A.M. & Holtzman D.M., 2000). 
APOE has three common forms or alleles: ε2, ε3, and ε4. The ε2 form may provide some 
protection against AD, and ε3 is thought to play a neutral role. In particular, ε4 form is a 
known risk-factor gene for the common LOAD, and many studies are underway to clarify its 
impact. In fact, APOE4 promotes Aβ deposition and tau phosphorylation (Holtzam D., et al., 
2000a; Holtzman D., et al., 2000b). Most experts believe that, in addition to APOE ε4, at 
least half a dozen more genes may influence the development of LOAD in some way.  
 
 
3. NEUROPATHOLOGICAL HALLMARKS 
 
 
 3.1 Aβ DEPOSITION  
 
Aβ deposition into SP has led to the development of the amyloid hypothesis of AD (Selkoe 
D.J., 2000). This hypothesis states that the amyloidogenic processing of APP ultimately 
results in Aβ deposition into Aβ plaques that initiates a cascade of events that culminate in 
neuronal dysfunction or death in AD. Gradual changes in the steady-state levels of Aβ 
protein in the brain are thought to initiate the amyloid cascade.  
 
 
3.2 NEUROTOXIC FORM OF Aβ  
 
Aβ principal forms are constituted by Aβ1-40 and Aβ1-42 peptides. These peptides form a 
variety of structures, including multiple monomer conformers, different types of oligomers, 
Aβ-derived diffusible ligands (ADDLs), protofibrils and fibrils (Fig. 5). In AD pathology, 
soluble Aβ undergoes a conformational change that renders it relatively insoluble, causing 
its deposition in brain parenchyma. Aβ peptide initially deposited into amorphous diffuse 
plaques, then becomes compacted into mature SP formed by fibrils displaying a β sheet 
conformation (Wisniewski H.M., et al., 1997). The structural relationships among these 
assemblies, as well as differences in the assembly processes of Aβ1-40 and Aβ1-42 are areas 
of active investigation (Klein W.L., et al., 2004). Of note, in some elderly individuals (high 
pathology controls, HPC) remain cognitively intact while showing high Aβ plaque loads, 
clearly demonstrating a poor correlation between Aβ plaques with pathological criteria used 
for AD diagnosis. Much of the fibrillar Aβ found in the neuritic plaques is the Aβ1-42 
species, the slightly longer more hydrophobic form that, with its C-terminal Alanine and 
Isoleucine residues, aggregates more rapidly, therefore forming stable Aβ oligomers at an 
earlier time point (Burdick D. & Soreghan B., 1992). Moreover, Aβ1-42 tends to form stable 
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trimeric and/or tetrameric oligomers, whereas Aβ1-40 does not (Chen Y.R. & Glabe, C.G., 
2006). The Aβ1-40 peptide is more frequently produced than Aβ1-42 by cells and probably 
by further cleavage of Aβ1-42 peptide. However, it is usually co-localized with Aβ1-42 in 
plaques. Early SP contain mainly Aβ1-42, whereas plaque maturation is associated with the 
progressive appearance of the shorter Aβ1-40 (Iwatsubo T., et al., 1994). The enhanced 
production of the Aβ1-42 peptide results from AD-causing mutations in APP and PSEN1 or 
PSEN2 (Scheuner D., et al., 1996). 
An increase in absolute Aβ1-42 levels, or at least an increase in the Aβ1-42/Aβ1-40 ratio, 
where Aβ1-42 can increase at the expense of Aβ1-40, seems to be sufficient to trigger the 
AD phenotype. Apart from the known neurotoxicity of the fibrillar form of Aβ, recently 
some studies have demonstrated that non-fibrillary structures, including oligomers, ADDLs 
and protofibrils are also neurotoxic (Dahlgren K.N., et al., 2002). In the contest of the human 
AD pathology, it was demonstrated that soluble Aβ oligomers detected in CSF showed 
correlation with the severity of the cognitive impairment (Santos A.N., et al., 2012). As 
confirmed by others, total levels of soluble Aβ correlate with cognitive decline even in the 
absence of detectable Aβ plaques (Dahlgren K.N., et al., 2002). Several studies show that Aβ 
oligomers are responsible of alterations in long-term depression (LTD) and long-term 
potentiation (LTP) while insoluble Aβ plaque cores from AD cortex did not impair LTP 
unless they were first solubilized to release Aβ dimers (Shankar G.M., et al, 2008). Thus, 
some authors suggested that oligomers could be the most significant biomarkers of early 
stage in AD pathology and may be used as future therapeutic target for the prevention of 
cognitive dysfunction (Lih-Fen Lue et al., 1999).  
 
 
Figure 5. The amyloid cascade hypothesis.  
[Haass and Selkoe, Nat Rev Mol Cell Biol, 2007] 
 
 
3.3 THE INTRACELLULAR Aβ  
 
Recent studies have documented the presence of intracellular Aβ in the human brain since 
first years of life, which increases in childhood, and stabilizes in the second decade of life, 
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remaining high throughout adulthood even in the healthy brain. The Aβ intracellular form 
has been described for the first time in a group of individuals with the age ranging from 38 
to 83 years old with or without AD using an antibody against residues 17-24 of Aβ (LaFerla 
F.M., et al., 2007). Cytoplasmic inclusions of Aβ are often associated with the human 
muscle disease inclusion body myositis where it causes muscle degeneration, while the 
presence in the mouse model 3xTg-AD is still unclear. Aβ1-42 seems to be localized in the 
outer membrane of the multivescicules body (MVB) in AD patients, and often the Aβ-MVB 
is localized in the perinuclear region in APP/PS1 mice. The accumulation of Aβ in MVB is 
pathological and causes proteasome inhibition, calcium dyshomeostatis and even facilitates 
hyperphosphorylation of tau in 3xTg-AD mice (LaFerla F.M., et al., 2007). The presence of 
Aβ in mitochondria, organelles in which all subunits of γ-secretase have been located, and 
mitochondrial defects are described in culture cells (Pavlov P.F., et al., 2011). LaFerla F.M., 
et al. hypothesize that intracellular APP could be produced in endoplasmatic reticulum (ER) 
as other secretory proteins, or alternatively Aβ may be internalized by binding to its 
transporters or receptors such as the α7 nicotinic acetylcholine receptor, LDL receptor 
related protein (LRP-1), receptor for advanced glycation end products (RAGE) and APOE. 
The presence of intracellular Aβ at 4 months of age in 3xTg-AD mice may be a sign of early 
disease; in fact, it precedes the extracellular deposition evident at 6 months of age (LaFerla 
F.M., et al., 2007). Winton M.J., et al. tested a panel of antibody that distinguishes APP 
from Aβ cleaved peptides because of antibody cross-reactivity might cause discordant 
results. This study shows co-localization of signal between extreme C-terminal and N-
terminal APP in 3xTg-AD mice deficient for β-secretase (3xTg-AD-BACE-/-), a protease 
involved in production of Aβ. Therefore, authors conclude that the intracellular Aβ 
corresponds to the full-length of intracellular APP and not the cleaved Aβ (Winton M.J., et 
al., 2011). Various authors have published controversial results in the context of intracellular 
Aβ, therefore further investigations are needed to clarify their existence. 
 
 
3.4  CLEARANCE of Aβ  
 
Aβ levels can be elevated by enhanced production and/or reduced clearance. The steady-
state level of Aβ depends on the balance between production and clearance. Dysfunction in 
Aβ clearance is crucial for the accumulation of Aβ in the brain. Aβ deposition in the 
vasculature leads to pro-inflammatory and cytotoxic events that contribute to the accelerated 
blood-brain barrier (BBB) permeability in the AD brain (Roher A.E., et al., 2003; Carrano 
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A., et al., 2011; Erickson M.A. & Banks W.A., 2013). Several mechanisms have been 
proposed for Aβ clearance, including receptor-mediated Aβ transport across the BBB and 
enzyme-mediated Aβ degradation. The BBB regulates Aβ transport to and from the brain, 
using two main receptors, the LRP-1 and RAGE. LRP-1 and RAGE are multiple ligands cell 
surface receptors that mediate the clearance of many proteins in addition to Aβ. RAGE and 
LRP-1 play opposing roles: while LRP-1 appears to mediate the efflux of Aβ from the brain 
to the periphery, RAGE has been strongly implicated in Aβ influx back into the CNS (Deane 
R., et al., 2004). LRP-1 is expressed in reactive astrocytes and in brain capillary endothelium 
(Donahue J.E., et al., 2006). It can bind a variety of ligands: apoE, α2-macroglobulin (α2-
M), and APP (Herz J., et al., 2003). Until recently, it has been assumed that Aβ could only 
bind LRP-1 indirectly, as part of a complex with the LRP-1 ligands apoE and α2M. 
However, recent data indicate that Aβ can be transported across the BBB and be cleared 
from the brain after directly binding to LRP-1. Dysfunction of LRP-1 leads to a reduced 
efflux of Aβ from brain and thus increased Aβ deposition (Shibata M., et al., 2000, Van 
Uden et al., 2002). Aβ levels negatively regulate LRP-1 expression, and this might explain 
the low activity of LRP-1 in brain microvessels in AD patients and mutant APP mouse 
models (Shibata M., et al., 2000).  
Moreover, epidemiological studies demonstrated the link between LRP-1 and AD (Lambert  
J.C., et al., 1998). Accordingly, a recent report has shown that 1,25(OH)D3, the active form 
of vitamin D, has a neuroprotective effect during AD pathogenesis by inducing the clearance 
of Aβ, which is achieved by inducing LRP-1 expression and reducing the expression of 
RAGE in brain endothelial cells (Guo Y.X., et al., 2016). RAGE is a multiple ligand-
receptor of the immunoglobulin superfamily of cell surface molecules and is expressed on 
endothelial and glial cells (Brett J., et al., 1993, Yan S.D., et al., 1996). RAGE is implicated 
in the development of the AD neurovascular disorder by mediating circulating Aβ 
transcytosis across the BBB. After BBB transport, circulating Aβ is taken up by neurons 
thus inducing cellular stress. The binding of Aβ to RAGE leads to the secretion of 
endothelin-1, a potent vasoconstrictor causing blood flow suppression (Deane R., et al., 
2004). Accordingly, an impaired endothelium-mediated vasodilation is one of the markers of 
endothelium dysfunction leading to cerebrovascular disease characterizing AD (Zlokovic 
B.V., 2008). Down-regulation of RAGE can inhibit the influx of Aβ (Deane R., et al., 2003) 
while an excessive amount of Aβ leads to the up regulation of RAGE through a positive-
feedback mechanism. During aging and in AD pathology, Aβ efflux is compromised and 
might exasperate cellular dysfunction because the increase of RAGE causes augmented 
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influx of Aβ (Shibata M., et al., 2000). Dysfunction in the clearance of Aβ through 
deregulated LRP-1/RAGE with arterial alteration may initiate neurovascular uncoupling, Aβ 
accumulation, cerebrovascular regression, brain hypoperfusion and neurovascular 
inflammation (Deane R. & Zlokovic B.V., 2007). In fact, severe AD is associated with 
significant changes in the relative distribution of RAGE and LRP-1 in the hippocampus, as 
compared with age-matched controls (Donahue J.E., et al., 2006). Moreover, LRP-1 and 
other Aβ-binding receptors (LDLR, RAGE, and CD36) were shown to be expressed on 
pericytes from post-mortem AD brains associated with CAA, and in vitro treatment of 
human pericytes with Aβ induces the expression of LRP-1 and LDLR, suggesting that these 
receptors are involved in the Aβ-mediated death of cerebral perivascular cells (Wilhelmus 
M.M., et al., 2007). In addition, some authors reported that endosomal compartment may be 
considered as a pathway for APP generation. They observed that uncleaved APP is 
internalized from the plasma membrane into retromer recycling endosomes by sortilin-
related receptor 1 (SORL1). Some genetic variants of SORL1 correlate with the increased 
production of APP. Then, reduction of Aβ level and increased secretion of soluble APP 
oligomers correlate with alterations in the internalization of APP (LaFerla F.M., et al. 2007).  
 
 
4. CEREBRAL AMYLOID ANGIOPATHY  
 
Deposition of Aβ at cerebrovascular level is one of the AD hallmarks, mainly starting at 
early stages of the disease (de la Torre J.C., 2004, Prohovnik I., et al., 1988). This 
dysfunction is due to Aβ deposition also in the vascular walls of intracerebral and 
leptomeningeal vessels causing CAA (Glenner G.G. & Wong C.W., 1984). Thus, the 
neurodegeneration and vascular disorders act together to cause dementia (Snowdon D.A., et 
al., 1997). CAA is a common characteristic in AD patients, although many patients with 
CAA do not develop AD. Therefore, it is not clear the correlation existing between the 
distribution of brain CAA, SP and NFTs. The true incidence and prevalence of CAA are 
difficult to be specified, also because the pathologic diagnosis is typically obtained post-
mortem. AD patients have increased incidence of vascular brain lesions (Snowdon D.A., et 
al., 1997), in fact numerous studies have demonstrated that CAA contributes to ischemic 
brain injury (Okazaki H., et al., 1979) and intracerebral hemorrhage (Itoh Y., et al., 1993). 
Aβ deposition damages the media and adventitia of cortical and leptomeningeal vessels, 
leading to thickening of the basal membrane, stenosis of the vessel lumen and fragmentation 
of the internal elastic lamina. These processes result in fibrinoid necrosis and 
microaneurysm formation, predisposing to hemorrhage. CAA is strongly associated with 
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aging and has been reported to be as high as 57% in case series of asymptomatic patients 
over 60 years (Yamada M., et al., 1987). The failure of Aβ elimination along with the 
perivascular pathways that serve as lymphatic drainage channels for the brain, probably 
causes CAA thus compromising the BBB integrity (Weller R.O., et al., 2008). BBB 
regulates solute exchange between blood plasma and brain interstitial fluid and is 
maintained in part by the presence of tight junctions (TJs) that restrict paracellular flux 
within brain microvessel endothelial cells (Kniesel U. & Wolburg, H., 2000; Zenaro E., et 
al., 2016). BBB impairment in CAA and AD patients is suggested by the detection of 
plasma proteins associated with Aβ plaques (Perlmutter L.S., et al., 1995, Wisniewski H.M., 
et al., 1997) and within AD brain parenchyma (Wisniewski H.M., et al., 1997, Zipser B.D., 
et al., 2007). In addition, increases in microvascular permeability associated with 
cerebrovascular Aβ deposits (Wisniewski H.M., et al., 1997) and the disruption of cerebral 
microvasculature endothelial TJs (Claudio L., 1996) have been directly observed in brain of 
AD patients (Carrano A., et al., 2011; Carrano A., et al., 2012). Aβ deposition in cerebral 
vessels is associated with pericyte and smooth muscle cell degeneration (Verbeek M.M. et 
al., 2000) and the direct treatment of acute hippocampal slices with Aβ1-42 oligomers 
increases the production of reactive oxygen species (ROS) by pericytes, which accelerates 
their loss (Veszelka S., et al., 2013). Impaired elimination and accumulation of soluble and 
insoluble Aβ peptide may underlie the pathogenesis of CAA and explain the link between 
CAA and AD. With progression of the disease, Aβ accumulation leads to vessel 
degeneration, capillary and arteriolar infiltration, and formation of dystrophic neuritic 
plaques. All data obtained by transgenic mice overproducing Aβ confined in the brain 
developed CAA (Herzig M.C., et al., 2006), which further supports the hypothesis that Aβ is 
entrapped in the perivascular pathways by which fluid and solutes drain from the brain 
(Weller R.O., et al., 2008). The major consequences arising from CAA are the weakening of 
arteries by deposits of Aβ in their walls, which tend to rupture and lead to intracerebral 
hemorrhage (Zhang-Nunes S.X., et al., 2006), the blockage of the Aβ perivascular drainage 
pathways that may be associated with accumulation of Aβ in the brain. Ultimately, the 
increased level of soluble Aβ correlates with cognitive decline in patients with AD (Lue L., 
et al., 1999). It is possible that drainage of other soluble metabolites from the brain may also 
be impeded in CAA. This would result in a loss of homeostasis in the neuronal extracellular 
environment that could contribute to cognitive decline in AD (Weller R.O., et al., 2008). 
 
 
5. NEUROFIBRILLARY TANGLES 
 
NFTs are one of the pathologic markers of AD and correlate with the degree of dementia 
(Arriagada P.V., et al., 1992). Neurofibrillary degeneration appears to be required for the 
clinical expression of the disease, in fact dementia or β-amyloidosis alone, in the absence of 
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neurofibrillary degeneration, does not produce the disease clinically (Iqbal K., et al., 2009). 
NFTs occur not only in AD, but also in other neurodegenerative diseases called Tauopathies 
(Lee V.M., et al., 2001). NFTs are formed by aggregates of the abnormal 
hyperphosphorylated protein Tau, belonging to the family of the microtubule-associated 
proteins (MAP) (Fig. 6).  Tau is coded by single gene on chromosome 17 but is expressed in 
several molecular isoforms that are generated by alternative splicing of its mRNA (Himmler 
A., et al., 1989). Six isoforms of the protein are known, which differ in the presence or 
absence of exons 2, 3 or 10. An alternative splicing of exon 10 produces Tau with four (4R 
Tau) or only 3 (3R Tau) repetitive motives (Goedert M. et al., 1989). 
Tau is involved in the stabilization of microtubules, which build up axonal cytoskeleton. In 
fact, this soluble protein binds to tubulin for facilitating its assembly into microtubules and 
stabilize their structure (Cleveland D.W., et al., 1977) (Fig. 6). Phosphorylation of Tau is 
regulated by addition or removal of phosphate residues at specific sites. 
Hyperphosphorylation of Tau renders the protein insoluble, decrease its affinity for 
microtubules and self-associates into paired helical filaments (PHF). Likewise, Aβ 
oligomers also intermediates of abnormal Tau molecules are cytotoxic (Khlistunova I., et al., 
2006). Intracellular accumulation of PHF leads to formation of NFTs in pyramidal neurons. 
Therefore, microtubules appear destabilized and so depolymerize, compromising 
axoplasmic flow with consequent neuronal degeneration. Similarly, tau could trigger a 
significant decrease of transendothelial electrical resistance and an increase of endothelial 
permeability in a model of rat BBB (Kovac A., et al., 2009). These data were confirmed in a 
transgenic tauopathy mouse model showing correlation between dysfunction of BBB and the 
appearance of perivascular tau around major hippocampal blood vessels (Blair L.J., et al., 
2015). 
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Figure 6. Formation of neurofibrillary tangles. 
[Querfurth H.W. & Laferla F.M., N Engl J Med, 2010] 
 
Several studies point out the relationship between neurofibrillary degeneration and β-
amyloidosis. In fact, the Amyloid Cascade Hypothesis, one of the principal hypothesis on 
the etiopathogenesis of AD, states that the generation of Aβ is the primary pathological 
event preceding and driving Tau aggregation and finally leading to neuronal death and the 
development of dementia (Oddo S., et al., 2003). However, some authors demonstrated that 
in the absence of Aβ production, in 3xTg-AD mice deficient for BACE, tau pathology forms 
independently from Aβ peptide generation, thus refuting the initial hypothesis (Winton M.J., 
et al, 2011).  
 
6. SYNAPTIC LOSS  
 
Another important pathological hallmark is synaptic loss, an early and invariant feature of 
AD. There is a strong correlation between the extent of synapse loss and the severity of 
dementia; in fact, this loss involves particularly the dentate region of the hippocampus, thus 
promoting the memory impairment (Shankar G., Walsh D.M., 2009). This evidence is 
supported by the common knowledge that the synapses are the major sites for LTP and 
plasticity in the neuron. Recent studies have indeed shown that in AD patients there is the 
55% of synaptic loss in the CA1; instead patients with MCI exhibited 18% synaptic loss in 
comparison to control cases (Scheff S.W., et al., 2007). These results have been obtained by 
using electron microscopy or immunohistochemical staining for synaptic markers that has 
documented significant decreases in synaptic density in the association cortices and 
hippocampus of AD brain (Hamos J.E., et al., 1989). A variety of mechanisms appear to 
contribute to synaptic dysfunction and have diverse consequences such as alterations in 
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synaptic proteins, membrane lipids, vesicular function and loss of plasticity (Coleman P., et 
al., 2004). The initial triggers may be Aβ plaques toxicity or disrupted intracellular transport 
of aggregated tau (Pereira C., et al., 2005). Indeed, in the intersinaptic space the presence of 
Aβ plaques impairs synaptic plasticity and important postsynaptic receptors, such as acetyl 
choline receptor. In addition, excitotoxicity, oxidative stress, and apoptosis have all been 
claimed to contribute to synaptic dysfunction (Querfurth H.W. & Laferla F.M., 2010). The 
initial decrease in synapse number and density seems disproportionate to the loss of 
neuronal cell bodies suggesting that loss of synaptic endings may precede neuronal loss 
(Davies C.A., et al., 1987). 
 
 
7. NEURON LOSS AND BRAIN ATROPHY 
 
During the progression of AD pathology, the communication between neurons is inhibited 
but neurons can also be damage to the point that they cannot function properly and 
eventually die. As neurons die throughout the brain, affected regions begin to shrink in a 
process called brain atrophy. By the final stage of AD, damages are widespread and brain 
tissue has shrunk significantly. In according with amyloid cascade hypothesis, accumulation 
of fibrillar Aβ into plaques damages neurons through two different mechanisms. In a direct 
mechanism, Aβ interacts with membrane components and damages directly neurons, 
causing neuronal injury and synaptic dysfunction (Koh J.Y., et al., 1990). While in indirect 
mechanism, Aβ activates microglia and astrocytes to produce inflammatory mediators, as 
nitric oxide, cytokines and free radicals, causing neurons death for apoptosis or necrosis 
(Meda L., et al., 1995).  
 
 
8. INFLAMMATION 
 
Inflammation is a relevant component of the innate immune response and it is the first line 
of defense of organisms to damage or injury, characterized by redness, heat, swelling, and 
pain. At first, it is characterized by dilation of capillaries to increase blood flow; then by 
microvascular structural changes and escape of plasma proteins from the bloodstream; and at 
last by leukocyte transmigration through endothelium and accumulation at the site of injury. 
The primary objective of inflammation is to localize and eradicate the irritant and repair the 
surrounding tissue. For the survival of the host, inflammation is a necessary and beneficial 
process. The phagocytes (monocytes, macrophages and neutrophils) are the main cells 
involved in the innate immune response. These cells, through patters recognition receptors 
(PRRs), bind to patterns molecular associates pathogens (PAMPs) and may internalize and 
kill the microorganisms. The other arm of immunity, called specific immunity, is 
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characterized by B and T lymphocytes participating in immune responses when the innate 
immune response is unable to eradicate a pathogen. The principal function of B cells is to 
produce and release antibodies against soluble antigens. On the contrary, T lymphocytes 
recognize foreign antigens that had to be first acquired and presented on major 
histocompatibility complex (MHC) molecules of an antigen-presenting cell (APC). B and T 
lymphocytes together assist innate immune cells and respond to whole microorganisms and 
to virtually any molecule that is ‘foreign’ to the host.  
The inflammatory condition resulting from a trauma, ischemia-reperfusion injury or 
chemically induced injury typically occurs in the absence of any microorganisms and has 
therefore been termed “sterile inflammation” (de la Torre J.C., 2004). Some authors ascribe 
AD as a sterile inflammatory condition, suggesting his contribution to the pathogenesis of 
AD (Halle A., et al., 2008, Rock K.L., et al., 2010). This type of inflammation occurs by 
liberation of danger signal of non-microbial origin (DAMPs) and characterizes many 
neurodegenerative disorders, including AD, as previously reported (Halle A., et al., 2008, 
Rock K.L., et al., 2010). DAMPs may be intracellularly secreted in response to cell stress or 
passively released following sterile injury or cell death. The Aβ is considered a DAMP 
capable of activating a wide array of receptors expressed on immune cells (Halle A., et al., 
2008, Rock K.L., et al., 2010). The inflammatory response induces the expression of 
vascular adhesion molecules, the mobilization of leukocytes in site of inflammation, and 
initiates a cascade of progressive interactions between leukocytes and others immune cells 
with the vascular vessels wall that precedes transmigration across the endothelial barrier and 
into the targeted tissue (Ley K., et al. 2007). 
 
 
8.1 LEUKOCYTE RECRUITMENT   
 
The leukocyte recruitment cascade is a sequence of adhesion and activation events in site of 
inflammation that ends with extravasation of the leukocyte, whereby the cell exerts its 
effects on the inflamed site. The simplified original four steps model involves: 1) rolling, 
mainly mediated by selectins; 2) chemokine-mediated activation; 3) arrest and 4) 
transmigration, mainly mediated by integrins (Ransohoff R.M., et al., 2003, Butcher and 
Picker, 1996, Luster A.D., et al., 2005). However, progress has been made in defining 
additional steps such as capture (or tethering), slow rolling, integrin-mediated leukocyte 
adhesion strengthening and spreading (post-binding phase of adhesion stabilization) and 
intravascular crawling (Ley K., et al., 2007) (Fig. 7). The specificity of leukocyte migration 
is mediated by the expression patterns of cell adhesion molecules and chemokine receptors. 
Expression of high levels of specific cell adhesion molecules on endothelium is the 
consequence of an inflammatory condition in that specific district. Molecular specificity in 
the targeting of leukocytes at sites of inflammation is mediated by selectins, integrins, and 
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immunoglobulin gene superfamily (Ig superfamily) proteins. The recruitment initiates with 
the leukocyte tethering and rolling on the activated vascular endothelium. The primary 
capture is mainly mediated by selectins, a three-member family of highly conserved “C-type 
lectins” expressed on the surface of leukocytes and activated endothelial cells. The selectins 
are identified by capital letters: L for leucocyte (L-selectin), E for endothelial cell (E-
selectin), and P for platelet and endothelial cell selectin (P-selectin). Some primary 
inflammatory cytokines released by activated leukocytes induce the up-regulation of 
selectins and other adhesion molecules, chemokines, growth factor and lipid mediators 
(prostaglandins and nitrogen monoxide) amplifying leukocyte recruitment and their survival 
in the tissue. For instance, Tumor Necrosis Factor-α (TNF-α) and interleukin-1 (IL-1) 
stimulate the endothelial cells lining blood vessels to express the surface adhesion molecule 
P-selectin (Eppihimer M.J., et al, 1997). Within few hours, a second surface adhesion 
molecule, E-selectin, is produced. L-selectin is expressed on most circulating leukocytes and 
is the key receptor that initiates leukocyte capture events in high endothelial venules in 
secondary lymphoid tissues and at the peripheral sites of injury and inflammation (Rosen 
S.D., et al., 2004). L- and P-selectin are particularly efficient tethering molecules. P- and E-
selectin are rapidly expressed in both acutely and chronically stimulated endothelial beds 
and are important determinants for neutrophil, monocyte, natural killer cell, eosinophil, 
effector T cell and B cell recruitment in most inflammatory processes (McEver P.L.M., et 
al., 2002). The interaction of selectins with their ligands enable leukocytes to roll along the 
inflamed vascular endothelial surface under condition of blood flow, thus allowing other 
molecules to interact with the “slowed” leukocytes and promoting their adhesion and 
transmigration into the tissue. Selectins bind sialyl-Lewis X-Like carbohydrate ligands 
presented by sialomucin-like surface molecules. P-selectin can bind PSGL-1 (P-Selectin 
Glycoprotien Ligand) which is constitutively expressed on all lymphocytes, monocytes, 
eosinophils, and neutrophils. Another P-selectin ligand is CD24, which appears to be 
important for tumor cell binding. L-selectin recognizes sulfated sialyl-Lewis X-like sugars 
in high endothelial venules and other ligands on inflamed endothelial cells as well as PSGL-
1 on adherent leukocytes. By contrast specific ligands for E-selectin are not yet known, 
however E-selectin can also interact with PSGL-1 and another sialyl-Lewis X-bearing 
glycoconjugates. The requirement for selectins in primary cell capture and rolling has also 
been confirmed by experiments using transgenic mice deficient for L-selectin, E-selectin, P-
selectin, and for the prototypic ligand PSGL-1 (Mayadas T.N., et al., 1993, Xia L., et al., 
2002).  
 
Integrins also participate in rolling and mediate firm leukocyte adhesion. Integrins are a 
large family of heterodimeric transmembrane glycoproteins whose ligand-binding activity 
can be rapidly regulated by conformational changes as well as by transcriptional induction 
and redistribution from intracellular pools (Carman C.V., et al., 2003). Integrins consists of 
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2 bound subunits: α (120-170 kDa) and β subunits (90-100 kDa). One of the most important 
integrin is the αLβ2 (CD11a/CD18) integrin, also known as Lymphocyte Function- 
Associated Antigen-1 (LFA-1), which not only participates in rolling but also in the 
adhesion and arrest of leukocytes in lymphoid organs or in inflamed tissues by linking the 
Intercellular adhesion molecule-1 (ICAM1) and Intercellular adhesion molecule-2 (ICAM-
2) (Rossi B., et al., 2011). Another prominent integrin expressed on leukocytes is the α4β1 
integrin, the Very Late Antigen-4 (VLA-4, CD49d/CD29) that binds the vascular adhesion 
molecule-1 (VCAM-1), and it is also essential for leukocytes adhesion to vascular 
endothelium and leukocyte recruitment to the inflamed area (Luster A.D., et al., 2005). 
On circulating leukocytes integrins are generally in a low affinity/avidity state and do not 
bind efficiently to their ligands expressed on endothelial cells. Rolling allows leukocytes to 
encounter activation factors, such as chemoattractants or chemokines, which bind to specific 
seven transmembrane receptors coupled to intracellular heterotrimeric Gi proteins. Binding 
of chemokines to their respective receptors on the leukocyte surface leads to the so called 
“inside-out- signalling” rapidly up-regulating integrin avidity and/or affinity (Ley K., et al., 
2007). Once activated, integrins can interact with cell adhesion molecules from the 
immunoglobulins (Ig) superfamily expressed on endothelial cells. The vascular endothelium 
expresses molecules of the immunoglobulin superfamily which act as counter-receptors for 
leukocyte integrins. Two immunoglobulins particularly important in leukocytes recruitment 
are ICAM-1 and VCAM-1. ICAM-1 (or CD54) is a member of the Ig superfamily of 
adhesion molecules, and contains 5 Ig like domains. It is one of the principal ligands for 
LFA-1 and Mac-1 integrins (Diamond et al., 1991), although in the context of 
transmigration it seems that CD11a predominantly binds to ICAM-1, whereas CD11b is 
more promiscuous (Shang X.Z. & Issekutz A.C., 1998). VCAM-1 (or CD106) contains six 
or seven Ig domains and is expressed on both large and small vessels only after the 
endothelial cells are stimulated by cytokines. The sustained expression of VCAM-1 lasts 
over 24 hours. Primarily, VCAM-1 is an endothelial ligand for VLA-4 and α4β7 integrins. 
VCAM-1 promotes the adhesion of lymphocytes, monocytes, eosinophils, and basophils.  
After slowing down their movement and arresting on endothelial cells, leukocytes pass 
through the crawling phase to find the optimal site of emigration that is usually different 
from the site of initial adhesion. There are regions defined “gates” for leukocytes 
transmigration with low matrix protein deposition in the venular basement membrane that 
facilitate their transmigration (Sanz M.J., et al, 2012). The final step of the cascade is the 
transmigration through endothelial cells in inflamed tissue; this process involves migration 
of leukocytes through two distinct barriers, namely the endothelial cell layer and the 
perivascular basement membrane. Of note, two ways of leukocyte diapedesis have been 
reported in vivo and in vitro models: the “paracellular way” that is the most prevalent type of 
extravasation processes, and the “transcellular route” for neutrophils and subsets of activated 
effector T cells (Ley K., et al., 2007). 
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Figure 7. Molecular mechanisms controlling leukocyte adhesion cascade.  
[Luster A.D., Nat Immunol, 2005] 
 
 
8.2 INTEGRINS  
 
On leukocyte membranes, integrins exist as heterodimers composed of one α and one β 
subunit. In humans, 18 α and 8 β subunits have been identified that in combination form at 
least 24 different heterodimers. Each subunit contains an extracellular domain involved in 
ligand binding, a single transmembrane domain, and a cytoplasmic domain, which regulates 
integrin function. The association of both subunits at N-terminal end forms the ligand-
binding site, whereas the C-terminal region traverses the plasma membrane and interacts 
with cytoskeleton. Integrins are bi-directional signaling molecules and binding to their 
ligands results in intracellular signals and conversely, cellular signaling events can modulate 
their affinity for extracellular ligands (Fig. 8). The most relevant integrins known to mediate 
leukocyte arrest belong to the β1 and β2 subfamilies. β2 integrins include 4 different 
heterodimers: LFA-1, Mac-1 (CD11b/CD18), p150,95 (CD11c/CD18), and CD11d/CD18. 
The most studied β2-integrin involved in leukocyte recruitment is LFA-1, which participates 
in rolling interactions but predominantly mediates the firm adhesion/arrest of leukocytes in 
the blood vessels of lymphoid organs or at sites of inflammation by binding the Ig 
superfamily ligands ICAM-1 and ICAM-2 (CD102), expressed by the vascular endothelium 
(Luster A.D., et al., 2005, Ley K., et al., 2007). The most important β1-integrin expressed on 
leukocytes is VLA-4, which binds to its ligand VCAM-1, and is chiefly responsible for 
leukocyte adhesion to vascular endothelium and leukocyte recruitment to the inflamed area 
(Luster A.D., et al., 2005, Ley K., et al., 2007).  
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The integrin LFA-1 has a heterodimeric structure with two subunits: CD18 and CD11a, the 
first is common at all β2-integrins and the second is specific for LFA-1. Additionally, LFA-
1 contains an extracellular domain of 200 aminoacidic residues (I-domain) with modulatory 
activity. LFA-1 I-domain has a high homology with the A-domain of Von Willebrand Factor 
(vWFA) and cartilage matrix protein. Instead, the integrin VLA-4 lacks the alpha I-domain 
(Chigaev A., et al., 2007). The I-domain is constituted by a central β-sheet that is surrounded 
by α-helices called α/β Rossman fold, a structure common to intracellular enzymes. At the 
C-terminal end of the central β-sheet of α/β Rossman fold there is a conserved Asp-X-Ser-
X-Ser motif termed the metal-ion-dependent adhesion site (MIDAS) used for binding 
divalent cations. The ligand binding is associated with Mg2+-mediated coordination by 
residues within MIDAS of αL and by an acidic residue donated by the ligand. The presence 
of isoleucine in position 311 of CD11a called “socket for isoleucine” play a role in LFA-1 
activation. The short cytoplasmic tail contains a conserved GFFKR motif that plays a role in 
heterodimerization and ligand affinity as so demonstrated by mutations in amino acids 
sequence that have effects on low affinity state conformation. The subunit CD18 contains a 
large extracellular domain of 676-685 residues, a single hydrophobic transmembrane region 
of 23 residues and short cytoplasmic tail of 46-48 residues. The extracellular region contains 
a cysteine-rich repeats so-called plexin semaphorin integrin (PSI) domain, an inserted I-like 
domain of 240 and 248 amino acids and a series of 4 cysteine-rich repeats that display a 
significant degree of similarity with the epidermal growth factor (EGF)-like domains. The 
CD18 cytoplasmic domain associate with cytoskeleton and is involved in endoplasmic 
reticulum retention, assembly, and transport to the plasma membrane of the mature LFA-1 
(Zecchinon L., et al. 2006, Kallen J. et al. 1999, Crump M.P., et al. 2004). The head region 
is characterized by propeller and thigh domains of the α-subunit and the βA (also known as 
βI), hybrid and semaphorin integrin (PSI) domain of the β-subunit. The remaining C-
terminal extracellular domains of the α- and β-subunit comprise two long ‘legs’ which are 
anchored in the plasmatic membrane.  
A major structural difference between VLA-4 and LFA-1 integrins is the presence of an 
additional "inserted" I-domain, which implies the difference in ligand binding kinetics. The 
binding of the fluorescent ligand to LFA-1 integrin was extremely slow without inside-out 
activation (at rest), compared to VLA-4 integrin. This suggests that an additional structural 
mechanism prevents rapid binding of the ligand to the resting LFA-1 integrin. For this 
blocking mechanism, LFA-1 integrin is not able to support cell rolling leading to the 
requirement for the selectin-mediated rolling step. On contrary, for VLA-4 integrin, the 
binding of the small fluorescent probe was not obstructed in its bent conformation. 
This physiological difference suggests that LFA-1/ICAM-1-mediated interactions will be 
more difficult to establish. Accordingly, from a biological perspective seems that an 
additional protective mechanism for the binding of a ligand to the LFA-1 binding site 
indicates an additional “check” for adaptive immune responses, where immune cell 
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interaction can directly lead to unwanted, or excessive immune activation resulting in cell 
and tissue damage. Therefore, VLA-4 integrin could be involved in innate antigen-
independent immune responses, while the LFA-1 integrin in adaptive immunity (Chigaev A. 
& Sklar L.A., 2012). Although the general mechanism that governs this conformational 
dependence of affinity has been laid out by structural and biophysical studies, a complete 
understanding of the intrinsic dynamics of the VLA-4 integrin is currently lacking. 
 
 
Figure 8. Integrin affinity triggering. The diagram shown the three different states (low, 
intermediate, and high affinity) for ICAM-1. The availability of the I-domain and I-like 
domain (in yellow), which are involved inligand binding with increasing affinity, increased 
with progressive extension of LFA-1 integrin. [Laudanna C., Bolomini-Vittori M., Wiley 
Interdiscip Rev Syst Biol Med. 2009]. 
 
However, integrins are expressed on the surface of a wide range of cell types in an inactive 
state to avoid inappropriate leukocyte adhesion and their activation is regulated by two 
mechanisms: binding affinity and valency of ligand binding (Ley K., et al., 2007). Higher 
affinity results from conformational changes, while the valency reflects the density of 
integrin heterodimers within the plasma membrane region involved in cell adhesion and can 
depend on the abundance of individual integrins and their lateral mobility (Ley K., et al., 
2007). Crystallography and electron microscopy studies evidenced multiple distinct 
conformational states. In addition, the use of conformational sensitive antibodies can 
reconstruct a model of integrin conformational states.  
The integrin conformation changes for LFA-1 are monitored using specific antibodies, such 
as Mab and 327C mAb that recognize the extended/open high affinity conformation of LFA-
1 integrin (Constantin G., et al, 2000, Lefort C.T., & Ley K., 2012). Another study 
performed during human neutrophils rolling reported the partial extension of the epitopes in 
the β2 and αL subunits recognized by KIM127 and KNI-L16 mAb respectively. 
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Accordingly, three different states (low, intermediate, and high affinity) that differ in ligand 
binding affinity have been reported for LFA-1 integrin. The inactive low-affinity state shows 
a bent structure with the ligand-binding headpiece near membrane-proximal stalk region. In 
the intermediate affinity state LFA-1 start to extend the stalk regions shifting the molecule to 
the active higher-affinity conformation, where LFA-1 integrin exhibits extended 
extracellular domain with the ligand-binding pocket for ICAM-1.  
Instead, changes in VLA-4 integrin affinity have been detected in real-time using a ligand-
mimicking LDV-containing fluorescent small molecule (4-((N′-2-methylphenyl)ureido)-
phenylacetyl-l-leucyl-l-aspartyl-l-valyl- l-prolyl-l-alanyl-l-alanyl-l-lysine-FITC (LDV-
FITC)) (Chigaev A., et al., 2001). Interestingly, the discovery of several distinct signaling 
mechanisms indicates the conformational complexity of this non-I-domain-containing 
integrin (Chigaev A., et al., 2007). The bent and low affinity state is observed on resting 
cells where the ligand binding site is close to the membrane, and it prevents cell tethering 
and rolling. The high affinity state induces the slow accumulation of cell aggregates in 
suspension and the rolling phase. However, this state is not fully extended and consequently 
the ligand binding affinity remains low. Finally, the high affinity results in the rapid 
accumulation of cell aggregates in suspension (Chigaev A., et al., 2007, Chigaev A., et al., 
2008) (Fig. 9).  
 
Figure 9. Model of VLA-4 integrin conformation and affinity. In suspension, this 
translates into rapid cell aggregation that reaches a steady-state intermediate between resting 
(I) and Gαi-coupled GPCR activated states (IV). [Chigaev A. and A. SklarJ L.A., Frontiers 
in Immunology 2012]. 
 
The mechanism of integrin conformational changes is adjusted by “inside-out” signaling, 
when chemoattractants cause modifications inside the cell that lead an “outside-in” signaling 
and allow the interaction of the integrin with its ligand (Heit B., et al., 2005).  
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The intracellular signaling comprises several inter-dependent pathways, including a) G-
protein-coupled receptors (GPCRs), b) small guanosine triphosphate hydrolase enzymes 
(GTPase) (such as RapA1 and Rho family) and c) Talin-1. The G-protein βγ subunit of 
GPCR activates phospholipase C (PLC), which cleaves phosphatidylinositol 4-5-
bisphosphate (PtdIns(4,5)P2) to produce inositol 1-4-5 triphosphate (InsP3) and 
diacylglycerol (DAG) with Ca2+ release from intracellular stores in the ER. However, the 
Ca2+ and DAG may trigger one or more guanine-nucleotide-exchange factors (GEFs) that 
activated GTPase. Pertussin toxin (PTx) completely inhibits the binding of LFA-1 to ICAM-
1 thus confirms that the induction of high-affinity state is dependent on heterotrimeric Gαi-
protein triggered “inside-out” signaling events (Constantin G., et al., 2000).  
 
Regulation of the affinity of the β2 integrin LFA-1 by Rho signaling module was 
investigated in vitro studies. The small GTPases RhoA and Rac1 regulate the activation of 
LFA-1 by CXCL12 in a dose-dependent manner causing a rapid adhesion. Inhibition of 
RhoA signaling resulted in the blockade of LFA-1 integrin conformeric transition to 
low/intermediate as well as to high-affinity states. Inhibition of Rac1 function blocked rapid 
CXCL12- triggered LFA-1 transitions to low/intermediate and to high-affinity states. The 
Rho effectors Phospholipase D1 (PLD1) and phosphatidylinositol-4-phosfate 5-kinase 
isoform 1γ (PIP5KC) are critical to LFA-1 affinity modulation. PLD1 was rapidly activated 
in a dose-dependent manner by CXCL12 and its inhibition resulted in markedly reduced 
adhesion on ICAM-1. PIP5KC is a downstream effector of RhoA, Rac1 and PDL1. It is a 
conformer-selective regulator of LFA-1 affinity controlling triggering of LFA-1 to a high-
affinity state, but no to low/intermediate-affinity state by CXCL12. Instead, CDC42 is a 
negative regulator of LFA-1 integrin and when constitutively active causes a block in LFA-
1-mediated adhesion (Montresor A., et al, 2009; Bolomini-Vittori M., et al, 2009).  
 
Talin-1, an anti-parallel homodimer involved in triggering integrin affinity upregulation, 
represents a shared regulator of all integrin classes expressed by leukocytes. Talin activity is 
regulated by activation of the small GTPase Ras-related protein 1 (Rap1), a known regulator 
of cell adhesion. RapA1 regulates rapid integrin-dependent adhesion either in the context of 
the LFA-1 integrin as well as VLA-4 integrin. Rap1-guanosine triphosphate (GTP)–
interacting adapter molecule (RIAM) is a Rap1 effector molecule. GTP-Rap1–bound RIAM 
recruits talin to the plasma membrane by binding the rod domain and subsequently activates 
talin by binding the integrin-binding region on the talin head. Interestingly, knockdown of 
RIAM abrogated Rap1-induced adhesion to integrin ligands, suggesting a role in integrin 
LFA-1 inside-out signaling (Klapproth S., et al., 2015). Instead, the RIAM/talin complex 
contribution to integrin activation for the VLA-4 integrin was only partially affected by 
RIAM deficiency in leukocytes. Therefore, that β2 and α4-integrins use different RIAM-
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dependent and -independent pathways to undergo activation by talin (Klapproth S., et al., 
2015).  
 
However, a pathway involving Rap GTPases and talin is critical for “inside-out” signaling 
but there are many unanswered questions. For example: the inactivation of Rap1 blocks 
SDF1α (CXLC12) stimulated LFA-1-mediated binding to ICAM1, but not binding of VLA-
4-mediated binding to VCAM-1 in human T cells. Similarly, silencing of CalDAG-GEFI 
inhibits SDF1α and phorbol 12-myristate 13-acetate (PMA) stimulated adhesion to ICAM-1 
but not VCAM-1. This data suggests that different pathways are used to activate LFA-1 
integrin and VLA-4 integrin (Ghandour H., et al., 2007). The underlying reason for this 
integrin class-specific requirement of CalDAG-GEFI, Rap1 and RIAM is not clear. It is 
conceivable that different chemokines show specificity for activation of different integrins. 
In addition, different integrin classes localize to defined membrane compartments that are 
targeted by different signaling pathways and are therefore differently activated. One 
interesting membrane compartment, which operates independently of Rap1 and RIAM, 
could be the leukocyte microvilli. It has been shown that the integrin VLA-4 on T cells is 
enriched on microvilli during adhesion to VCAM-1 under flow conditions, whereas the 
integrin LFA-1 is enriched in non-microvillar compartments. 
 
In addition, there are also other differences in the adaptive molecules that mediate the 
cascade of these two integrins as the hematopoietic Progenitor kinase 1 (HPK1) and the 
paxillin. A recent study identifies the HPK1 as specific regulator for LFA-1. HPK1 is 
critical for CXCL1-LFA-1-mediated neutrophil adhesion to ICAM-1 under flow conditions 
(Jakob S.M., et al., 2013). Instead, an unusual feature of α4 integrin signaling is the direct 
binding of a cytoplasmic adaptor protein, the paxillin, to the α4 cytoplasmic domain. This 
protein–protein interaction is regulated by trans-regulation by enhancing the activation of 
tyrosine kinases, focal adhesion kinase (FAK) and/or proline-rich tyrosine kinase-2 (Pyk2). 
The α4–paxillin interaction is required for the ability of α4-integrins to enhance migration 
(Kummer C., et al., 2006). Collectively, these data indicate multiple potential targets exist 
within these signaling pathways thus the integrin signaling might be a favorable therapeutic 
target for the treatment of chronic inflammatory disorders.  
 
LFA-1 integrin is one of the most important and widely expressed integrin on leukocyte but 
its function partially overlaps with the integrin Mac-1. In in vitro studies have demonstrated 
that both LFA-1 and Mac-1 integrins are involved in the adhesion of neutrophils to 
endothelial cells and ICAM-1, but that adhesion through LFA-1 integrin overshadows the 
contribution from Mac-1 integrin (Ding Z.M., et al, 1999). In agreement, by intravital 
microscopy studies, other authors demonstrated the role of LFA-1 and Mac-1 in wild type 
(WT) and LFA-1 and Mac-1 deficient mice. These results delineate two different molecular 
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mechanisms for LFA-1 and Mac-1, with LFA-1-dependent adhesion followed by Mac-1-
dependent crawling (Phillipson M., et al, 2006). All these data together underline that the 
integrin LFA-1 is mainly involved in neutrophil adhesion, which is an obligate step 
preceding extravasation, whereas Mac-1 play a main role in the crawling phase on 
endothelial cells. 
 
VLA-4 integrin is most prominent integrin expressed on mononuclear leukocytes, but is also 
expressed on neutrophils (Johnston B. & Kubes P., 1999; Engelhardt B. & Ransohoff R.M., 
2012). VLA-4 integrin mediates cells adhesion to VCAM-1 and is essential for 
embryogenesis, hematopoiesis, lymphocyte homing and the recruitment of leukocytes to 
sites of inflammation (Rose D.M., et al., 2002; Imai Y., et al., 2010).  
Notably, mouse neutrophils in the blood show very low levels of VLA-4 integrin compared 
to bone murine marrow neutrophils, suggesting that VLA-4 integrin expression decreases 
during neutrophil maturation (Petty J.M., et al., 2009). In addition, human neutrophils do not 
constitutively express the VCAM-1 binding integrin VLA-4 or it is non-existent on the 
surface of resting neutrophils (Davenpeck K.L., et al. 1998). This has led to the general 
assumption that VLA-4 integrin is not involved in neutrophil recruitment or function. In 
contrast, several authors have demonstrated that neutrophils can express VLA-4 integrin by 
mediating adhesive interactions with endothelium and consequently, neutrophils can 
infiltrate numerous tissues independent of β2-integrin (Pereira S. et al. 2001, Reinhardt P.H., 
et al., 1997, Ibbotson G.C., et al., 2011; Taooka Y., et al., 1999; Neumann J., et al., 2015). 
However, one major difference in leukocyte recruitment is that while LFA-1 integrin is 
mainly involved in neutrophil firm adhesion, VLA-4 integrin directly participates in 
leukocyte tethering and rolling on the endothelium. In addition, signaling from α4 integrins 
can stimulate β2 integrin-dependent leukocyte adhesion. Thus, leukocyte arrest and 
spreading can be mediated directly by VLA-4 ligation and indirectly via α4 regulation of β2 
integrin-dependent adhesion (Kummer C., et al., 2006). Unlike the β2-integrin-dependent 
recruitment pathway, which dominates under normal and acute inflammatory conditions, α4-
integrin might play roles in mediating neutrophil recruitment in more chronic inflammatory 
processes (Johnston B. & Kubes P., 1999).  
 
 
9. LEUKOCYTE TRAFFICKING IN AD 
 
For the past decades, molecular mechanisms underlying AD pathology have been studied in 
exclusive relation by Aβ, considering mainly its effects on neuronal activity and functions 
(“the Amyloid Hypothesis”). However, most therapeutic efforts targeting Aβ have failed to 
show efficacy and none of numerous clinical investigations and drug developments has not 
even slow disease progression (Chiang K. & Koo E.H., 2014). This failure has raised many 
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doubts about the Amyloid Hypothesis and despite the Aβ plaque remains a well-established 
hallmark of AD pathology other aspects of pathology has been investigated.  
Several evidences from basic research studies and clinical research suggest the inflammation 
and innate immune mechanism in the CNS enhance AD pathology (Rogers J. et al., 2008; 
Heneka M.T., et al., 2010). Interestingly, recent studies on the AD brain revealed that Aβ 
plaques are co-localized with a variety of inflammation-related proteins (complement 
factors, acute-phase proteins, pro-inflammatory cytokines) and clusters of activated 
microglia, suggesting a strong implication of endogenous brain immune responses in AD 
patients (Eikelenboom P., et al., 2006). In fact, glial cells (microglia and astrocytes) actively 
contribute to immune cell trafficking by integrating signals between the brain and the 
periphery. (Persidsky Y., et al., 1999; Hudson L.C., et al., 2005; Choi S.S. et al., 2014; 
Lécuyer M.A.,  et al., 2016; Rogers J., et al., 2008; Heneka M.T., et al., 2010). Microglial 
cells are involved in the active surveillance of the CNS and continuously scan the 
environment to detect pathogens or tissue damage (Yang J. et al., 2011). The activation of 
microglia induces an innate immune response dominated by the release of the pro-
inflammatory cytokines and chemotactic factors that may act on circulating leukocytes 
(Heneka M.T., et al., 2015). However, microglial cells in AD pathogenesis seems to have a 
dual role: a protective role in clearing Aβ or a detrimental role in inducing an inflammatory 
state with the production of proinflammatory cytokine and chemokines (Hickman S.E., et al. 
2008). In addition, also astrocytes have an important defensive function in brain by 
triggering a mechanism knows as astrogliosis, with which glial cells can repair and remodel 
damaged brain tissue (Li L., et al., 2008). Astrocytes are also important in regulating the 
turnover of the main excitatory neurotransmitter glutamate in the brain (Swanson R.A. et al., 
2005). However, astrogliosis is associated also with cognitive decline in neurodegenerative 
diseases such as multiple sclerosis because it is correlated with neuroinflammation 
(Hostenbach S, et al., 2014). Indeed, also astrocytes activated by Aβ plaques are involved in 
the inflammation process in AD brain (Matos M., et al., 2008). Microglia and astrocytes are 
resident cells within the brain, which can be activated against injuries, however also 
circulating leukocytes invading the brain (such as monocytes, T cells and neutrophils) may 
contribute to wound healing but indeed may also cause tissue damage (Mcdonald B. & 
Kubes P., 2011).  
 
Monocytes are the most widely-studied circulating immune system cells in AD and they 
migrate through the BBB into the AD brain in a CCR2-dependent manner (El Khoury J. et 
al., 2007; Naert G. & S., Rivest, 2013). The beneficial role of monocytes in AD relies on the 
clearance of Aβ, thus CCR-2 deficiency in the Tg2576 and APPSwe/PS1 mouse models of 
AD exacerbates amyloidosis and memory deficit (El Khoury J., et al., 2007; Naert G. & S., 
Rivest, 2011). Furthermore, APPSwe/PS1 mice are characterized by the defective 
production of CCR2+ monocytes leading to cognitive decline, the accumulation of soluble 
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Aβ and the disruption of synaptic activity (Naert G. & S., Rivest, 2012; Naert G. & S., 
Rivest, 2013). In agreement with these data, in vivo two-photon microscopy (TPM) studies 
indicate that patrolling monocytes are attracted to and crawl onto the luminal walls of Aβ+ 
veins and that their selective removal in APP/PS1 mice significantly increases the Aβ load 
in the cortex and hippocampus, suggesting that monocytes can naturally target and eliminate 
Aβ within the lumen of veins (Michaud J.P., et al., 2013). Despite these evidences, two 
studies have recently challenged the view that circulating monocytes help to clear Aβ in AD 
models. The replacement of brain-resident myeloid cells with circulating peripheral 
monocytes in mouse models of cerebral amyloidosis showed that monocyte repopulation 
does not modify the amyloid load, arguing against a long-term role of peripheral monocytes 
in Aβ clearance (Prokop S., et al., 2015; Varvel N.H., et al., 2015). 
Interestingly, in addition to monocytic-derived cells also T cells were observed in 
association with Aβ deposited in leptomeningeal and cortical vessels, suggesting that Aβ 
angiopathy rather than Aβ plaques support T cell infiltration into the AD brain (Yamada M. 
et al., 1996). An increased frequency of T cells has been shown adherent to the vascular 
endothelium or migrated into the brain parenchyma in hippocampus and cortical regions of 
post-mortem AD subjects and AD-like mice (Itagaki S., et al., 1988; Rogers J. et al., 1988; 
Togo T., et al., 2002; Town T., et al., 2005; Ferretti M.T., et al., 2016).  
Several studies found an altered frequency of CD4+ and CD8+ T cells in the peripheral 
circulation of AD patients in comparison to patients with other forms of dementia or age-
matched controls (Tan et al., 2002; Town T., et al., 2005; Bonotis K., et al., 2008; Pellicanò 
M., et al., 2012; Lueg G., et al., 2015). In particular, a significant decrease in CD4+ T cell 
count was reported in AD patients of severe compared to mild-moderate stages of diesease 
and control patients (Bonotis K., et al., 2008; Pellicanò M., et al., 2012). In agreement, a 
report show augmented vulnerability to apoptosis in CD4+ T cells of AD subjects differently 
from normal elderly (Schindowski K., et al., 2006). Contrary, other reports showed either no 
differences in CD4+ T cells (Speciale L., et al., 2007) or the opposite situation, with total 
CD4+ T cells significantly increased in AD patients in comparison to healthy controls 
(Shalit F., et al., 1995; Lombardi V.R., et al., 1999; Richartz-Salzburger E., et al., 2007). 
Therefore, these data are inconsistent and do not allow drawing definite conclusions.   
In the context of CD8+ T cells, a recent report showing higher numbers of activated CD8+ T 
cells in peripheral blood and in the CSF of MCI and mild AD patients, that seems to 
correlate with clinical AD markers (Lueg G., et al., 2015). Interestingly, these circulating 
CD8+ T cells in AD subjects were found to express the activation marker CD38 (Zhang R., 
et al., 2013), that is associated with migration into peripheral tissues and cytotoxic effector 
functions (Savarino A., et al., 2000). The inflammatory response stimulated by migrated T 
cells into the AD brain may activate microglia and astrocytes and may recruit other 
inflammatory cells that are potentially harmful to the CNS, thus exacerbating the 
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pathogenesis of AD. One of the major culprits in causing collateral damage during sterile 
inflammation is the neutrophil (Rock K.L. et al., 2010).  
Polymorphonuclear leukocytes (PMNs), also called neutrophils, are most abundant 
population of cells in blood and represent the primary mediators of the innate immune 
response. They rapidly deployed to sites of inflammation, where perform a variety of 
antimicrobial functions such as degranulation and phagocytosis, to kill invading pathogens. 
The presence of neutrophils in human AD brains was also known in the past, but their 
specific role in the pathology was still everything to prove. Savage M.J., et al. showed by 
immunohistochemistry the distribution of cathepsin-G, a protease contained specifically in 
neutrophils, within the brain parenchyma as well as inside cerebral blood vessels of AD 
subjects and sometimes associated with Aβ deposits (Savage M.J., et al. 1994). Interestingly, 
the presence of CAP37, an inflammatory mediator expressed in neutrophils, was reported in 
blood vessels and in hippocampal vasculature in patients with AD (Grammas P., et al., 2000; 
Brock A.J., et al., 2015). Other reports investigate the neutrophils/lymphocytes ratio as an 
inflammatory marker, which levels in the blood are elevated in people with AD than healthy 
controls (Kuyumcu M.E., et al., 2012), and increase in function of age, but are weakly 
correlated with Aβ deposition (Rembach A., et al., 2014). A recent pioneering study of our 
laboratory reports neutrophil accumulation in the brain of AD animal models as well as AD 
subjects. We demonstrated that neutrophils can migrate in the brains of AD patients and they 
can induce cognitive dysfunction (Zenaro E., et al., 2015). For these reasons, neutrophils are 
under investigation in the attempt to treat AD (Zenaro E., et al., 2015).  
Neutrophils are the most abundant type of white blood cells in mammals, and play an 
essential role in the innate immune system (Nathan C., 2006). They are one of the 
firstresponders of inflammatory cells to migrate toward the site of inflammation through the 
blood vessels, recruited by chemoattractant such as IL-8 and C5a in a process called 
chemotaxis. Neutrophils have an average diameter of 12–15 µm and a 12-h life span in 
circulation in non-activated condition. However, after activation and migration into tissues, 
they are able to survive for 1–2 days.  
Neutrophils have three strategies to attack invaded microorganisms: phagocytosis, release of 
soluble antimicrobials (including granule proteins) and generation of neutrophil extracellular 
traps (NETs) (Brinkmann, V. et al, 2004; Hickey, M.J. et al, 2009). In phagocytosis the 
release of ROS is essential to degrade the pathogens in phagosomes. However, in excessive 
quantity they may damage host tissue and cells. As a result of digestion of pathogens 
(bacteria, fungi, and viruses), they often are phagocytosed by macrophages. In addition, the 
massive degranulation of neutrophils with release of their proteolytic enzymes may be 
another source of tissues damage. Neutrophils have four types of granules and each has 
specific proteolytic enzymes with a function correlated. These are: azurophilic (primary), 
specific (secondary), gelatinase (tertiary), and secretory granules. The main proteolytic 
enzymes contain in their granules are myeloperoxidase, serine proteases, α-defensins, 
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lysozyme, human neutrophil elastase (NHE), cathepsin G (CatG) lactoferrin, 
metalloproteinases (MMP-8 and −9 in particular), CD13 (aminopeptidase N) and CD16 (Fc 
gamma receptor III). (Yonggang Ma et al, 2013). In addition to their antimicrobial activity, 
the neutrophils play an essential role in non-infectious inflammation, innate immunity, 
present antigen though the MHC I and tissue remodeling. Recently, various authors reported 
that neutrophils release NETs decorated with proteins such as elastase and histones to 
entangle pathogens (Zawrotniak M. et al, 2013). 
 
According to this study, the role of leucocytes recruitment could be an important step in the 
pathogenesis of AD, so it may represent a therapeutic target for AD. Nowadays, a real care 
for AD has not yet been found. The current treatments are prescribed for treatment of mild 
to moderate AD symptoms and slow down progression of the disease, helping people with 
AD to maintain their mental functions. Unlike current treatments, a different and possible 
therapeutic approach may be turned towards other directions. The blockade of leukocyte 
recruitment may lead to suppression of the immune responses and this approach has been 
successfuly proved for the treatment of multiple sclerosis (MS), a chronic inflammatory and 
demyelinating disease of CNS. Indeed, the humanized monoclonal antibody Natalizumab 
(Tysabri) blocks VLA-4 integrin by inhibiting the adhesion and migration of lymphocytes in 
cerebral parenchyma and, consequently, preventing the damage of nervous cells. Therefore, 
it can be hypothesized that a possible intervention aimed to block leukocyte recruitment may 
have beneficial effect also in AD. 
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 MATERIALS AND METHODS 
 
10. REAGENTS  
 
The following rat-anti mouse monoclonal antibodies were purified from serum-free 
hybridoma media in our laboratory: anti-ICAM-1 (clone YN 1.1.7.4), anti-LFA–1 (clone 
TIB213 and clone KIM127), anti-VCAM–1 (clone MK 2.7), anti-E-Selectin (clone RME-1), 
anti-CD45 (clone 30G12), anti-RAS (clone Y13259) and anti-Gr–1 (clone RB6-8C5). The 
anti-LFA–1 antibody (clone 327A) was kindly provided by Dr. Kristine Kikly (Eli Lilly and 
Co.) and the anti-α–integrins mAb (PS/2) were purchased from Bioxcell. The chemical 
reagents are: mouse mAb anti-human to Aβ 1-16 (6Ε10) (Covance-Signet), rabbit mAb anti-
mouse to Iba-1 (Wako), mouse mAb anti-human to total tau 159-163 (HT7) (Thermo 
Scientific), mouse mAb anti-human to phospho-tau to residue Thr231 (AT180) (Thermo 
Scientific). The following were purchased from commercial sources: anti-mouse P-selectin 
(clone CD62P) (BD Pharmingen), fluorescence-conjugated anti-mouse CD45 (clone 
30F11.1), rat mAb anti-mouse to CD45 (RA3-6B2) (Biolegend); rat mAb anti mouse to 
CD11b (M1/70) (Biolegend); rat mAb anti mouse Gr-1–PE (Mlteny Biotech); rat mAb anti 
mouse to-Ly6G–FITC (1A8) (Biolegend); rat mAb anti- mouse CD4 (RM4-4) (Biolegend); 
rat anti mouse to-CD8 (53-6.7) (Biolegend); Biotinylated secondary antibodies and Avidin 
Texas Red were purchased from Vector Labs. CXCL12 were purchased from R&D systems. 
Dako mounting medium were purchased from DAKO. PTx and bocMLF were purchased 
from Tocris Bioscience. Cell trackers CMTPX, CMAC, and the 655-nm and 525-nm non-
targeted Q-dots were obtained from Molecular probes. 
 
 
11. ANIMALS 
 
The transgenic AD animal models used are 5xFAD, 3xTg-AD and LFA-1-deficient mice 
(Itgal-/-) mice purchased from ‘The Jackson Laboratory’ (Sacramento, CA).  
 
5xFAD is a double transgenic APP/PSEN1 mouse model that co-expresses five familial AD 
mutations (FAD) under transcriptional control of the neuron-specific mouse Thy-1 promoter 
(Oakley H., et al., 2006; Ohno M., et al., 2006). 5xFAD represents one of the most early-
onset and aggressive amyloid predominant mouse models. It starts to develop visible 
amyloid deposits as early as ~2 months of age consistent with their dramatically accelerated 
Aβ1-42 production. Later, these structures undergo a continuing process of 
sprouting/swelling and dystrophy, associated with the emergence and deposition of 
extracellular Aβ (Zhang X.M., et al., 2009). At 4- and 6-month-old 5xFAD mice show 
hippocampal dysfunctions, impaired contextual fear memory formation and a significant 
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remote memory dysfunction (Kimura, R. & Ohno, M., 2009). 5xFAD mouse is also one of 
the few currently available AD-like models known to develop neuron loss. 5xFAD mice 
were reported to develop neuron loss by 9 months of age at the cortex and subiculum 
(Oakley H., et al., 2006). As a consequence of the extensive pathology seen in 5xFAD 
mouse, this model develops different electrophysiological and behavioral impairments.  
 
3xTg-AD mice were previously obtained by co-microinjecting two independent transgenes 
encoding human APPSwe and the human tauP301L (both under control of the mouse 
Thy1.2-regulatory element) into single-cell embryos harvested from homozygous mutant 
PS1M146V knock-in (PS1-KI) mice (Oddo S., et al., 2003). 3xTg-AD mice are of a mixed 
129/C57BL6 genetic background. The Aβ plaques and NFTs deposition are detected in 
correlation with age; Aβ deposits initiate in the cortex and progress to the hippocampus, 
whereas tau pathology is first apparent in the hippocampus and then progresses to the cortex 
(Oddo S., et al., 2003). The extracellular Aβ deposits start in frontal cortex at 6 months of 
age and become marked at 12 months of age in cortical regions and hippocampus. By 15 
months, Aβ plaques are apparent in posterior cortical regions such as the occipital and 
parietal cortices, suggesting a related regional dependence to the Aβ deposits in 3xTg-AD 
mice. NFTs are evident at 12-18 months of age in hippocampus, thus suggesting that their 
formation may be influenced by generation of Aβ (Oddo S., et al., 2003; Billings L.M., et 
al., 2005). The first memory deficits in 3xTg-AD mice are detectable at 4 months of age, 
such as deficits in long-term retention, and correlates with intracellular deposits of Aβ 
plaques in hippocampus and amygdala. Interestingly, this early cognitive dysfunction may 
be associated with early stages of MCI. At 6-months of age, these mice start presenting 
difficulties to retain the information from day by day. The continued accumulation of Aβ is 
likely to account for the continued decline of the cognitive phenotype to include short-term, 
as well as long-term, memory deficits (Billings L.M., et al., 2005).  
 
We also used LFA-1 knockout mouse (also called CD11a or Itgal-/- mutant mice) was 
generated by using a targeting vector containing neomycin resistance gene driven by the 
mouse RNA polymerase II promoter. The neomycin resistance gene was used to disrupt a 
2.1 kb region containing exons 1 and 2. The construct was electroporated into 
129s7/SvEvBrd-Hprt b-m2 derived AΒ2.1 embryonic stem (ES) cells. Correctly targeted ES 
cells were injected into recipient C57BL/6 blastocysts and chimeric male were mated with 
C57BL/6 female to obtain the LFA-1 mutant mice. Then, we crossed 3xTg-AD and Itgal-/- 
mice to obtain a transgenic mouse with all transgenes that characterized 3xTg-AD and LFA-
1-/- models (APPSwe, tauP301L, PS1M146V knockin and LFA-1 knockout). 
5xFAD, 3xTg-AD, 3xTg-ADxItgal-/-, and Itgal-/-- mice were housed in pathogen-free 
climate controlled facilities and allowed to have food and water ad libitum.  
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Experiments in mice were approved by the board of the Interdepartmental Center of 
Experimental Research Service from the University of Verona and by the Italian National 
Institute of Health and followed the principles of the US National Institutes of Health Guide 
for the Use and Care of Laboratory Animals and the European Community Council directive 
(86/609/EEC). 
 
 
11.1 MICE TYPIZATION 
 
The genetic backgrounds of 5xFAD mice were 50% C57Bl/6 and 50% B6/SJL. Transgenic 
lines were maintained by crossing heterozygous transgenic mice with B6/SJL F1 breeders. 
All transgenic mice used were heterozygotes with respect to the transgene, and non-
transgenic littermates served as controls. In addition, we performed genotyping to 
distinguish 3xTg-ADxItgal-/- homozygous from heterozygous mice by PCR analysis of APP 
and PSEN1 insertion and LFA-1 deletion. In addition, the PSEN1 PCR was followed by a 
step of restriction enzyme digestion with BstE II. 
 
 
11.1.1 DNA EXTRACTION FROM TAIL BIOPSIES 
 
Final part of mice tail was accurately cut in sterile condition and placed into polypropylene 
microfuge tube and then kept on ice. We performed DNA extraction using DirectPCR Lysis 
reagent (Viagen Biotech, Cat # 101-T, 101- T) containing freshly prepared 0,2-0,4 mg/ml of 
proteinsase K (P2308, 115K8614, Sigma-Aldrich, St.Louis, MO). We used 300 µl for 0,5 
cm tail. Proteinsase K was stable in DirectPCR Lysis reagents for 24 hours. Proteinasi K 
was needed to degrade tissue proteins such as keratin. To obtain complete tissue lysis, tubes 
were incubated overnight at 55°C in agitation. After vigorous mechanical agitation, vials 
were incubated in water bath at 85°C for at least 45 min and mixed every 15 min. Tail were 
considered completely digested when at the bottom of vials were present only hairs and 
eventually bone residues. To eliminate tail residues tubes were centrifuged for 5-10 sec at 
maximum speed. Crude lysates were stored at -20°C for 1 years or at 4°C for 1 week 
without losing efficacy. 1µl of crude lysate was used for direct PCR reaction. 
 
 
11.1.2 PCR 
 
The PCR mix contained: 200 mM dNTPs (U1511, Promega, Madison, WI), 0.4 mM forward 
and reverse primers, 1.5 mM MgCl2 (A351H, Promega, Madison, WI), 1.25 U GoTaq® Hot 
Start Polymerase (M5005, Promega, Madison, WI), 5X PCR Green GoTaq® Flexi Buffer 
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(M8911, Promega). 1µl of crude DNA lysate was used as template. Final PCR volume was 
20 µl. PCR program consisted of an initial denaturation at 94°C for 4 min, followed by 35 
cycles of 3 repeated steps: denaturation (94°C for 30 sec), annealing (54°C for APP, 65°C 
for PSEN1 and 58°C for LFA-1, for 30 sec) and extension (72°C for 30 sec) (GeneAmp® 
PCR System 9700). The following primers purchased from Life Technologies were used: 
RV APP (5’ CGG GGG TCT AGT TCT GCA T 3’), FW APP (5’ AGG ACT GAC CAC 
TCG ACC AG 3’), RV APP ctrl (5’ GTC AGT CGA GTG CAC AGT TT 3’), FW APP ctrl 
(5’ CAA ATG TTG CTT GTC TGG TG 3’), RV LFA-1 (5‘CAC GGG TAG CCA ACG 
CTA TGT C 3’), FW LFA-1 (5’ GCC CTG AAT GAA CTG CAG GAC GAC G 3’), RV 
LFA-1 ctrl (5’ AGA AGC CAC CAT TTC CCT CT 3’), FW LFA-1 ctrl (5’ AGC TGG 
AGT CCC AGT AGC AA 3’), RV PS1 (5’ CAC ACG CAC ACT CTG ACA TGC ACA 
GGC 3’), FW PS1 (5’ AGG CAG GAA GAT CAC GTG TTC AAG TAC 3’). A final 
extension at 72°C for 5 min ended the program. To estimate qualitatively the presence of 
APP, LFA-1 and PSEN1 PCR product of amplification, 5µl of PCR mixture were run on 1% 
agarose gel and visualized by Nancy staining (Sigma, Nancy-520). TrackItTM 100bp DNA 
Ladder (10488-058, Life Technologies) was used for sizing the double-stranded DNA from 
100 to 1500 bp on the agarose gel. 
 
 
11.1.3 RESTRICTION ENZYME DIGESTION 
 
BstE II recognizes the DNA sequence: (5’ G GTNAC C 3’) and (3’ C CANTG G 5’). BstE 
II restriction enzyme mix contained: BUFFER D 10X (60mM Tris- HCl pH 7.9, 1.5M NaCl, 
60mM MgCl2 and 10mM DTT), acetylated BSA 100X, 30 µl of PCR product, 10U of BstE 
II restriction enzyme and deionized water. The final volume of the mix is 50 µl. The solution 
was then incubated at 37°C for 3 hours. After incubation, 5µl of 10X loading buffer was 
added to proceed for the agarose gel analysis of DNA fragments obtained. The mixture was 
run on 1% agarose gel and visualized by Nancy staining (Sigma, Nancy- 520). TrackItTM 
100bp DNA Ladder (10488-058, Life Technologies) was used for sizing the double-stranded 
DNA from 100 to 1500 bp on the agarose gel. 
 
  
11.2 TISSUE PREPARATIONS FOR NEUROPATHOLOGY 
 
Myocardial perfusion was used as a method to clean blood from circulation, allowing to 
conserve organs for future analysis. In fact, much better morphologic details were obtained 
when examining standardly fixed and processed tissue preparations. 4% paraformaldehyde 
(PFA) was commonly used for perfusion fixation, which renders good morphologic 
preparations. Mouse was anaesthetized by intraperitoneal injection (i.p.) with phosphate 
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buffered saline pH 7.4 (PBS) containing ketamine (5 mg/ml) and xylazine (1 mg/ml). Once 
mouse was sedated, the abdomen was wet with ethanol. Mouse was then placed with 
abdomen facing up and by using four small needles was secured on the four paws as wide as 
possible. Skin was grabbed with forceps at the level of the diaphragm, and cut to expose the 
liver, thus by cutting through the ribs the heart was easily accessible. Butterfly needle was 
placed into the left ventricle and immediately after the right atrium was cut so that blood 
flows out as the circulation is replaced (Fig. 14). A peristaltic pump (Minipuls3 Gilson) with 
a flow no higher than 0.5 ml/min is used to inject 25 ml with Ca2+/Mg2+(1µM) and glucose 
PBS. If the perfusion was successful, tongue color become light pink, ears and tail veins 
were not visible, and the liver and the kidneys became blanch as the blood was replaced. 
After this was observed, the buffer solution was replaced with fixative (freshly made 4% 
PFA solution). We used approximately 25 ml of PFA for mouse. Once perfusion was 
finished, organs such as brain, spinal cord, lung, liver, kidney and spleen were removed and 
maintained in ice-cold PFA solution overnight at 4°C. Mouse organs were then post-fixed at 
4°C overnight. The day after, organs were rinsed with PBS for at least 30 min at RT°C and 
then transferred in 30% sucrose solution in PBS until they sank. Sucrose was used in order 
to cryoprotect and to prevent freeze artefact and loss of tissue architecture. Finally, organs 
were included in a cryo-embedding matrix such as optimum cutting temperature (OCT) 
(DDK Italia) and store at -80°C. 
 
 
11.3 IMMUNOFLUORESCENCE STAINING ON TISSUE SECTIONS 
 
Frozen tissues correctly stored with OCT compound were cryo-sectioned in a cryostat. Brain 
coronal sections, if made at specific sites, allow similar areas to be examined, so that 
comparisons can be made between littermate controls and AD transgenic animals. Mouse 
brains were cut in coronal slices of 30-40 µm. Sections were collected and placed in 24-well 
plates containing 1 ml of PBS. Then, free floating sections were incubated in blocking 
buffer, corresponding to species for secondary mAb, for 1h at RT°C; then treated with 
primary antibody overnight at 4°C (40 µg/ml of anti-VCAM, 10 µg/ml of anti-ICAM, 10 
µg/ml of anti-P-selectin, 5 µg/ml of anti-E-selectin, 5 µg/ml of anti-CD45, 5 µg/ml of anti-
Gr1). Slices were incubated with biotinylated secondary mAb (7.5 µg/ml of rabbit anti-rat, 
T0226, VectorLAB) for 1h at RT°C, then washed with PBS. To reveal immunostaining, 
slices were treated with Avidin Texas Red (at 25 µg/ml, A2006, VectorLAB) for 1h at RT°C 
in the dark. After rinsing in PBS, sections were incubated with Dapi (at 1 µg/ml, D9542, 
Sigma-Aldrich, St.Louis, MO), for 8 min in the dark. Finally, brain portions were washed 
with PBS, transferred on glass slides and mounted with Dako (S3023 DAKO, Carpinteria, 
CA). Glass slices were kept at 4°C in the dark. Usage of this mounting medium help 
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reducing fading of immunofluorescence during microscopy acquisition. Slides were 
analysed by Tandem Confocal Scanning-SP5 (Leica, Germany). 
 
 
11.4 ISOLATION OF BRAIN LEUKOYTES AND FLOW-
CYTROMETRIC ANALYSIS 
 
Mice were anesthetized and perfused through the left cardiac ventricle by injection of 35 ml 
of cold PBS. The brain was dissected, cut into small pieces and digested with DNaseI 
(20U/ml, Life Technologies) and collagenase (1mg/ml, Sigma) at 37°C for 45 min. Cells 
were isolated by passing the digested tissue through a cell strainer (70 µm), resuspended in 
30% percoll and loaded onto 70% percoll. Then, tubes were centrifuged at 1300 xg for 20 
min at 4°C. Cells were removed from the interphase, washed twice in PBS and resuspended 
in staining buffer for further analysis. Sensitive identification of various immune cell 
populations in a single sample was performed by antibody staining and flow cytometry with 
MACSQuant Analyzer (Miltenyi Biotec, Germany). The following anti-mouse antibodies 
were used: anti- CD45-Vioblue, anti-CD11b-APC Cy7, anti-Gr1-Viogreen, anti-Ly6G-
FITC, anti-CD4-APC, anti-CD8-PE Cy7 and anti-γδTCR-PE (Miltenyi Biotec, Germany).  
Data were analysed using FlowJo software. 
 
 
11.5 NEUTROPHIL PREPARATION 
 
Mouse neutrophils 
We isolated bone-marrow neutrophils from femurs and tibias of WT control mice. Mice 
were sacrificed by cervical dislocation. On average, 10-20 x 106/mL neutrophils can be 
expected for mouse. Therefore, the number of sacrificed animals depends on the number of 
neutrophils necessary for the experiment. Femurs and tibias were cut out and muscles 
removed. We flushed the marrow cells from the bones with Ca2+/Mg2+ free 0.1% BSA 
HBSS solution (GIBCO). Then, the cell suspension is mixed with 18G-needle syringe to 
disrupt cell clumps and centrifuged 1200 rpm for 10 min. Then, 3mL of 0,2% NaCl solution 
was added to cell pellet for hypotonic lysis of erythrocytes, and after 30 sec 7ml of 1,2% 
NaCl was added to restore the osmolarity. The cell suspension was filtered through a 70µm 
cell strainer (Falcon) to get rid of the clot and any bone remnants. Cell pellet obtained after 
centrifugation at 1200 rpm for 10 min was resuspended in 3ml of 45% Percoll solution and 
loaded on a Percoll discontinuous density gradient. Percoll gradient was prepared by slowly 
adding in a 15-mL tube the following solutions: 4ml of 81% Percoll at the bottom, 3 mL of 
62% Percoll, 3 mL of 55% Percoll and 50% Percoll (Fig. 10). Then centrifugation was 
performed at 2700 rpm for 30 min without brake. Neutrophils were harvested at the 80%-
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65% interface with a Pasteur pipette, washed twice with PBS, resuspended in RPMI and 
counted for use. More than 90% of the isolated cells were Gr-1 positive cells as assessed by 
flow cytometry analysis (data not shown). 
 
 
 
Figure 10. Percoll discontinuous density gradient.  
The figure represents bone-marrow cells separated in Percoll discontinuous gradient in a 15-
mL tube with the bands at 45%, 50%, 55%, 62% and 81%. Neutrophils were found at the 
80%-65% interface. 
 
Human neutrophils 
Human PMNs were prepared from buffy coats of healthy volunteers by centrifugation 
through Ficoll Paque Plus (Amersham) at 2700 rpm for 30 minutes without brake. Patients 
provided their informed consent before samples were taken. Contaminating erythrocytes 
were removed by Dextran 500 (Amersham) sedimentation followed by 0.2% NaCl for 
hypotonic lysis of erythrocytes and after 50 seconds, 1.2% NaCl were added to restore the 
osmolarity. PMNs were washed with PBS and centrifugated at 1200 rpm for 5 minutes. Cell 
pellet was resuspended in RPMI and counted for the use in in vitro assays. 
 
 
11.6 Aβ PREPARATION 
 
Aβ (1–42) and Aβ (42–1) were purchased from Bachem AG. Oligomeric Aβ was prepared 
as reported previously (Kim et al., 2003). Briefly, after removal of hexafluoroisopropanol 
(Sigma), Aβ (1–42) was dissolved at 5 mM in DMSO and diluted to 100 µM in Dulbecco's 
Modified Eagle Medium, with nutrient mixture F-12 (DMEM/F12). After incubation for 24 
h at 4°C, Aβ solution was centrifuged at 15,000 rpm for 10 min at 4°C and the supernatant, 
containing soluble oligomeric Aβ, was collected and quantitated by MicroBCA assay 
(Pierce, Rockford, IL). The same procedure was used for Aβ (42–1).  
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For the preparation of fibrillar Aβ, 5 mM Aβ 1-42 in DMSO was diluted to 200 µM, using 
100 mM HEPES buffer, pH 7.5 and incubated for 1 week at 37°C. After aging, the Aβ 
sample was centrifuged at 15000 xg for 10 minutes at RT°C and the supernatant was 
removed. The pellet fraction was re-dissolved in HEPES buffer and quantitated by 
MicroBCA assay. The identity of fibrillar and oligomeric Aβ was evaluated by 
electrophoresis as previously described (Dahlgren K.N., et al., 2002). The identity fibrillar 
and oligomeric Aβ was evaluated by electrophoresis as previously described (Kim et al., 
2003, Dahlgren K.N., et al., 2002). Briefly, 1–2 µg of Aβ peptides were diluted in lithium 
dodecyl sulfate sample buffer and loaded on precast 12% bis-Tris NuPAGE gel (Life 
Technologies) using MES running buffer. Proteins were transferred on polyvinylidene 
difluoride membrane (Millipore) using NuPAGE transfer buffer (Life Technologies). Both 
gel electrophoresis and protein blotting were made in non-reducing conditions. Membranes 
were blocked in 5% non-fat dry milk/TBSTween (TBS-T) for 1h, followed by incubation 
with 0,5 µg/ml of a mouse monoclonal Aβ antibody to residues 1–12, BAM-10 (A5213, 
Sigma, St. Louis, MO). Membranes were then washed in TBS-T and incubated with 
horseradish peroxidase-conjugated anti-mouse antibody (1:2000), and developed with the 
ECL system (Amersham). Western blot analysis of soluble oligomeric Aβ (1–42) 
preparation (24h at 4°C) reveals the presence of monomers, trimers and tetramers. 
 
 
11.7 RAPID ADHESION ASSAYS 
 
Eighteen-well glass slides were coated for 16 hours at 4°C with purified human ICAM-1 
(3000 sites/mm2). Neutrophils (105/well; 5x106/mL in PBS containing 10% heat-inactivated 
FCS, CaCl2 1 mmol/L, MgCl2 1 mmol/L, pH 7.2; adhesion buffer) were added, incubated 
for 10 min at 37°C, and then stimulated by the addition of the agonists for 2 min before 
washing. Fixation was performed on ice in 1.5% glutaraldehyde for 60 min. Cell count was 
obtained by computer-assisted enumeration of cells bound in 0.2 mm2, as previously 
described (Laudanna et al., 1996). When required cells were pre-incubated for 20 min with 
100 µM of boc-MLF or 2h with 2 µg/ml of PTx at 37°C. 
 
 
11.8 MEASUREMENT OF LFA-1 AFFINITY STATES 
 
Human neutrophils re-suspended in standard adhesion buffer at 2x106/mL were briefly pre- 
incubated with 10 µg/ml of monoclonal antibodies KIM127 (Robinson et al., 1992) to study 
the extended conformation epitope corresponding to an inter- mediate-affinity state of LFA-
1 (Shimaoka et al., 2006, Stanley et al., 2008), or 327C (Lum et al., 2002) to study the high- 
affinity state of LFA-1. The cells were stimulated for 10 sec with 0.5 µmol/L of CXCL12, 
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0,1 µM N-Formylmethionine-leucyl-phenylalanine (fMLP), 20 µM Aβ1-42 or Aβ42-1 under 
stirring at 37°C. After rapid washing, cells were stained with FITC-conjugated secondary 
polyclonal antibody and analyzed by cytofluorimetric quantification. 
 
 
11.9 TWO-PHOTON MICROSCOPY SURGICAL PREPARATION 
 
“Thinned skull preparation” for long-term high-resolution imaging in vivo was performed as 
previously described (Zenaro E., et al., 2013; Pietronigro E.C., et al., 2016). Mice were 
deeply anesthetized and core body temperature was monitored and maintained using a 
regulated heating pad. The hair on the scalp was removed with an electric razor. The scalp 
was then sterilized with alcohol. An incision was made along the midline of the scalp to 
expose the skull overlying the cortical region of interest. Any fascia overlying the skull was 
scraped away with a scalpel blade. The skin and periosteum were removed. A 1 mm 
diameter region of skull was thinned using a high-speed micro drill and a stainless-steel 
burr. Drilling was halted every few seconds to prevent heating and bone dust is removed 
using a compressed air canister. Care was taken not to deflect the skull during drilling. 
Drilling continued until the fine vasculature of the dura madre was visible (Fig. 11). At this 
point, thinning continued by hand using a microsurgical blade. This process was repeated 
until image clarity is maximized. Animals showing any signs of damage, such as subdural or 
epidermal bleeding were discarded from the study. When imaging was complete, the wound 
margins of the scalp were sutured together using nylon suture. Mice were given a bolus of 
warm saline for rehydration and are allowed to recover from anesthesia on a water-
circulating heating pad. Neutrophils were isolated from bone marrow and labeled with 
fluorescent cell trackers CMTPX or CMAC (Molecular Probes, Life Technologies). TPM 
studies were performed at 24-36h after intravenous injection of cells. To visualize blood 
vessels, 20 µL of 655-nm or 525-nm non-targeted Q-dots (Molecular Probes, Life 
Technologies) in 100 µL of PBS were injected intravenously before mice were anaesthetized 
using 1.5% isoflurane with a facemask.  
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Figure 11. TPM study. Thinned skull preparation obtained by gentled scraping a little 
region of cranial skull on somatosensory cortex, until the fine vasculature of the dura madre 
was visible 
 
 
 
11.10 TPM ACQUISITIONS AND DATA ANALYSIS 
 
Time-lapse imaging was performed using a Tandem Confocal Scanning-SP5 (Leica). Each 
plane represents an image 525 µm by 525 µm (xy dimensions), and approximately 22-44 
sequential planes were acquired at 2.5 µm increments in the z-dimension to obtain z-stacks. 
Z-stacks were acquired every approximately 32-63 seconds during time-lapse recordings. 
Image reconstruction, multidimensional rendering and manual cell tracking were done with 
Imaris software (Bitplane). Data were transferred and plotted in GraphPad Prism 5.0 (Sun 
Microsystems) for the creation of the graphs. The neutrophil movement analysis was 
performed by using functions of the T cell Analysis program (TCA; John Dempster, 
University of Strathclyde, Glasgow, Scotland). 
 
 
11.11 MOUSE TREATMENT WITH LFA-1 OR α-INTEGRINS 
BLOCKING ANTIBODY 
 
Anti-LFA–1 mAb (hybridoma TIB213) and an anti-α–integrins mAb (PS/2) was used to 
block leukocyte recruitment from peripheral circulation to inflammatory sites. Anti-RAS 
mAb (hybridoma Y13259) was used as control antibody and should not affect any mouse 
activity. The mAbs were diluted into sterile endotoxin-free PBS at a concentration of 
1mg/mL. mAbs were injected i.p. at a dose of 0,5 mg per mouse in the first treatment at 
approximately 22 weeks of age in 3xTg-AD mice. Then, mice were injected with 300 µg of 
mAbs i.p. every second day. The treatment was continued for approximately 4 weeks in 
3xTg-AD mice until behavioral testing. Control mice were injected with endotoxin-free 
PBS. Mice were selected on the bases of specific inclusion and exclusion criteria. For 
instance, mouse body weight (20-40 gr) was checked and mice with body weight higher than 
40 g were excluded from the experiments. Age and gender of AD-like disease models and 
WT control mice was matched. Mice with evident physical defects such as loss of the 
whiskers or dwarfism, and cutaneous defects (i.e alopecia) were excluded from the 
experiment. Moreover, to reach statistical significance a minimum number of 12-15 
mice/experimental condition was used to study the effect of immune mechanisms inhibition 
in behavioural tests for cognitive functions (Zenaro E., et al., 2015). The experimental 
schedule is shown in Figure 12. 
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11.12 BEHAVIOURAL ASSESSMENT 
 
Memory loss is the cardinal and one of the earliest clinical manifestations of AD. The 
animal behavior is usually evaluated with either operative or associative learning tasks. 
However, in the contest of AD pathology, where adult/old mice are usually tested, it is also 
important to distinguish learning/memory deficits from general deficits in task performance. 
Therefore, pre-cognitive tests such as “Hindlimb clasping” and “Ledge test” were run before 
behavioral assessment. Instead, learning and memory capacity were evaluated using Y-maze 
and Contextual Fear Conditioning (CFC) tests. 12-15 mice for treatment condition were 
tested in both tasks, approximately equal number of males and females were included in 
each group. The animals were housed with free access to water/food and were maintained on 
a 12-hour light/dark cycle. All behavioral testing was performed during the light phase of 
this circadian cycle. Experiments were made blind with respect to the genotype of the mice. 
All behavioral tests were performed as previously described (Sarter et al., 1988; Imbimbo et 
al., 2010). Y-maze and CFC tests were performed after one month of treatment, to avoid 
possible variable-like stress, generating by continuer injections (Fig. 12). 
 
 
 
 
 Figure 12. Experimental protocol of behavioral performances.  
We treated 3xTg-AD mice with an anti-LFA–1 or anti-α-integrins antibody starting at  6 
months of age (peak of maximum neutrophilic infiltration) for 4 weeks. An isotype 
antibody was used as control antibody and age-matched control mice were 
injectedwith endotoxin-free PBS. After the antibody treatment, 3xTg-AD and age-matched 
control mice were behaviorally tested at early stages of disease (at 8-9 months of age) or at 
later time-points to evaluated the long-term effect of the treatment (at 11-12 months of age). 
At the end of behavioral assessment, mice were sacrificed for neuropathological analyses. 
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11.12.1 HINDLIMB CLASPING 
 
Hindlimb clasping is used as a marker of disease progression in many mouse models of 
neurodegeneration. To record the score, the tail was grasped near its base and mouse was lift 
away from all surrounding objects. The hindlimb position was observed for at least 10 sec 
and the test was conducted three times. If the hindlimbs were consistently splayed outward, 
away from the abdomen, a score of 0 was assigned. If one hindlimb was retracted toward the 
abdomen for more than 50% of the time suspended, it received a score of 1. If both 
hindlimbs were partially retracted toward the abdomen for more than 50% of the time 
suspended, it received a score of 2. If its hindlimbs were entirely retracted and were 
touching the abdomen for more than 50% of the time suspended, it received a score of 3. 
 
 
11.12.2 LEDGE TEST 
 
After the antibody treatment, 3xTg-AD mice were tested with ledge test. The ledge test was 
a direct measure of coordination, which is impaired in many other neurodegenerative 
disorders. The mouse was lift from the cage and placed on the cage's ledge. Mice will 
typically walk along the ledge and attempt to descend back into the cage. Then, the mouse 
was observed as it walked along the cage ledge and lowerd itself into the cage. A WT mouse 
typically walked along the ledge without losing its balance, and lowered itself back into the 
cage gracefully, using its paws. This was assigned as score of 0. If the mouse losed its 
footing while walking along the ledge, but otherwise appears coordinated, it received a score 
of 1. If it did not effectively use its hind legs, or lands on its head rather than its paws when 
descending into the cage, it received a score of 2. If it falled off the ledge, or nearly so, while 
walking or attempting to lower itself, or shacked and refused to move at all despite 
encouragement, it received a score of 3. Some mice required a gentle nudge to encourage 
them to walk along the ledge or descend into the cage. The above procedure was performed 
four times and the score was averaged between 4 tests. 
 
11.12.3 Y-MAZE TEST 
 
Y Maze Spontaneous Alternation is a behavioral test used to evaluate, without training, 
reward, or punishment, the willingness of rodents to explore new environments and to assess 
hippocampus-dependent spatial working memory, which is classified as short-term memory. 
Testing occurs in a Y-shaped maze with three gray opaque plastic arms at a 120° angle from 
each other, extending from a central space (Fig. 13). After introduction to the center of the 
maze, the animal, nai ̈ve to the apparatus, was allowed to freely explore the maze for 8 
minutes. Rodents typically prefer to investigate a new arm of the maze rather than returning 
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to one that was previously visited. So during the session, mouse should show a less tendency 
to enter in the recently visited arm. The sequence and the total number of arm entries were 
recorded to calculate the percentage of alternation. An entry occurs when all four limbs are 
within the arm. Each arm of the Y maze was arbitrarily assigned as zone A, B, or C. 
Alternation was defined as successive entries into the three arms in overlapping triple sets 
(e.g., ABC or ACB but not ABA). The alternation percentage was calculated as (number of 
triads containing entries into all three arms / maximum possible alternations) x 100. To 
diminish odor cues, the maze was cleaned with 70% ethanol solution prior to test each 
mouse. 
 
 
Figure 13. Representative image of Y-maze. 
 
 
11.12.4 CONTEXTUAL FEAR CONDITIONING 
 
CFC is an associative learning task in which mice learn to associate a particular neutral 
Conditional Stimulus (CS; a tone) with an aversive Unconditional Stimulus (US; a mild 
electrical foot shock) and show Conditional Response (freezing). After repeated pairings of 
CS and US, the animal learns to fear both the tone and training context. Contextual Fear 
Conditioning is learned rapidly and is a useful test for neurobehavioral, genetic, and 
pharmacological studies. Both amygdala and hippocampus are key structures for the 
learning and retrieval of memories in this task. 
CFC occurred in 30 x 24 x 21 cm operant chambers (Ugo Basile, Comerio, Italy). Each 
chamber was equipped with a stainless-steel rod floor through which a footshock could be 
administered, two stimulus lights, one house light, and a solenoid, all controlled by ANY-
maze computer software (Stoelting, Wood Dale, Illinois) (Fig. 14a). The chambers were in a 
sound-isolated room in the presence of red light. Mice were trained and tested on 2 
consecutive days (Fig14b). Training consisted of placing a subject in a chamber, 
illuminating stimulus and house lights, and allowing exploration for 2 min. Afterwards, the 
15 sec tone stimulus [2 Hz clicking via the solenoid; conditioned stimulus (CS)] co-
terminated with 2 sec footshock [1.5 mAmp; unconditioned stimulus (US)]. This stimuli 
pairing was repeated two times, with presentation spaced 2 min apart. 30sec after the second 
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shock, the mice were removed from the chamber. Before the first mouse and between mice, 
the chambers were wiped clean with isopropyl alcohol and allowed to dry before testing. 24 
hours later, mice were placed back to the same chamber in which training occurred (context) 
for the 5 min contextual conditioning test without tone or shock presentation, and freezing 
behavior was recorded by the experimenter. Freezing was defined as lack of movement 
except that required for respiration. At the end of the 5 min contextual test, mice were 
returned to their home cage. Approximately 2 hours later, freezing was recorded in a novel 
environment and in response to the cue. The novel environment consisted of modifications 
including an opaque Plexiglas divider diagonally bisecting the chamber, a Plexiglas floor, 
and decreased illumination. Mice were placed in a novel environment, the computer 
program recorded mouse movement during 3 min test without any stimulus presentation. 
The auditory cue (CS) was then presented for 3 min, and again mouse movement was 
recorded. Freezing scores for each subject were expressed as a percentage for each portion 
of the test. Memory for the context (contextual memory) for each subject was obtained by 
subtracting the percentage of freezing in the novel environment from that in the context (Fig. 
14b). 
 
 
 
Figure 14. (a) CFC chamber [ugobasile.it]; (b) schematic representation of contextual fear 
conditioning procedure. Mice were trained and tested on 2 consecutive days. The first day 
mice were placed in the box and submitted to 3 rounds of tone stimulus [conditioned 
stimulus (CS)] co-terminated with unconditioned stimulus (US)](context A, day 1). In the 
first part of the second day mice were placed back to the same box in which training 
occurred without tone or shock presentation (context A, day-2). In the second part of same 
day, mice were placed in a novel environment (context B) and freezing was evaluated in 
response to the tone.  
 
 
11.13 HISTOPATHOLOGICAL ANALYSIS 
 
Brain sections of treated mice with anti-LFA–1 and anti-α–integrins antibodies and 3xTg-
ADxItgal-/- mice were cut at 30µm thickness in coronal portions. Aβ and 
tau/phosphorylated-tau staining required epitope retrieval with 70% formic acid for 20 min 
and 10mM sodium citrate buffer (pH 8.5) preheated to 85°C in water bath, respectively. 
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After epitope retrieval, brain sections were treated with 2% normal goat serum (Vector) and 
0.4% Triton and then incubated with primary antibodies at 1µg/ml in blocking solution 
overnight at 4°C. The primary antibodies used are: for microglial staining the anti-mouse 
Ionized calcium binding adaptor molecule-1 antibody (Iba-1; Wako); for Aβ staining mouse 
anti-Aβ (6E10; Covance); for total tau staining mouse anti-tau HT7 (Thermo Scientific) and 
for total phosphorylated tau staining mouse anti-phospho-tau AT180 and AT8 (Thermo 
Scientific).  After washing with PBS with 0.05% Tween20, we added 3% H2O2 for 10 min at 
RT°C to block endogenous peroxidase. Subsequently, brain slices were washed and 
incubated with a biotinylated secondary antibody at 10µg/ml (goat anti-rabbit for Iba-1 
antibody, Sigma-Aldrich and goat anti-mouse for anti-Aβ 6E10, anti-tau HT7 and mouse 
anti-phospho-tau AT180 antibody) in blocking solution for 2h at RT°C. The 
immunoreactivity was visualized using the VECTASTAIN® ABC kit (Vector) for 30 min 
and Vector® NovaREDTM (Vector) as chromogen for 3 min at RT°C. Finally, brain 
portions were washed with PBS, transferred on glass slides and mounted with Eukitt® 
mounting medium (Sigma-Aldrich). Glass slides were kept at RT°C and acquired by LEICA 
fluorescence microscopy (DM6000B, Leica). 
 
 
11.14 QUANTIFICATION OF MICROGLIA CELLS, AMYLOID LOAD 
AND HYPERPHOSPHORYLATED TAU PROTEIN 
 
The numerical density (nr/µm2) and area of Iba-1 immunoreactive microglia, Aβ plaques 
and hyperphosphorylated tau protein was determined in 4 non-consecutive coronal sections 
throughout the cortex and the dorsal hippocampus of treated 3xTg-AD, 3xTg-ADxItgal-/- 
and age-matched controls. Sections were taken from the anterior hippocampus through the 
bregma −2.9mm at an intersection interval of 500 µm (every fourth section) to analyze the 
whole area of the cortex and the hippocampus. The specific areas analysed were: the parietal 
cortex, the dentate gyrus (DG), the CA1 area of hippocampus and the amygdala (Fig. 15). 
Iba-1 microglia cells were clearly labeled against a light background making them easy to be 
identified with an equal chance of being counted. Microglia cells, Aβ plaques and hyper-
phosphorylated tau protein images were acquired with LEICA fluorescence microscopy 
(DM6000B, Leica) at magnification 20x with a resolution of 1392 x 1040 pixels (449x335 
µm of area) and then counted with a computer-assisted imaging analysis (ImageJ 1.32j) 
software. To ensure consistency and reproducibility, samples were counted blindly. 
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Figure 15. Coronal section of mouse brain, in which the main area investigated with 
immunohistochemistry are indicated: Cortex, CA1, DG and Amydgala.  
 
 
STATISTICS  
 
A two-tailed Mann-Whitney U-test was used for the statistical comparison of two samples. 
Multiple comparisons were carried out with Kruskall-Wallis test with the Bonferroni 
correction of P. For two-photon analysis, non-normally distributed data were presented as 
mean and compared using the Mann-Whitney U-test (two groups) or ANOVA followed by a 
suitable multiple comparison procedure (Dunn’s or Dunnett’s test). 
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12. RESULTS 
 
12.1 EXPRESSION OF VASCULAR ADHESION MOLECULES IN 
3xTg-AD MICE 
 
Adhesion molecules are fundamental mediators of the leukocyte recruitment in sites of 
inflammation. Their expression on the surface of brain endothelium may be induced by pro-
inflammatory cytokines, which can induce endothelial activation and amplification of the 
immune reactions. In the present study, we evaluated the expression of several adhesion 
molecules (ICAM-1, VCAM-1 and E-and P-selectin) by immunofluorescence staining in 
3xTg-AD mice. At 4 months, we did not detect adhesion molecules expression in brain 
vessels except to some rare ICAM-1 positivity in post-capillary venules (data not shown). 
Surprisingly, we found an increased expression of all the adhesion molecules in the limbic 
system (hippocampus and amygdala) at 5-6 months of age in 3xTg-AD mice, compared to 
age-matched controls. Among integrin ligands, ICAM-1 was the most expressed adhesion 
molecule in 3xTg-AD mice. We found high level of expression of ICAM-1 in hippocampal 
blood vessels. Low levels of VCAM-1 expression was also found in the same brain districts. 
Among selectins, E-selectin was found expressed only in hippocampal vessels. We did not 
observe adhesion molecule expression in the brain of age-matched WT littermates (Fig. 16). 
 
 
 
 Figure 16. Expression of adhesion molecules in the brain of 3xTg-AD mice at the 
 early stages of disease.  
Confocal microscopy images show expression of endothelial integrin ligands (ICAM-1 and 
VCAM-1) and selectins (E- and P-selectin) in brain sections of 3xTg-AD mice (top panel)  
at early stages of disease and WT age-matched control mice (bottom panel). High 
expression of E- and P-selectin and moderate expression of ICAM-1 and VCAM-1 was 
found in hippocampal vessels in 3xTg-AD mice (top panel) at early stages of disease 
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compared to WT age-matched control mice (bottom panel). Nuclei are stained with Dapi in 
blue; adhesion molecules are stained with Avidin Texas Red. Scale bar: (a) 30 µm and (b) 
50 µm.  
 
 
12.2 LEUKOCYTE MIGRATION INTO THE BRAIN OF 3xTg-AD 
MICE 
 
The results we described in the previous section suggest that the endothelial expression of 
ICAM-1, VCAM-1 and E- and P- selectin may mediate leukocyte adhesion in brain vessels 
and the subsequent migration of leukocytes in brain parenchyma. We also performed some 
confocal microscopy experiments to investigate the presence of leukocyte populations in 
3xTg-AD mice at 5 and 6 months of age. The inflammatory cells were detected using 
antibodies towards specific antigens expressed on their surface.  
To detect the presence of leukocytes, we used the following antibodies: anti-CD45 as a 
general leukocyte marker and anti-Gr1 for neutrophils. At 4 months, we did not detect any 
inflammatory infiltrates (data not shown). We observed that CD45+ leukocyte infiltration 
constituted principally of Gr1+ cells at 5-6 months of age in 3xTg-AD mice. These results 
are supported by the results obtained by Subramanian S. et al. showing an increase in Gr1+ 
granulocyte population in the brains of 5-6-month-old 3xTg-AD mice (Subramanian S., et 
al., 2010). Migrated leukocytes were localized in pial vessels, choroid plexus and 
hippocampus (Fig. 17). These data suggest that a consistent number of Gr1+ cells can 
migrate into the brain parenchyma at early stages of AD-like pathology. We did not observe 
any Gr1+ cell infiltrating the brain of age-matched WT littermates (data not shown). Of 
note, these results agree with the up-regulation of adhesion molecules on brain endothelium 
in 3xTg-AD mice, which might facilitate tethering, rolling and firm adhesion of neutrophils 
in postcapillary venules. 
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Figure 17. Inflammatory cells infiltrate the brain of 3xTg-AD mice during early 
disease. 
Confocal microscopy images show the presence of CD45+ leukocytes (top panel), and Gr1+ 
cells (bottom panel) localized in (I) the choroid plexus, (II) the hippocampal blood vessels 
and (III) in the pial vessels in brain of 3xTg-AD mice. Scale bar: 20 µm Nuclei of the cells 
were labeled with Dapi in blue; CD45 and Gr1 staining was performed with Avidin Texas 
Red. 
 
 
12.3 FLOW-CYTOMETRY ANALYSIS IN BRAINS OF 3xTg-AD 
MICE  
 
Since the characterization of infiltrates in the mice brain, by histological approach, has the 
limitation of being a qualitative technique, we decided to extract the entire leukocyte 
infiltrating population. Then the leukocytes were immune-phenotyped and analyzed using 
flow cytometry to quantify the composition of the cell infiltrate. We quantified the 
accumulation of leukocytes from the brains of 3xTg-AD mice using flow cytometry. 
To quantify the neutrophils population, CD45+ cells were sub-gated by using CD11b and 
Gr1 double gate allow the identification of three different populations: CD11b-/Gr1- cells 
(not shown), CD11b+/Gr1- cells (not shown) and CD11b+/Gr1+ cells (presumably 
granulocytes). For a more specific neutrophil labelling, Gr1 and Ly6G sub-gate was also 
performed during the analysis. The results showed that the number of  
CD45 CD45
Gr1 Gr1
I II
IIIII
- 63 - 
 
infiltrating neutrophils peaked in the early phases of the disease at 6 months of age in the 
3xTg-AD mice and then gradually descended in the subsequent months (Fig. 18). No 
neutrophils were detected in the brains of the healthy controls (data not shown). Taken 
together these data suggest that neutrophils migrate into the brain at the early stage of the 
disease and continue to accumulate also during later phases of disease, suggesting they may 
play a role in chronic disease evolution. 
Surprisingly we found also a high numbers of T cells infiltrating the brain of AD-like 
disease mice during all the progression of disease. T cell subsets showed different 
accumulation profiles during the progression of the disease. CD4+ T cells gradually 
increased showing a peak of accumulation during later phases of disease (Fig. 18). On the 
contrary, CD8+ T cells infiltrated the brain in the early phases of the disease with a wide 
peak of infiltration at 6-9 months of age and then gradually decreased during later stages of 
the disease (Fig. 18). WT age matched control mice did not show accumulation of 
infiltrating leukocyte in their brain (data not shown).  
Taken together these data show that different leukocyte subtypes migrate into the brain of 
3xTg-AD mice at different time-points of disease, suggesting that neutrophils and T cells 
may play different roles in disease evolution. 
 
 
 
 
Figure 18. Leukocyte accumulation in 3xTg-AD mice during different time-points of 
disease.  
Flow-cytometry quantitative analysis of leukocytes accumulated in the brain of 3xTg-AD 
mice at different months of age (6-9-12-15 months). 8-10 animals/group of same age were 
analysed. Error bars represent SEM. 
 
 
12.4 CHARACTERIZATION OF Aβ-INDUCED ADHESION IN 
NEUTROPHILS 
 
The results shown above suggest that the high expression of vascular adhesion molecules is 
associated with the presence of infiltrating leukocytes in the brain of 3xTg-AD mice at 
different months of age. To fully understand the mechanisms responsible for the neutrophil 
migration in the brain, we studied the effect of Aβ1-42 peptide on LFA-1 integrin-dependent 
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rapid adhesion assays. We prepared in vitro oligomeric and fibrillar Aβ1-42, characteristic 
of early and late-time points of disease respectively, to stimulate neutrophil adhesion in in 
vitro.  
 
12.4.1 Aβ PREPARATION 
 
Oligomeric and fibrillar Aβ were prepared as described in the Materials and Methods 
section. The preparations were run on native gel to verify the correct formation of Aβ. The 
native gel has revealed a progressive decrease of monomers, the formation of larger 
oligomers and a small quantity of insoluble aggregates that did not migrate from the well, 
presumably fibrillar Aβ (Fig. 19). The reverse Aβ peptide Aβ42-1 was used as negative 
control (data not shown). 
 
 
 
Figure 19. Representative Western blot of oligomeric and fibrillar preparations of Aβ 
(1–42).  
Fibrillar (line1) and oligomeric (line 2) preparations of Aβ (1-42) were separated on 12% 
bis-Tris NuPAGE gel and probed with monoclonal antibody clone BAM-10 (recognizing 
residues 1-12 of Aβ). Relative molecular masses (Mr x 1000) are shown on the left side of 
gel lines. 
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12.4.2 Aβ INDUCES RAPID LFA-1 INTEGRIN DEPENDENT 
ADHESION  
 
Neutrophils were extracted from bone-marrow as described in the Materials and Methods 
section. We have investigated the effect of Aβ1–42 on neutrophil LFA-1 integrin-dependent 
rapid adhesion (Fig. 20a). The results demonstrated that Aβ1–42 triggered a rapid 
neutrophils adhesion to ICAM-1 in a dose-dependent manner (Fig. 20b). In addition, our 
data showed that soluble the Aβ oligomer is a more effective trigger for the neutrophil 
integrin-dependent rapid adhesion if compared to fibrillary Aβ (Fig. 20c). The maximum 
effect was observed with a dose of 20 µM oligomeric Aβ. fMLP was used as positive control 
at the dosage 0.1 µM. The reverse Aβ peptide Aβ42-1 did not have any significant effect on 
LFA-1 dependent neutrophil adhesion (data not shown). Interestingly, one of the receptors 
for Aβ is a formyl-peptide chemotactic receptor (FPR) (Iribarren P., et al., 2005). To 
evaluate the contribution of this receptor on neutrophil adhesion, we inhibited its function 
using boc-MLF, i.e. an FPR antagonist. Our results clearly showed that LFA-1-dependent 
adhesion of neutrophils to ICAM-1 with both fMLP and Aβ1–42 was strongly blocked by 
the pre-treatment of the cells with boc-MLF (Fig. 21a). To exclude the possibility that the 
rapid integrin triggering was a consequence of a generic plasma membrane alteration due to 
the lipofilic nature of Aβ, we evaluated rapid adhesion in lymphocytes. These cells are 
known because of their lack of fMLP receptors and because they did not adhere to integrin 
ligands in the presence of Aβ (data not shown). In addition, to check whether GPCRs are 
responsible for Aβ-induced neutrophil adhesion, we treated the neutrophils with pertussin 
toxin (PTx) before performing the adhesion assays. The PTx, produced by Bordella 
pertussis, inhibits the α subunit of GPCRs and it is commonly used to investigate the 
involvement of GPCRs in biological assays. Our results demonstrated that neutrophil 
adhesion on ICAM-1 was abrogated by the pre-incubation of cells with PTx suggesting that 
both fMLP and Aβ1–42 stimulated adhesion is mediated by Gαi-coupled receptors (Fig. 
21b).  
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Figure 20. Oligomeric and fibrillar Aβ1-42 induce rapid neutrophil adhesion to ICAM-
1. (a) Representative image of eighteen-well glass slides coated with human ICAM-1 as 
described in Materials and Methods. Samples were spotted in triplicate. (b) We coated 18-
well glass slides with human ICAM-1 and mouse neutrophils were incubated for 2 min in 
buffer (Ctrl) or the stated concentrations of oligomeric Aβ (Aβ1-42). We used 1 µM fMLP 
as a positive control (fMLP). (c) Fibrillar Aβ1-42 (Fib Aβ) efficiently triggered the rapid 
adhesion of human neutrophils, but the oligomeric soluble form Aβ1-42 (sol Aβ) was twice 
as effective. Values represent mean counts of bound cells in a 0.2-mm2 field in one 
representative experiment from a series of three independent experiments with similar 
results. Bars represent means ± SEM. (*P <0.05; **P <0.005 ***P <0.0005). 
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Figure 21. Rapid neutrophil adhesion to ICAM-1 triggered by Aβ is inhibited by 
bocMLF and PTx.  
Eighteen-well glass slides were coated with human ICAM-1 as described in Materials and 
Methods. Human neutrophils were incubated for 2 minutes with buffer (Blank) or with 
oligomeric soluble Aβ1-42 (Aβ). 0,1 µM fMLP was used as a positive control (fMLP). 
Values are expressed as the mean counts of bound cells in 0.2mm2 from three independent 
experiments in duplicate. Bars represent means ± SEM. (a) bocMLF inhibitor of FPR 
receptor and (b) PTx significantly inhibited neutrophil adhesion. (***P <0.0005). 
 
 
12.4.3 Aβ1-42 OLIGOMERS TRIGGER LFA-1 INTEGRIN HIGH 
AFFINITY STATE IN HUMAN NEUTROPHILS 
 
In vitro and in vivo studies have established that the leukocyte arrest is rapidly triggered by 
chemokines or other chemoattractants and is mediated by the binding of leukocyte integrins 
to immunoglobulin superfamily members, such as ICAM-1 and VCAM-1, expressed by 
endothelial cells (Ley K., et al., 2007). LFA-1 is one of the most relevant integrin involved 
with the neutrophil arrest, and classical chemoattractants and chemokines are the most 
powerful physiological activators of LFA-1–mediated adhesion in vivo. Ligation of specific 
heterotrimeric GPCRs through chemokines activates integrins by triggering a complex 
intracellular signaling network leading to the increase of both integrin affinity and valency. 
Inside-out signaling induces integrins to undergo a dramatic transition from a bent low- 
affinity conformation to extended intermediate- and high-affinity conformations, which lead 
to opening of the ligand-binding pocket (as described in paragraph 8.2) (Ley K., et al., 
2007). We hypothesized that Aβ may trigger intermediate and high affinity state of LFA-1 
integrin. So, we decided to investigate the effect of Aβ1-42 oligomers on human LFA-1 
integrin using KIM127 and 327A conformer-specific antibodies for intermediate- and high- 
affinity state respectively. The data we obtained clearly confirmed the ability of Aβ1-42, but 
not scramble Aβ42-1 peptide, to trigger LFA-1 conformation to an intermediate- and high- 
affinity state (Fig. 22), demonstrating that Aβ enhances the propensity of LFA-1 integrin to 
bind its endothelial ligands and explaining the surprising capacity of neutrophils to perform 
arrest in areas with Aβ deposition in vivo. 
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Figure 22. Soluble oligomeric Aβ1-42 trigger LFA-1 high affinity state in human 
neutrophils.  
LFA-1 affinity states were detected with KIM127 mAb detecting low-intermediate affinity 
state or 327A mAb detecting high affinity state as described in Materials and Methods. 
Values represent geometric mean of fluorescence intensities measured by flow cytometry, 
normalized against the untreated control (Ctrl) condition for each experiment. Bars represent 
means ± SEM for three independent experiments. (*P <0.05; ***P <0.0005). 
 
 
12.5 LFA-1 INTEGRIN IS FUNDAMENTAL FOR NEUTROPHIL 
INFILTRATION IN BRAIN PARENCHYMA 
 
Neutrophil adhesion is largely mediated by β2-integrins and its extravasation is LFA-1– 
dependent (Ding Z.M., et al., 1999). Recently other authors have elegantly demonstrated, by 
TPM studies, that LFA-1 is the unique β2-integrins mediating the adhesion step of the 
leukocyte recruitment cascade (Phillipson M., et al., 2006). Therefore, we thought it would 
be significant to assess whether the ablation of LFA-1 integrin on neutrophils or the 
blockage of the molecule with an antibody prevented the cells to interact with blood vessels 
and to enter the brain parenchyma. 
Our TPM video clearly demonstrated the success of this approach. Indeed, LFA-1 deficient 
neutrophils (Itgal-/-) did not crawl/adhere on blood vessels (Fig. 23a) and did not accumulate 
in brain parenchyma (Fig. 23b) in 4 months old 5xFAD mice. Moreover, we demonstrated 
that LFA-1–blocking antibody interfere with the movement of already extravasated cells 
(Fig. 23c) and prevented further parenchyma invasion by neutrophils. After the injection of 
LFA-1 blocking antibody, neutrophil velocities were significantly slowed down as well as 
meandering index and motility coefficient (Fig. 23d), indicating a prominent role of LFA-1 
integrin in neutrophil movement in brain parenchyma. 
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Figure 23. LFA-1 integrin is fundamental for neutrophil infiltration in brain 
parenchyma. 
Blockade of integrin LFA-1 in TPM experiments lead to a diminished entrance and brain 
parenchyma accumulation, in 4 months old 5xFAD mice. Injection of 1:1 mixture of 
differentially labeled neutrophils isolated from bone marrow of WT and LFA1-deficient 
mice (Itgal-/-). Blood cortical vessels are labeled in green, using 525-nm non-targeted Qdots, 
injection before image acquisition. (a) WT neutrophils (blue cells) invade brain parenchyma 
of 5xFAD mice, on the contrary Itgal-/- neutrophils (red cells) do not interact with brain 
vessels and are not able to infiltrate. Image from one representative experiment is shown, 
scale bar: 50 µm. (b) Quantification of neutrophil numbers with time during image 
acquisition clearly shows that Itgal-/- neutrophils are unable to infiltrate brain parenchyma. 
Neutrophils isolated from bone marrow of WT control mice, were labeled and injected in 
5xFAD mice. 24 hours after cell injection images were acquired. 200 µg of mAb anti-LFA1 
were injected into tail vein and images were acquired immediately; (c) images from one 
representative experiment are shown, scale bar: 30 µm. (d) Analysis of cell migration 
obtained with IMARIS software shows a significant difference in neutrophil movement after 
antibody injection, (***P <0.0005). 
 
 
12.6 LFA-1 BLOCKADE RESCUES BEHAVIORAL IMPAIRMENT IN 
3xTg-AD MICE AT EARLY STAGES OF DISEASE 
 
Based on our TPM findings, showing that the in vivo blockade of LFA-1-mediated adhesion 
interferes with the neutrophil migration in the brain parenchyma, we asked whether the 
mouse treatment with LFA-1 blocking antibody might have benefit on AD pathology. 
Therefore, we decided to evaluate the effect of the blockade of LFA-1 integrin by treating 
3xTg-AD mice with an anti-LFA1–1 integrin-specific mAb and to study the effect of LFA-1 
genetic deficiency on AD-like disease. Then, we treated the 3xTg-AD mice with an anti-
LFA1–1 antibody starting at 6 months of age. At the first day, the mice were injected i.p. 
with 500 µg of LFA-1 integrin-specific mAb (TIB213) and the treatment continued with 300 
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µg of antibody every other day, for 4 weeks. At the end of the treatment mice were left 
untouched for 4 weeks before performing the behavioral tests. This aspect allows 
minimizing the stress and fear induced in mice due to the frequent manipulation by 
experimenter that could eventually influence the results in behavioral tests. Finally, mice 
were tested for behavioral assessments, as described Materials and Methods section and in 
Fig. 12. Our results showed that the blockade of integrin LFA-1 at early stages of AD-like 
pathology inhibited the cognitive impairment as shown by the data obtained in the Y-maze 
(Fig. 24a) and CFC test (Fig. 24b). In fact, the treatment with anti-LFA1–1 antibody at early 
time-points of disease allowed the restoration of the memory impairment almost to WT 
situation in control mice (Fig. 24). Collectively, these experiments clearly showed that an 
intervention, designed to block the neutrophils recruitment in the brain of 3xTg-AD mice, at 
early time-points of the disease, allowed the recovery of the cognitive impairment and has 
neuroprotective effects. 
 
 
 
Figure 24. Anti-LFA–1 mAb inhibits cognitive deficits in behavioral tests.  
LFA-1 integrin blockade was performed by treating mice with anti-LFA–1 antibody (Anti-
LFA-1) for 4 weeks starting at 6 months of age in 3xTg-AD mice, as described in Materials 
and Methods and in Fig. 12. Control treatment was performed with an isotype control 
antibody (Isotype). WT age-matched control mice were treated with endotoxin-free PBS 
(WT ctrl). Mice were tested in behavioral paradigms after one month of treatment, to avoid 
possible variable-like stress, generating by mouse handling. (a) histogram shows the percent 
alternation performance in the Y-maze test in 3xTg-AD mice treated with anti-LFA–1 or 
isotype control antibodies. (b) histogram shows freezing response in 3xTg-AD mice treated 
with anti-LFA1–1 or isotype control antibodies. Values represent mean ± SEM of the data 
obtained from a representative experiment with 10-12 mice/group. (**P <0.005; ***P 
<0.0005). 
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12.7 THE LONG-TERM EFFECT OF LFA-1 BLOCKADE ON 
COGNITIVE FUNCTIONS IN 3xTg-AD MICE 
 
3xTg-AD mice were treated with an anti-LFA–1 antibody at 6 months of age for 4 weeks. 
Control treatment was performed with an isotype control antibody, anti-RAS antibody. 
C57BL/6 mice were used as WT control mice. These mice were tested in behavioral 
paradigms 6 months after treatment termination, at 11-12 months of age, to assess if the 
restoration of the cognitive function was completely maintained also at later time points of 
disease. Surprisingly, we found that the temporarily blockade of LFA-1 integrin, during the 
early stages of the disease (6 months of age) improved the cognitive functions in 3xTg-AD 
mice at later time-points (11-12 months of age), as shown by the results obtained from the 
CFC test (Fig. 25).  
 
 
Figure 25.  The early LFA-1 integrin blockade has long-term benefits.  
 LFA-1 integrin blockade was performed by treating mice with anti-LFA–1 antibody (Anti-
LFA-1) for 4 weeks starting at 6 months of age in 3xTg-AD mice, as described in Materials 
and Methods and in Fig. 12. Control treatment was performed with an isotype control 
antibody (Isotype) . WT age-matched control mice were treated with endotoxin-free PBS 
(WT ctrl). Mice were tested in behavioral paradigms 6 months after treatment termination, at 
11-12 months of age. The histogram shows freezing response in 3xTg-AD mice treated with 
anti-LFA1–1 or isotype control antibodies. Values represent mean ± SEM of the data 
obtained from a representative experiment with 10-12 mice/group. (*P <0.05; ***P 
<0.0005). 
 
12.8 THE BLOCKADE OF LFA-1 INTEGRIN REDUCES 
MICROGLIAL ACTIVATION 
 
Furthermore, significant reduction in the density of microglia Iba-1 positive cells, was 
detected in the CA1 and DG area of hippocampus in LFA-1–treated compared with isotype 
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control treated mice (Fig. 26a-b). Microglia cells showed different morphologies, indicating 
that modifications occurred in their activation state. Indeed, isotype control treated mice 
showed microglia with larger cell soma, suggesting an activated phenotype. Also, retraction 
and thickening of the processes is typical of highly activated microglia while, most of 
microglial cells in LFA-1–treated mice showed a small roundish soma and long processes, 
corresponding to a non-activated or intermediately activated cells (Figure 26c-d). Taken 
together, these results demonstrated a role for neutrophils in inflammatory brain activation 
and behavioral impairments in AD-like disease, suggesting that inhibition of neutrophil 
trafficking may represent a new therapeutic approach in AD. 
 
 
Figure 26.  Blockade of LFA-1 integrin affects microglial cell activation in 3xTg-AD 
mice.  
At the end of behavioral tests, mice were sacrificed for neuropathological analyses as 
described in Materials and Methods and Figure 12. Bar graph showing the density 
(nr/0.4x0.3mm2) and area (Pixel2 /0.4x0.3mm2) of microglia cells in (a-b) the CA1 and (c-d) 
in DG of isotype control-treated (Isotype) compared to anti-LFA–1–treated 3xTg-AD mice 
(Anti-LFA-1). Bar is expressed as mean ± SEM (**P <0.005; ***P <0.0005). 
Representative images of Iba-1 microglia in (b) CA1 and (d) in DG: isotype control-treated 
3xTg-AD mice show highly activated amoeboid cell morphology with large bodies and 
several cellular processes, 3xTg-AD mice treated with anti-LFA-1 antibody show a less 
activated microglia phenotype. Scale bars, 10 µm in c,d left panels. Higher magnifications 
are shown in the right panels; scale bars, 25 µm. 
 
 
 
- 73 - 
 
12.9 GENERATION OF 3xTg-ADxItgal-/- MOUSE MODEL OF AD 
 
In the present project, we also generated a 3xTg-ADxItgal-/- AD animal model to investigate 
the effect of the LFA-1 genetic deficiency on the development of AD-like disease in 3xTg-
AD mice. To this aim, we have crossed 3xTg-AD and Itgal-/- mice. The colony of 
homozygous 3xTg-ADxItgal-/- was produced in two steps. In the first step, we obtained 
hemizygous 3xTg-ADxItgal-/- mice. In the second step, we cross-breaded heterozygous 
3xTg-ADxItgal-/- to obtain homozygous mice for all transgenes. DNA was extracted from 
mouse’s tail and we next performed PCR to evaluate the insertion of APP and PSEN1 and 
the deletion of LFA-1 transgenes as described in the Materials and Methods section. The 
insertion of APP transgene was evaluated by conventional PCR using primers (forward and 
reverse) annealing inside the APP transgene sequence. The deletion of LFA-1 gene was 
obtained using a targeting vector containing neomycin resistance gene used to disrupt the 
region containing exons 1 and 2 of LFA-1 gene. Therefore, we performed two conventional 
PCR: one was aimed at amplifying the WT LFA-1 gene and the other was aimed at 
amplifying the neomycin resistance gene. In homozygous WT control mice, we amplified 
only the WT LFA-1 gene, whereas in homozygous mutant mice we amplified only the 
construct. In hemizygous mice were present WT and mutant sequence of the LFA-1-/- 
transgene. We amplified a sequence outside the PSEN1 transgene insertion site (Fig. 27a). 
The sequence of PSEN1 transgene contains a specific cleavage site for BstE II restriction 
enzyme (Fig. 27b). Therefore, we performed an enzymatic digestion on PCR product to 
reveal the insertion of the PSEN1 transgene as described in the Materials and Methods. This 
digestion allowed us to identify not only the insertion of PSEN1 transgene, but also if the 
PSEN1 transgene is in the homozygous or heterozygous condition. The homozygous 
condition represents the incorporation of PSEN1 transgene in both alleles. The cleavage of 
BstE II produces respectively two fragments of 350 bp and 180 bp (Fig. 27b). We obtained 
only a band of 530 bp because the site of cleavage (within PSEN1 transgene) is not present 
and BstEII does not cut it (Fig 27c). Three bands were normally obtained in hemizygous 
situation: one of 530 bp corresponding to the WT allele and two bands of 350 bp and 180 bp 
respectively, deriving from the 3xTg-AD homozygote allele in which PSEN1 transgene 
PCR product is enzymatically cleaved (Fig. 27c). PCR products and restriction enzyme 
digestions were visualized by Nancy after run in 1% agarose gel as described in Materials 
and Methods (Fig. 28). We used C57BL/6J mice as negative control, as they do not carry the 
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transgenes (data not shown). 3xTg-AD and Itgal-/- mice were used as positive controls (Fig. 
28). 
 
 
 
Figure 27. Schematic representation of sequence of PSEN1 transgene and enzymatic 
digestion procedure.  
(a) figure a represents the amplified sequence with the PSEN1 transgene inserted within; (b) 
figure b represents the cleavage site of the restriction enzyme (BstE II) with two fragments 
generated of 350 bp and 180 bp respectively; (c) figure c represents the three possible results 
from enzymatic digestion of PCR product. The WT condition (left) has two sequences 
without the insertion of the PSEN1 transgene (line blue). In the homozygous condition 
(central) both sequences contain the PSEN1 transgene (line red). In the hemizygous 
condition (right) one sequence contains the insertion of the PSEN1 transgene (line red) 
whereas the other does not (line blue). 
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Figure 28. Agarose gel electrophoresis of amplified PCR fragments. 
Representative images of agarose gels show PCR products of (a) APP and (b) Itgal-/-
 transgenes. (c) Figure in c shows the restriction reaction of PSEN1 PCR products. 
 First line in all images designates marker. (a) samples 2 and 3 produce only the band of 294 
bp (APP ctrl); sample 1 produces both bands of 307 bp (APP) and 294 bp (APP ctrl), 
therefore it is assessed as positive for APP transgene insertion. (b) sample 1 produces only 
the band of 500 bp and it is assessed as homozygous for Itgal-/-; samples 2 and 3 produce 
both bands of 500 bp and 151 bp and they are assessed as hemizygous for Itgal-/- mice. (c) 
sample 1 produces both bands of 350 bp and 180 bp and it is assessed as homozygous for 
PSEN1 transgene; samples 2, 3 and 4 produce all three bands of 500 bp, 350bp and 151 bp 
and they are assessed as hemizygous for PSEN1 transgene.  
 
 
12.10 LFA-1 DEFICIENCY IN 3xTg-AD MICE RESTORES 
COGNITIVE FUNCTIONS AT EARLY STAGES OF DISEASE 
 
Billings L.M., et al. previously reported that the onset of the disturbances in 3xTg-AD mice 
start at 6-9 months of age and correlates with the accumulation of intraneuronal Aβ in the 
cortex and hippocampus. Aβ plaques and hyper-phosphorylated tau are not apparent at this 
age, suggesting that they contribute to cognitive dysfunction at later time points (Billings 
L.M., et al., 2005). Initially, we assessed 3xTg-ADxItgal-/-, 3xTg-AD and WT age-matched 
control mice in behavioral paradigms at 9 months of age (Fig. 29). As expected, in Y-maze 
(Fig. 29a) and CFC (Fig. 29b) tests, 3xTg-ADxItgal-/- did not perform significantly worse 
when compared with WT age-matched control mice. As expected, a significantly decreased 
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alternation in Y-maze task was detectable in 3xTg-AD mice compared with WT age-
matched control mice. Interestingly, 3xTg-ADxItgal-/- mice did not show cognitive 
impairment and mice performed at comparable levels of WT age-matched control mice (Fig. 
29a). In CFC test, WT age-matched control mice exhibited a robust freezing in response to 
the sound tone (Fig. 29b). In contrast, 3xTg-AD mice were significantly impaired. In fact, 
they were no longer able to associate the sound to the electric foot shock they received 
during the conditioning phase. Interestingly, the genetic deletion of the integrin LFA-1 in 
3xTg-AD mice rescued memory impairment, indeed 3xTg-ADxItgal-/- mice spend 
significantly more time freezing than age-matched 3xTg-AD littermates (Fig. 29b).  
 
 
Figure 29. LFA-1 deficiency in 3xTg-AD mice induces normal cognitive performance 
in behavioral tests.  
3xTg-AD, 3xTg-ADxItgal-/- and WT control mice were tested in the Y-maze and CFC tests 
at 9 months of age. (a) histogram shows the of spontaneous alternation performance in the 
Y-maze test; (b) histogram shows a comparable freezing response between 3xTg-ADxItgal-/- 
and WT age-matched control mice compared to 3xTg-AD mice. Data derived from one 
representative experiment with 8-12 mice per condition. Values represent mean ± SEM in 
each group (*P < 0.05; **P < 0.005).  
 
 
12.11 LFA-1 DEFICIENCY IN 3xTg-AD MICE RESTORES 
COGNITION AT LATE STAGES OF AD 
 
Next we explored the cognitive performance of 3xTg-ADxItgal-/- mice at 12 months of age, 
to verify whether the amelioration in cognitive impairment obtained at 9 months of age was 
also maintained at later time-points. As expected, 3xTg-ADxItgal-/- mice performed at 
comparable levels than WT control mice at 12 months of age in Y-maze (Fig. 30a) and CFC 
(Fig. 30b) tests. These experiments clearly confirmed the beneficial effect of LFA-1 integrin 
ablation on behavioral impairment on AD-like pathology. Therefore, we speculate that the 
0
20
40
60
80
*
*
3x
Tg
-
AD
 
x It
ga
l -
/-
3x
Tg
-
AD
 
WT
 
Ctr
l
%
 
o
f A
lte
rn
a
tio
n
0
20
40
60
80
**
*
3x
Tg
-
AD
 
x It
ga
l -
/-
3x
Tg
-
AD
 
WT
 
Ctr
l
%
 
o
f  F
re
e
zi
n
g
a b
- 77 - 
 
inhibition of neutrophil trafficking through the ablation of LFA-1 integrin was contributing 
to the cognitive function re-established in 3xTg-ADxItgal-/- mice. 
 
 
Figure 30. LFA-1 deficiency in 3xTg-AD mice has long-term beneficial effects in 
behavioral tests.  
3xTg-AD, 3xTg-ADxItgal-/- and WT age-matched control mice were tested in the Y-maze 
and CFC tests at 12 months of age. (a) histogram shows the of spontaneous alternation 
performance in the Y-maze test; (b) histogram shows a comparable freezing response 
between 3xTg-ADxItgal-/- and WT age-matched control mice compared to 3xTg-AD mice. 
Data derived from one representative experiment with 8-12 mice per condition. Values 
represent mean ± SEM in each group (*P < 0.05; **P < 0.005). 
 
 
12.12 EFFECT OF LFA-1 DEFICIENCY ON NEUROPATHOLOGICAL 
CHANGES IN 3xTg-AD MICE 
 
In the present study, we quantified through immunohistochemistry analysis the presence of 
Aβ deposition, tau hyper-phosphorylation and microglial activation in different brain areas 
such as hippocampus and cortex of 3xTg-ADxItgal-/- mice compared to age and sex-
matched 3xTg-AD mice. C57BL/6 mice were used as control mice. Mice were sacrificed 
after behavioral assessment at 9, 12 and 20 months of age, and histological analysis was 
performed as described in Materials and Methods.  
 
 
12.12.1 Aβ DEPOSITION 
 
At 12-13 months of age only the intracellular presence of Aβ deposits were evident in 3xTg-
AD mice, while extracellular deposition has not been detected, confirming a study reporting 
that the extracellular deposition begins to be apparent at ages later than 15 months 
(Mastrangelo et al., 2008). We documented a reduction of Aβ deposition in 3xTg-ADxItgal-
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/-
 mice compared to 3xTg-AD mice in the cortical area (Fig. 31). The Aβ deposition 
highlighted by 6E10 staining in the cortex did not appreciable in 3xTg-ADxItgal-/- mice, 
whereas age-matched 3xTg-AD mice showed a marked intracellular expression of Aβ in the 
same examined areas (Fig. 31). We performed a quantitative stereological analysis to 
determine the total area occupied by Aβ-positive neurons (pixel2/total examined area). As it 
can be appreciated from the graphs, 3xTg-ADxItgal-/- mice showed a reduction of Aβ 
deposition in cortical area (Fig. 31a). In fact, the values of both density and area occupied by 
Aβ-positive neurons reached a significant difference when compared to age and sex-
matched 3xTg-AD mice. These data confirmed our hypothesis and agree with data 
previously obtained in 3xTg-AD mice treated with LFA-1 blocking antibody, showing a 
decreased deposition of Aβ in cortical neurons. The absence of the integrin LFA-1 in these 
mice might prevented neutrophil infiltration into the brain thus reversing Aβ deposition. 
 
Figure 31. LFA-1 deficiency in 3xTg-AD ameliorates Aβ pathology. 
(a) Unbiased quantitative analysis was performed in the cortex to quantify the area (left 
panel) and the density (right panel) of Aβ containing cells. Bar is expressed as mean ± SEM 
(**P <0.005). (b) Representative images of Aβ load in the cortex of (left) 3xTg-AD and 
(right) 3xTg-ADxItgal-/-. Scale bar: 50 µm. 
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12.12.2 TAU PROTEIN EXPRESSION  
 
Since it has been shown that the abnormal morphologic entity in AD brains known as the 
neurofibrillary tangle is comprised primarily of tau, it has been proposed that abnormalities 
of tau, directly or indirectly, play a central role in the pathogenesis of AD by progressively 
leading to a loss of fast axonal transport (Mastrangelo et al., 2008). Oddo S., et al. have 
previously shown that numerous phospho-tau epitopes are immunohistochemically 
detectable in the hippocampus and cerebral cortex of 3xTg-AD mice (Oddo S., et al., 2003). 
To determine the effect of LFA-1 ablation on tau pathology we performed 
immunohistochemical staining for tau protein in 3xTg-AD mice compared to 3xTg-
ADxItgal-/- mice. 
We used the HT7 antibody to detect total tau expression. We did not detect any significant 
difference in total tau level in examined hippocampus (CA1 and DG) and cortical areas in 
3xTg-ADxItgal-/- compared to 3xTg-AD mice at 12 months of age (Fig. 32).  
  
 
 
Figure 32.  LFA-1 deficiency in 3xTg-AD mice does not affect total tau expression at 12 
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months of age.  
Human tau detection was performed with HT7 antibody. Unbiased quantitative analysis was 
carried out on the brains of 3xTg-AD and 3xTg-ADxItgal-/- mice to quantify the area 
occupied in the (a) CA1 (c, left) DG and (e, left) cortex and the density in the (c, right) DG 
and (e, right) cortex of human tau positive cells. Bar is expressed as mean ± SEM. 
Immunohistochemical staining of total tau in the (a) CA1 (d) DG and (f) cortex are 
illustrated at 12 months of age. Scale bar: 50 µm.   
 
The comparable levels of expression of total tau in 3xTg-ADxItgal-/- mice allowed us to 
further evaluate the expression of phospho-tau epitopes. Thus, we performed the 
immunohistochemical staining for AT180 and AT8 phospho-tau epitope in 3xTg-AD and 
3xTg-ADxItgal-/- mice at 12 and 20 months of age, respectively.  
We used AT180, an antibody which binds the protein tau at residue Thr231 and AT8, an 
antibody which binds the protein tau at residue Ser202/Thr205. 3xTg-AD mice showed tau 
hyperphosphorylation in the CA1 region of hippocampus, whereas 3xTg-ADxItgal-/- mice 
showed a significant reduction of tau phosphorylation in the same brain area at 12 months of 
age (Fig. 33a-b). The phosphorylation of tau was only detectable in the CA1 region of the 
hippocampus at 11-12 months of age in 3xTg-AD mice with the AT180 antibody, therefore 
we could not perform any evaluation of tau phosphorylation in cortical regions. In addition, 
the AT8 positivity was detectable at 20 months of age in hippocampus CA1 field in 3xTg-
AD mice compared 3xTg-ADxItgal-/- mice (Fig. 33c-d). Oddo S., et al. reported that AT8 
immunoreactivity could be observed at approximately 12 months of age (Oddo S., et al., 
2003). However, we were not able to detect AT8 expression in 3xTg-ADxItgal-/- and 3xTg-
AD mice until 20 months of age. These observations agree with what was reported by others 
showing that AT180-positive cells were not detectable until 26 months in cortical regions of 
3xTg-AD mice (Mastrangelo et al., 2008). 
These data clearly demonstrated a decreased phosphorylation of the protein tau in 3xTg-
ADxItgal-/- mice when compared with 3xTg-AD mice, probably leading to a reduced tangle 
formation. 
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Figure 33. LFA-1 deficiency in 3xTg-AD induces a decreased phosphorylation of tau at 
20 months of age.   
(a) Bar graphs showing the area of AT180 positive cells in the CA1 of 3xTg-AD and 3xTg-
ADxItgal-/- mice. (b) Representative images clearly show a lack of AT180 expression in the 
3xTg-ADxItgal-/- mice compared to 3xTg-AD mice in the CA1 area of hippocampus at 12 
months of age. (c) Bar graphs showing the area of AT8 positive cells in the CA1 area of 
hippocampus of 3xTg-AD and 3xTg-ADxItgal-/-. (d) Representative images clearly show a 
lack of AT8 expression in the 3xTg-ADxItgal-/- mice compared to 3xTg-AD mice at 20 
months of age. Bar is expressed as mean ± SEM (**P <0.005). Scale bar: 50 µm. 
 
 
12.12.3 MICROGLIA ACTIVATION 
 
Microglial cells play an important role in AD pathology as they appear to be activated in the 
brain of both AD patients and AD-like disease mice (El Khoury et al., 2007; Hickman S.E., 
et al., 2008; Krabbe G., et al., 2013; Zenaro E., et al., 2015). Therefore, we assessed their 
activation status in our 3xTg-ADxItgal-/- mice compared to age and sex-matched 3xTg-AD 
mice. We revealed the microglia phenotype by staining the cells with an antibody against the 
protein Iba-1, a specific marker expressed both on resident as well as monocyte-derived 
microglia. Stainings were performed as described in the Materials and Methods. Our data 
showed that neutrophil depletion or the inhibition of neutrophil trafficking by blocking 
LFA-1 dramatically reduces microglial activation, suggesting that neutrophils play a role in 
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the microglial pathophysiology during AD (Zenaro E., et al., 2015). In the present study, we 
found a significant reduction in the area occupied by microglial cells in hippocampus CA1 
field and DG in 3xTg-ADxItgal-/- compared with 3xTg-AD mice at 12 months of age (Fig.  
34). Of note, 3xTg-ADxItgal-/- mice showed many resting microglial cells with a non-
activated phenotype compared to activated microglia with enlarged cell bodies and thick 
processes present in 3xTg-AD mice of the same age. Indeed, 3xTg-AD mice showed larger 
microglia cells soma and retraction and thickening of processes typical of highly activated 
microglia, on the contrary most the microglial cells in 3xTg-ADxItgal-/- mice showed a 
small roundish soma and long processes, corresponding to non-activated cells. The 
morphological differences clearly indicate changes in the activation state of microglia in the 
two experimental conditions. Interestingly, microglia phenotype in 3xTg-ADxItgal-/- mice 
closely resembled the one of age-matched control mice (data not shown). Therefore, LFA-1 
ablation in 3xTg-AD mice prevented the interconnectivity between neutrophils and 
microglial cells in the brain by reducing several feedback loops between these two 
phagocytes that amplify and sustain their activation.  
 
 
 
 
 
Figure 34. Microglial cell density, area and morphology diversity in 3xTg-ADxItgal-/- 
and 3xTg-AD at 12 months of age.  
Quantitative analysis was carried out on the brains of 3xTg-AD and 3xTg-ADxItgal-/- mice 
to quantify microglia density and area occupied by cell soma in (a) CA1 and (b) DG area of 
ippocampus. Bar is expressed as mean ± SEM (*P <0.05; ***P <0.0005). Representative 
images of Iba-1 microglia (c) in CA1 and (d) in DG: 3xTg-AD mice show highly activated 
cell morphology with large bodies and several cellular processes, whereas 3xTg-AD mice 
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lacking the integrin LFA-1 show a less activated microglia phenotype. Scale bars, 10 µm in 
c and d panels. Higher magnifications are shown in the right panels; scale bars, 25 µm. 
 
Overall our results demonstrated a role of LFA-1 integrin in neutrophil trafficking in the 
induction of behavioral impairment, Aβ deposition, tau phosphorylation and inflammatory 
brain activation in 3xTg-AD mice, suggesting that inhibition of LFA-1 integrin function 
may represent a new therapeutic approach in AD. 
 
 
12.13 EFFECT OF ALPHA-4 INTEGRINS BLOCKADE IN 3xTg-AD 
MICE  
 
Anti-α4 integrins antibodies have been used to block the integrin-mediated leukocytes 
migration to inflammatory sites and the homing to lymphoid tissues (Issekutz T.B. & 
Wykretowicz A., 1991; Issekutz and Wykretowicz, 1991; Johnston B., et al. 1996; Martin-
Blondel G., et al., 2015). The interference with leukocyte adhesion by anti-α4 integrins 
antibodies showed the decreasing rolling interactions and arrest of neutrophils after status 
epilepticus in mouse brain (Fabene P.F., et al., 2008) and the inhibition of endothelial 
interaction and brain entry of neutrophils in animal models (Fleming J.C., et al., 2009; 
Kadioglu A., et al., 2011; Neumann J., et al., 2015). The use of anti-α integrins antibodies 
proved that this strategy is robust for the treatment of inflammatory pathologies through the 
blockade of leukocyte recruitment. Based on these evidences, we decided to evaluated the 
effect of α4-integrins antibody blockade on cognitive functions, Aβ deposition, tau 
phosphorylation and microglial activation in 3xTg-AD mice.   
 
 
12.13.1 THE α4-INTEGRINS BLOCKADE RESCUES 
BEHAVIORAL IMPAIRMENT IN 3xTg-AD MICE AT EARLY 
STAGES OF DISEASE 
 
We treated 3xTg-AD mice with an anti-α4–integrins antibody starting at 6 months of age. 
At day one, the mice were injected i.p. with 500 µg of α4–integrins-specific mAb (PS/2) and 
treatment continued with 300 µg of antibody every other day for 4 weeks. At the end of 
treatment, the mice were tested for behavioral assessment as described in Materials and 
Methods and in Fig. 12. Our results showed that the blockade of α4–integrins at early stages 
of AD-like pathology inhibits the cognitive impairment as shown by the data obtained in the 
Y-maze (Fig. 35a) and CFC (Fig. 35b) tests. In fact, the treatment with anti-α4–integrins 
antibody at early time-points of disease allowed the restoration of the memory impairment 
almost to WT situation in control mice (Fig. 35). Collectively, these experiments clearly 
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showed that an intervention aimed to block the leukocyte recruitment in the brain of 3xTg-
AD mice at early time-points of disease allowed rescuing the cognitive impairment and have 
neuroprotective effects. 
We hypothesized that the therapeutic efficacy of this treatment could be a consequence of 
the blockade of VLA-4/VCAM-1-mediated extravasation of neutrophils into the AD brain. 
For instance, VLA-4 integrin is expressed by activated lymphocytes that may also use VLA-
4/VCAM-1 interactions to adhere in brain venues and subsequently migrate into the brain 
(Becker et al., 2001; Martin-Blondel G., et al., 2015). Therefore, we cannot exclude that the 
effects of the anti-α4 integrins treatment is due to the inhibition of the T cells infiltration.  
 
 
Figure 35. Anti-α4–integrins mAb inhibits cognitive deficits in behavioral tests.   
α4–integrins blockade was performed by treating 3xTg-AD mice with anti-α4–integrins 
antibody (Anti-α4 integrins) for 4 weeks starting at 6 months of age in 3xTg-AD mice, as 
described in Materials and Methods and in Fig.12. As control, 3xTg-AD mice were treated 
with an isotype control antibody (Isotype). WT age-matched control mice were treated with 
endotoxin-free PBS (WT ctrl). (a) histogram shows the percent alternation performance in 
the Y-maze test. (b) histogram shows freezing response of mice in CFC test. Values 
represent mean ± SEM of the data obtained from a representative experiment with 10-12 
mice/group. (*P <0.05; **P <0.005). 
 
 
12.13.2 THE BLOCKADE OF α4-INTEGRINS HAS LONG-TERM 
BENEFICIAL EFFECTS 
 
To evaluated the long-term effect of α4–integrins blockade, 3xTg-AD mice were treated 
with an anti-α4–integrins antibody at 6 months of age for 4 weeks and behaviorally test in 
CFC test 6 months after treatment termination (at 11-12 months of age) as described in 
Materials and Methods and in Fig. 12. Notably, the restoration of cognitive function in 
3xTg-AD mice, treated during early stages of disease, was maintained also in aged animals. 
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This result suggested that the therapeutic blockade of the leukocyte adhesion during the 
early stages of the disease provides a long-term beneficial effect on cognition in older mice 
(Fig. 36). 
 
 
Figure 36. The early α4-integrins blockade has long-term benefits.  
α4–integrins blockade were performed by treating mice with anti-α4–integrins antibody 
(Anti-α4–integrins)  for 4 weeks starting at 6 months of age in 3xTg-AD mice, as described 
in Materials and Methods and in Fig.12. Control treatment was performed with an isotype 
control antibody (Isotype). WT age-matched control mice were treated with endotoxin-free 
PBS (WT ctrl). Mice were tested in behavioral paradigms 6 months after treatment 
termination, at 11-12 months of age. Histogram shows the percent alternation performance 
in the CFC test in 3xTg-AD mice treated with anti-α4–integrins or isotype control 
antibodies. Values represent mean ± SEM of the data obtained from a representative 
experiment with 10-12 mice/group. (*P <0.05; **P <0.005). 
 
 
12.13.3 THE BLOCKADE OF α4-INTEGRINS INDUCES 
NEUROPATHOLOGICAL CHANGES  
 
We next investigated the effect of α4-integrins blockade by immunohistochemical 
evaluation of brain samples of 3xTg-AD mice treated with anti-α4 integrins or isotype 
control antibodies at early stages of disease. The immunohistological analysis of different 
brain areas allowed the identification of subtle pathophysiologic changes in neuronal 
population that might be associated to behavioral changes. We quantified by 
immunohistochemistry the presence of Aβ accumulation, tau phosphorylation and microglial 
cell activation in different brain areas. We observed a reduction of Aβ loading in 3xTg-AD 
mice treated with an anti-α4 integrins antibody in cortex, amygdala and subiculum at 12-13 
months of age compared to 3xTg-AD mice treated with isotype control antibody (Fig. 37). 
In addition, the expression of total tau protein was investigated by immunohistochemistry 
staining with HT7 antibody in 3xTg-AD mice treated with isotype control antibody and anti-
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α4 integrin antibody at 12-13 months of age. We did not detect any difference in total tau 
protein expression in CA1 region of hippocampus (Fig. 38a-b). However, we found a 
reduction of AT180 tau expression in CA1 region of hippocampus in anti-α4 integrins 
antibody treated 3xTg-AD mice compared to 3xTg-AD mice treated with isotype control 
antibody (Fig. 38c-d). Also, we observed a lower density and activation state of microglia in 
the cortex of 3xTg-AD mice, treated at early stages of disease with anti-α4 integrins 
antibody, compared to animals treated with an isotype control antibody, suggesting α4 
blockade reduces neuroinflammation (Fig. 39). The area occupied by microglia cell soma 
was reduced, indicating a resting state of microglia cells in 3xTg-AD mice treated with an 
anti-α4 integrins antibody compared to mice treated with an isotype control antibody as 
shown in Fig. 39.  
Taken together, these results showed that the anti-α4 integrin antibody treatment could 
inhibit early pathogenesis and progression of AD in 3xTg-AD mice. Thus, we speculated 
that VLA-4 integrin may represent a novel attractive therapeutic target in AD able to 
interfere with leukocyte subpopulations that contribute to disease pathogenesis.  
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Figure 37. Anti-α4–integrins mAb treatment ameliorates Aβ pathology.  
At the end of behavioral tests, mice were sacrificed for neuropathological analyses as 
described in Materials and Methods and in Figure 12. Quantitative analysis was carried out 
on the brains of 3xTg-AD mice treated with an α4–integrins antibody (Anti-α4–integrins) 
compared to 3xTg-AD mice treated with isotype control antibody (Isotype) to quantify the 
area of Aβ containing cells in (a) the cortex, (c) the subiculum and (e) the amygdala. Bar is 
expressed as mean ± SEM (*P <0.05; ***P <0.0005). Representative images show a 
reduction of Aβ deposition in (b) the cortex, (d) the subiculum and (f) amygdala of 3xTg-
AD mice treated with an α4–integrins antibody compared to 3xTg-AD mice treated with 
isotype control antibody at 12-13 months of age. Scale bar: 50 µm. 
 
 
 
 
 
 
 
 
Area Cortex
0
20000
40000
60000
Iso
typ
e
An
ti- α
4 
int
eg
rin
s
***
Pi
xe
l 2
 
 
/ 0
.
4x
0.
3m
m
2
Area Subiculum
0
50000
100000
150000
Iso
typ
e
An
ti- 
α4
 
int
eg
rin
s
*
Pi
xe
l 2
 
 
/ 0
.
4x
0.
3m
m
2
Area Amygdala
0
20000
40000
60000
80000
100000
Iso
typ
e
An
ti- α
4 
int
eg
rin
s
*
Pi
xe
l 2
 
 
/ 0
.
4x
0.
3m
m
2
Isotype Anti- α4 integrins
Isotype Anti- α4 integrins
Isotype Anti- α4 integrins
a b
c d
e f
- 88 - 
 
 
Figure 38.  Anti-α4–integrin treatment affects tau phosphorylation.  
At the end of behavioral tests, mice were sacrificed for neuropathological analyses as 
described in Materials and Methods and in Figure 12. Human tau detection was performed 
with HT7 antibody. (a-b) Anti-α4–integrins treatment does not affect total tau expression. 
(a) Unbiased quantitative analysis was performed in the CA1 to quantify the area of total tau 
protein. (b) Representative images show comparable levels of total tau expression in 3xTg-
AD mice treated with an anti-α4–integrins antibody (Anti-α4–integrins) compared to 3xTg-
AD mice treated with isotype control antibody (Isotype). (c-d) Tau phosphorylation was 
investigated by staining with AT180 antibody that detects the Thr231 phospho-epitope of 
tau protein. (c) Bar graph showing the area of AT180 positive cells in the CA1 of 3xTg-AD 
mice treated with an anti-α4–integrins antibody (Anti-α4–integrins) compared to 3xTg-AD 
mice treated with isotype control antibody (Isotype). Bar is expressed as mean ± SEM (**P 
<0.005). (d) Representative images clearly showing a reduction of AT180 expression in 
3xTg-AD mice treated with an anti-α4–integrins antibody (Anti-α4–integrins) compared to 
3xTg-AD mice treated with isotype control antibody (Isotype). Scale bar: 50 µm.  
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Figure 39. Anti-α4–integrins treatment reduces microglial activation in 3xTg-AD mice.  
At the end of behavioral tests, mice were sacrificed for neuropathological analyses as 
described in Materials and Methods and in Figure 12. (a) Bar graph showing microglia 
density (nr/0.4x0.3mm2) in the cortex of isotype control-treated (Isotype) compared to α4-
integrins–treated (Anti-α4 integrins) 3xTg-AD mice . Bar is expressed as mean ± SEM 
(***P <0.0005). (b) Representative images of Iba-1 microglia in the cortex: isotype control-
treated 3xTg-AD mice (Isotype) show highly activated amoeboid cell morphology with 
large soma and several thick cellular processes, conversely 3xTg-AD mice treated with anti-
α4–integrin antibody (Anti-α4 integrins) show a less activated microglia phenotype. Scale 
bars, 50 µm in left panels. Higher magnifications are shown in the right panels; scale bars, 
25 µm. 
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13. DISCUSSION  
 
The main neuropathological hallmarks of AD are extracellular beta amyloid (Aβ) peptides 
deposition, and neurofibrillary tangles (NFTs) formation, which are composed of 
hyperphosphorylated tau protein (Kidd M., 1963; Wisniewski T., Frangione B., 1992; 
Heneka M.T., et al., 2015). The pathogenesis of AD also involves chronic brain 
inflammation, synaptic loss and neuronal loss, that lead to cerebral atrophy (Wyss-Coray T. 
& Rogers J., 2012; Heppner F.L., et al., 2015).  
 
The BBB is a highly specialized endothelial cell membrane that operates within the 
neurovascular unit (NVU), which includes clusters of glial cells, neurons and pericytes. The 
NVU controls BBB permeability and cerebral blood flow, and maintains the chemical 
composition of the brain interstitial fluid, which is required to maintain functional neuronal 
circuits (Zlokovic B.V., 2011). Vascular deposition of Aβ in the intracerebral and 
leptomeningeal vessels, also known as CAA, is associated with degeneration of smooth 
muscle cells, pericytes, endothelial and BBB breakdown (Roher A.E., et al., 2003; Carrano 
A., et al., 2011; Erickson M.A. & Banks W.A., 2013; Zenaro E., et al., 2016). In addition, 
Aβ deposition in the vasculature alters the expression of tight junctions (TJs) proteins and 
changes mechanical properties of the endothelial membranes thus favoring the 
transmigration of immune cells (Giri R., et al., 2002; Gonzalez-Velasquez F.J. & Moss 
M.A., 2008; Yang X., et al., 2010). Vascular inflammation and a dysfunctional blood-brain-
barrier (BBB) have been implicated in the pathogenesis of AD suggesting that vascular 
pathology, hemodynamic changes and peripheral leukocytes may be involved in the 
initiation and progression of AD. 
 
Several studies showed that the peripheral innate and adaptive immune cells, including 
monocytes, neutrophils, T cells and B cells can enter the CNS when the BBB is impaired 
during CNS diseases such as Parkinson's disease (PD), multiple sclerosis (MS) and AD 
(Theodore S., et al., 2008; Korn T., 2008; Brochard V., et al., 2009; Bhat R. & Steinman L., 
2009; Goverman J., 2009; Chung Y.C., et al. 2010; Popescu B.F., & Lucchinetti C.F., 2012; 
Zenaro E., et al., 2015). In PD, several studies showed the presence of various peripheral 
immune cells, such as T cells, B cells and macrophages in the midbrain of PD patients and 
also in the brain regions in the toxin-based models of PD, suggesting that penetration of 
immune cells plays an important role in the degeneration of death of dopaminergic neurons 
in PD (Theodore S., et al., 2008; Brochard V., et al., 2009; Chung Y.C., et al. 2010). In MS, 
autoimmune disease of the CNS characterized by demyelination, several studies showed that 
infiltration of autoreactive T cells, which are targeted against antigens of the myelin sheath, 
is a critical event in the pathogenesis (Korn T.,, 2008; Bhat R. & Steinman L., 2009; 
Goverman J., 2009; Popescu B.F., & Lucchinetti C.F., 2012; Simmonset al., 2013). In AD, 
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Zenaro E., et al. reported the presence of neutrophils and their role in the induction of neuro-
pathological changes and memory deficits associated with AD in 5xFAD and 3xTg-AD 
mice (Zenaro E., et al., 2015). Neutrophils are the first line of defense in our innate or non-
specific immune system and are rapidly deployed to sites of inflammation, where they 
perform a variety of antimicrobial functions such as degranulation and phagocytosis, to kill 
invading pathogens. They are highly reactive cells that release ROS, enzymes, neutrophil 
extracellular traps (NETs) and cytokines and thus their inappropriate activation can cause 
long-term collateral tissue damage. Zenaro E., et al., found neutrophils within the brain 
parenchyma, especially in the cortex, hippocampus and in zones adjacent to vascular Aβ 
deposits and rich in Aβ plaques in 3xTg-AD and 5xFAD mice. Importantly, the 
accumulation of elevated numbers of neutrophils has been observed in human cortical brain 
samples from AD subjects compared to controls of the same age. Once the neutrophils 
infiltrate into the brain, they may contribute to neuronal damage causing cognitive decline in 
AD. In addition, soluble Aβ can generate ROS in mouse and human neutrophils. The 
production of ROS, carried out by neutrophils, can induce neuronal damage and release of 
structures composed of chromatin DNA, histones and granular proteins into the extracellular 
environment, known as NETs (Kolaczkowska E. & Kubes, P.P., 2013). Interestingly, they 
found intravascular and intra-parenchymal NETs in mouse models of AD, but also in 
cortical brain samples from human subjects with AD. These results suggest that NETs cause 
BBB damage and neuronal death and, also, that it may represent a neutrophil-dependent 
disease mechanism in AD. The deleterious role of neutrophils in the induction of cognitive 
dysfunctions in animal models was revealed by treating AD mice with monoclonal antibody 
to deplete neutrophils at the early stage of disease. In this case, it was possible to observe 
how the neuro-pathological hallmarks of AD and memory deficits are considerably reduced. 
In addition, the neutrophil depletion had a beneficial long-term effect in older animals, 
indicating that neutrophils have a potential role in the development of chronic disease 
(Zenaro E., et al., 2015). However, the role of circulating immune system cells in AD-
related brain damage is still unclear (Wyss-Coray T., 2006; Schwartz M., et al., 2013; Baik 
S.H., et al., 2014; Zenaro E., et al., 2015). 
 
Leukocyte trafficking into the brain parenchyma involves three distinct routes. The first path 
begins in the blood and reach the parenchyma through the walls of the parenchymal post-
capillary venules; the second path goes from the blood to the subarachnoid space through 
the walls of the meningeal vessels; finally, the last path starts in the blood and reach the CSF 
across the venule wall and then the stroma and epithelium of the choroid plexus (Ransohoff 
R.M., et al., 2003). Under inflammatory conditions, the first two routes are used by 
leukocytes for CNS invasion, while the last route is considered the major site of CNS 
immunosurveillance under physiological conditions (Ransohoff R.M., et al., 2003; 
Engelhardt B.& Ransohoff R.M., 2005; Man S.M., et al., 2007; Shechter R., et al., 2013). 
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However, the leukocytes extravasation can be mediated by the release of pro-inflammatory 
mediators from activated glial cells. Interestingly, glial cells and neurons are source of 
various cytokines and chemokines (Ambrosini E., et al., 2004; Carpentier P.A., et al., 2005; 
Biber K., et al., 2008; Choi S.S., et al., 2014; Liu C., et al., 2014), thus they play a crucial 
role in immune response initiation and maintenance during several neuroinflammatory 
diseases. In particular, increased levels of CXCL8/IL-8 and monocyte chemotactic protein-1 
(CCL2/MCP-1) were found in the CSF of MCI subjects and AD patients, and have been 
correlated with age and neuropathological changes during disease progression (Galimberti 
D., et al., 2003; Galimberti D., et al., 2006; Weeraratna A.T., et al., 2007; Galimberti D., et 
al., 2008; Li M., et al., 2009). In addition, cultured microglia from the adult human brain 
stimulated with Aβ strongly up-regulated the gene for CXCL8/IL-8 and monocyte 
chemotactic protein-1 CCL2/MCP-1 (Walker D.G., et al., 2001), two potent 
chemoattractants respectively for neutrophils and monocytes. The CCL2 overproduction by 
micorglia cells may induce monocyte recruitment from the blood to the brain, and their 
differentiation, thus enhancing neuroinflammation and AD pathogenesis (Naert G. & Rivest 
S., 2011, 2012, 2013).  
 
Leukocytes extravasation is generally considered the initial step of inflammatory responses 
and it is composed of several steps mediated by interaction between selectins and integrin 
ligands, expressed on vascular endothelial cells, with their counter-ligands expressed on 
leukocyte surfaces. During inflammation, leukocyte–vascular interactions in CNS venules 
are mediated predominantly by endothelial P selectin and E-selectin and their mucin ligands 
PSGL-1 and TIM-1, as well as leukocyte integrins that include α4β1 (also known as very 
late antigen 4, VLA 4) which bind VCAM-1, and leukocyte integrins αLβ2 (LFA-1) and 
αMβ2 (Mac-1) which bind ICAM-1 and ICAM-2 (Ley K., et al., 2007; Rossi B., et al., 2011; 
Angiari S. et al., 2014; Angiari S., & Constantin G., 2014).  
The expression of vascular adhesion molecules that mediate the leukocyte trafficking is 
undetectable or minimal under physiological conditions, with P-selectin, E-selectin and 
ICAM-1 immunoreactivity detected in pial and choroid plexus venules in the normal brain 
(Kivisäkk P., et al., 2003). However, during brain inflammation, the expression of 
endothelial adhesion molecules strongly increases, and their soluble forms are released into 
the circulation to provide a biomarker of endothelial dysfunction and vascular inflammation 
(Bö L., et al., 1996; Jander S., et al., 1996; Stins M.F., et al., 1997; Staykova M., et al., 
2000; Garton K.J., et al., 2006; Alvarez J.I., et al., 2011; Rossi B., et al., 2011). Several 
studies have reported the presence of ICAM-1 and VCAM-1 in AD body fluids, including 
serum and the CSF, thus suggesting a role for leukocyte trafficking mechanisms in the 
pathogenesis of AD (Engelhart M.J., et al., 2004; Rentzos M., et al., 2005; Nielsen H.M., et 
al., 2007; Zuliani G., et al., 2008; Davinelli S., et al., 2011; Doecke J.D., et al., 2012; Huang 
C.W., et al., 2015). Interestingly, soluble ICAM-1 level was included among the 18 plasma 
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proteins that can be used to classify blinded samples from AD and control subjects with 90% 
accuracy, and to identify patients that progress from mild cognitive impairment to AD 
within 2-6 years (Ray S., et al., 2007). In addition, higher levels of soluble VCAM-1 
correlate with more advanced dementia, including poor short-term memory and visuospatial 
functions, and with changes in white matter hyperintensities observed during MRI (Huang 
C.W., et al., 2015). Similarly, these evidences suggest the use of soluble VCAM-1 and 
ICAM-1 as a biomarker for cognitive decline during AD. However, their role as blood-based 
markers of AD require further validation role because it is unclear if these systemic 
alterations are an early or late pathological events.  
Recently, Zenaro E., et al. showed that the expression of E-selectin, P-selectin, VCAM-1 
and ICAM-1 was significantly higher in 4-month-old 5xFAD mice than in age-matched WT 
control mice, supporting the role of vascular inflammation in AD (Zenaro E., et al., 2015). 
Similarly, in the present study we observed up-regulation of ICAM-1 in choroid plexus and 
in hippocampal blood vessels, if compared to other adhesion molecules in 3xTg-AD mice at 
early stages of disease. In addition, VCAM-1 was also found in the same brain districts 
although to a lesser extent. In agreement with our observations a recent study performed in 
Arc/SweAβ mice also have shown increased expression of VCAM-1 and ICAM-1 in the 
brains of 20–24-month-old mice compared to WT littermates, further supporting a role for 
integrins and their ligands in AD (Ferretti M.T. et al., 2016).  
 
 Important our previous findings demonstrated the direct presence of neutrophils in 
AD brain and their deleterious role in the induction of neuropathological changes and 
memory deficits in 5xFAD and 3xTg-AD mice (Zenaro E., et al., 2015). Based on these 
results we decided to interfere with leukocyte recruitment in the AD-like mice by blocking 
the adhesion mechanisms controlling leukocyte–endothelial interactions. In particular, we 
studied the LFA-1 integrin which is the main β2-integrin mediating the firm adhesion step of 
the leukocyte recruitment cascade (Issekutz A.C. & Issekutz T.B., 1992; Ding Z.M., et al., 
1999; Phillipson M., et al., 2006). In the first step, we assessed whether the ablation of LFA-
1 integrin on neutrophils or the LFA-1 blockade with an antibody may prevent the 
interaction between the neutrophils and the blood vessels before entering in the brain 
parenchyma by TPM studies. After, we studied the effect of LFA-1 integrin blockade in AD 
animal models for its potential therapeutic application in AD.  
In addition, we focused our attention also on the VLA-4 integrin that contributes to T cell 
trafficking in the CNS (Engelhardt B. & Ransohoff R.M., 2012; Gorina R., et al., 2014). In 
fact, in the present study we quantified the accumulation of leukocytes from the brains of 
3xTg-AD mice compared to sex- and age -matched WT control mice using flow cytometry. 
Interestingly, the results showed a high numbers of infiltrating T cells, such as CD4+, CD8+ 
and T cells at different time-points of the disease in 3xTg-AD mice as well as the neutrophil 
infiltration.  
- 94 - 
 
 
Our data demonstrated that LFA-1 integrin controls intravascular adhesion, but also 
intraparenchymal migration of neutrophils in transgenic mice with AD-like disease (Zenaro 
E., et al., 2015). Most LFA-1 deficient neutrophils did not slow down enough to adhere and 
crawl on blood vessels and did not accumulate in brain parenchyma in in vivo studies. Our 
findings agree with the results obtained by Li W., et al. that show how the blockade of LFA-
1 integrin prevented neutrophil adherence to endothelium and extravasation in heart grafts 
(Li et W., al., 2012). Notably, we observed a significant difference in the movement of 
already extravasated cells after injection of LFA-1–blocking antibody, suggesting that LFA-
1 integrin has a key role not only in the neutrophil adhesion on the endothelium inside brain 
venules, but also in the intraparenchymal motility in the AD brain (Lämmermann T., et al., 
2013). Importantly, Zenaro E. et al. found a higher number of neutrophils infiltrating at early 
stages of disease when 3xTg-AD mice show the first memory dysfuncitons. In addition, the 
appearance of the cognitive impairment coincides with the presence of soluble oligomers of 
Aβ in human AD pathology (Oddo S., et al, 2003, Santos A.N., et al, 2012, Zenaro E., et al., 
2015). Then, we investigated the effect of Aβ1-42 peptide on LFA-1 integrin-dependent 
rapid adhesion assays. Our data showed that soluble Aβ oligomers are more effective than 
fibrillar Aβ to trigger LFA-1–dependent adhesion of neutrophils, through the FPR 
engagement, on mouse neutrophils in in vitro, proving a possible mechanisms responsible 
for the neutrophil migration in the brain. In addition, we demonstrated that Aβ oligomers 
trigger LFA-1 transitions from low-intermediate state to high-affinity state thus enhancing 
the propensity to bind ligand efficiently. These results suggested that Aβ soluble oligomers 
activating neutrophil integrins might be responsible for the spreading and adhesion of 
neutrophils on blood vessels in AD-like mice. Therefore, the LFA-1–mediated neutrophil 
adhesion may represent a new therapeutic approach in AD.  
For a potential therapeutic application of anti-adhesion therapy in AD, we studied the effect 
of LFA-1 integrin blockade in 3xTg-AD mice with cognitive deficits during early stages of 
disease using a blocking anti-LFA–1 integrin antibody. We clearly showed a recovery in 
cognitive deficits of anti-LFA–1 antibody-treated 3xTg-AD mice compared with control 
antibody-treated 3xTg-AD mice. In addition, the blockade of the LFA-1 integrin during the 
early stages of disease in 3xTg-AD mice had long-term beneficial effects, allowing a 
preservation of the cognitive function in old animals. We confirmed the impact of LFA-1 
integrin on AD-like disease in 3xTg-ADxItgal-/- mice by demonstrating the positive outcome 
in cognitive functions at early and late stages of disease. The beneficial effect that we 
observed in anti-LFA–1 antibody-treated 3xTg-AD mice and in 3xTg-ADxItgal-/- mice 
might be partially due to a reduction of microglia cells density and their activated state in the 
hippocampus, especially in the DG and CA1 field, regions that play an important role in 
memory function.  In fact, microglia accumulation in senile plauqes is an integral part of the 
disease process in AD and it is widely accepted that microglia-mediated neuroinflammatory 
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responses have a role in AD–associated neurodegeneration (Wyss-Coray T., 2006; El 
Khoury J. & Luster A.D., 2008). Microglia may initially play a protective role in AD by 
facilitating the clearance of Aβ, whereas at later disease stages the chronic activation of 
microglia is accompanied by the diminished phagocytosis and the more abundant secretion 
of pro-inflammatory cytokines, leading to the accumulation of Aβ and the amplification of 
neuroinflammation (El Khoury J., et al., 2007; Hickman S.E., et al., 2008; Krabbe G., et al., 
2013; Heneka M.T., et al., 2015). Therefore, the blockade of LFA-1–mediated neutrophil 
adhesion during the early phases of the disease might also inhibit microglia-induced 
neurodegeneration, allowing the preservation of cognitive functions in AD-like mice. 
In addition, our immunohistochemical analysis demonstrated a clear reduction of Aβ load in 
the cortex of 3xTg-ADxItgal-/- mice compared to 3xTg-AD mice. We found a reduction in 
the amount of AT8 (Ser202/Thr205) and AT180 (Thr231) hyper-phosphorylated tau in the 
hippocampus areas (CA1 and DG) of 3xTg-ADxItgal-/- compared to 3xTg-AD mice, but 
without modifications in the quantity of total tau protein. In this context, several studies 
demonstrated that Aβ and tau play a role in the NVU dysfunctions, exacerbating the vascular 
inflammatory response and neurodegenerative process (Kovac A., et al., 2009; Erickson 
M.A. & Banks W.A., 2013; Zenaro E., et al., 2016). Aβ deposition is also observed in the 
cerebrovasculature, and is usually described as CAA (Jellinger K.A., 2002; Viswanathan A. 
& Greenberg S.M., 2011) and leads to pro-inflammatory and cytotoxic events that 
contributes to the accelerated BBB permeability in the AD brain (Roher A.E., et al., 2003; 
Carrano A., et al., 2011; Erickson M.A. & Banks W.A., 2013). Likewise, the appearance of 
perivascular tau around major hippocampal blood vessels contribute to the disruption of the 
BBB (Blair L.J., et al., 2015). Both tau and Aβ may therefore promote the loss of BBB 
integrity, exacerbating the neurodegenerative process and associated inflammatory 
responses. Therefore, our results demonstrated that the blockade of neutrophils infiltration 
through the blocking LFA-1 integrin may have a therapeutic effect on the progression of the 
pathology by reducing Aβ accumulation, tau phosphorylation and microglial activation in 
3xTg-AD mice. These data, together with TPM analysis, provide consistent evidence on the 
key role of LFA-1 integrin in the pathogenesis of AD-like disease.  
 
Although the role of T cells in the pathogenesis of AD is unclear, evidences suggest that 
activated T cells may play a detrimental role in disease evolution (Togo T., et al., 2002; 
Ferretti M.T., et al., 2016; Zenaro E., et al., 2016). T cells are a subtype of the lymphocyte 
family that include also natural killer (NK) cells, and B cells. They have a central role in 
cell-mediated immunity, but their activity normally decreases with advancing age (Linton 
B.P., et al., 1996). The involvement of T-cells in AD has been studied and it was first 
described by Lombardi et al. in 1999 when they immunophenotyped T cells from AD 
patients and healthy age-matched controls, founding evidence of a higher presence of 
different subpopulations of T cells in the blood of AD patients (Lombardi V.R., et al., 1999). 
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Furthermore, MCI and mild AD patients contained a greater number of activated CD4+ and 
CD8+ T cells in the CSF, with the proportion of activated CD8+ T cells showing the highest 
increase, supporting the hypothesis that activated T cells migrate from the blood into the 
brain during AD (Lueg G., et al., 2015). Similarly, T cells also infiltrate into the brains of 
APP/PS1 mice, and may secrete IFNγ or IL-17 (Browne T.C., et al., 2013), suggesting that 
the release of these cytokines could accelerate AD neuropathology. In addition, recent 
studies suggest that regulatory T (Treg) cells, which suppress adaptive T cell responses and 
T cell activation, play a beneficial role in AD models during the early phase of the disease, 
by slowing disease progression and modulating microglial responses to Aβ deposition 
(Dansokho C., et al., 2016). More recently, lymphocyte-depleted transgenic models of AD 
lacking T- and NK cells contribute to better understanding of the involvement of 
lymphocytes in AD. In fact, these experimental mice showed an increase in Aβ deposits and 
a severe gliosis and neuroinflammation (Marsh S.E. et al., 2016). 
The role of T cell populations at different AD stages therefore remains to be determined, and 
future studies should aim to clarify the role of these cells in AD pathology. In addition, the 
mechanisms controlling T cell recruitment in the AD brain are not well understood. 
However, several evidences show that the brain amyloidosis promotes T cell migration into 
the brain and the expression of vascular adhesion molecules in brain vessels (Ferretti M.T., 
et al., 2016). Notably, Aβ1-42- induces the release of TNFα by microglial cells, which in 
turn promotes major histocompatibility complex I expression on the brain endothelium 
followed by the transendothelial migration of T cells in in vitro study (Yang Y-M., et al., 
2013). Accordingly, T cells together with macrophages and monocytes were observed in 
leptomeningeal and cortical vessels, associated with CAA, suggesting that Aβ and CAA 
favor T cell migration into the AD brain (Yamada M., et al., 1996). Furthermore, circulating 
T cells in AD patients also overexpress CXCR2, a chemokine receptor that is widely 
expressed on immune system cells that may promote their transendothelial migration (Liu 
Y.J., et al., 2010). The inflammatory response stimulated by T cells that have migrated into 
the AD brain may activate microglia and astrocytes and may recruit other inflammatory cells 
that are potentially harmful to the CNS, thus exacerbating the pathogenesis of AD. In fact, 
activated T cells could contribute to the delayed cell death of PMNs. Indeed, some in vitro 
experiments demonstrated that T cell-derived cytokines, particularly IFN-γ, extend the 
lifespan of PMN in a functionally active state (Klebanoff S.J., et al., 1992). So, T cells and 
neutrophils may cooperate to have deleterious effects on the progression of the disease. 
However, it is not clear how circulating T cells penetrate the BBB and infiltrate the AD 
cerebral parenchyma, or how local inflammatory milieu influences T cell migration or 
survival resulting in the accumulation of T cells in the brain. It is important to determine 
whether T cell trafficking is involved in the pathogenesis of AD or is solely an 
epiphenomenon, and whether T cells are beneficial or deleterious in AD. 
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Our data on the expression of VCAM-1 in blood vessels in transgenic animal models 
of AD suggested that it may interact with VLA-4 integrin expressed by several leukocyte 
subpopulations.  VLA-4 integrin is expressed by activated lymphocytes and its blockade has 
been shown to have therapeutic effect in numerous experimental models of inflammatory 
diseases including experimental autoimmune encephalomyelitis, the animal model of 
multiple sclerosis (Luster A.D., et al., 2005). However, recently the anti-VLA-4 treatment 
improved stroke outcome mainly by blocking the entry of neutrophils, but not T-cells, in a 
mouse model of stroke (Neumann J. et al., 2015). Indeed, the VLA-4 integrin is expressed 
by approximately 3% of circulating neutrophils in both humans and mice and previous 
studies demonstrated it represents an alternative pathway for neutrophils migration to sites 
of inflammation (Johnston B. & Kubes P., 1999; Massena S., et al., 2015). VLA-4 integrin 
expressed on neutrophils can mediate cellular responses such as tight adhesion, spreading, 
sustained respiratory burst, and specific granule release. In addition, neutrophils could 
migrate across purified VCAM-1 or through activated endothelial monolayers (Taooka Y., 
et al. 1999; Pereira S., et al.2001). 
Our promissing data show that α4-integrin blockade rescues memory impairment in 3xTg-
AD mice, suggesting that VLA-4 integrin could represent a novel attractive therapeutic 
target in AD pathology. Interestingly, the restoration of cognitive functions was maintained 
also in aged animals in 3xTg-AD mice treated during early stages of disease. We also 
performed immunohistochemical labelling of microglial cells to identify their degree of 
activation and evaluated the accumulation of Aβ and tau phosphorylation. The results 
showed a reduction of microgliosis in the cortex of 3xTg-AD mice treated with an anti-α4 
integrins antibody compared to animals treated with an isotype control antibody. Moreover, 
we found a reduction of Aβ load in the cortex, amygdala and subiculum and a reduction of 
AT180 hyper-phosphorylated tau protein in the CA1 region of the hippocampus in 3xTg-AD 
mice treated with an anti-α4 integrins antibody compared to animals treated with an isotype 
control antibody at 12-13 months of age. These data confirmed the therapeutic potential of 
α4 integrin blockade in 3xTg-AD mice, consistent with our initial hypothesis that interfering 
with  leukocyte infiltration can ameliorate AD disease progression. 
 
Notably, preclinical and clinical therapeutic applications of antibodies that target leukocyte 
integrins in various inflammatory disorders confirmed the validity of their utilization as key 
therapeutic targets (Yonekawa K., et al., 2005; Mitroulis I., et al., 2014; Ley K., et al., 
2016). Integrins are probably the most important class of cell-adhesion receptors to be 
targetted for a therapeutic approach (Shimaoka M., et al.2003; Mitroulis I., et al., 2015; 
Williamson et al., 2015). In effect, anti-integrin therapy has been tested in humans in several 
pathologies, especially autoimmune diseases. The usage of Natalizumab, a recombinat 
humanized monoclonal IgG4 antibody against the α4 chain of integrin VLA-4, is 
emblematic for anti-integrin therapies. Natalizumab strongly blocks leukocyte trafficking 
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across the BBB into the CNS by blocking the interaction between VLA4-integrin and 
VCAM-1. Initial clinical studies performed in 2003 have shown that Natalizumab, is 
effective in patients with Crohn's disease as well as those with as and multiple sclerosis 
(MS) (Ghosh S., et al. 2003). Subsequently Natalizumab was approved in 2004 by the U.S. 
Food and Drug Administration and the European Medicines Agency as monotherapy for 
highly active relapsing–remitting MS. However, in 2005 the drug was temporary withdrawn 
form the market due to the occurrence (in >1:1000 patients) of an exceedingly rare virus-
induced neurodegenerative process, progressive multifocal leukoencephalopathy (PML) 
(Van Assche G., et al. 2005; Kleinschmidt-DeMasters B.K., et al., 2005; Langer-Gould A., 
et al., 2005). However, natalizumab represents the most potent drug tested for the treatment 
of MS as demonstrated by a phase III clinical trial and was then reintroduced as a second-
line therapy for relapsing-remitting MS (Steinman L., et al., 2005; Polman C.H., et al., 2006; 
L., Steinman et al., 2009). Other agents have been developed to block α4 such as small 
molecules that may be administered orally with lower safety concerns, representing further 
therapeutic opportunities for inflammatory diseases. 
LFA-1 integrin was effectively targeted in psoriasis by the humanized anti-αL antibody 
efalizumab (Lebwohl M., et al. 2003; Frampton J.E., et al., 2009). Efalizumab was 
withdrawn in 2009 after several PML cases occurred (occurrence 1:1000) as well as 
natalizumab treatment or other immunomodulatory therapies including rituximab and 
belatacept (Major E.O., et al., 2010; Klintmalm G.B., et al. 2014). The generation of new 
integrin antagonists based on structure-based drug design has been proposed to interfere 
with LFA-1-ICAM-1 interaction opening new therapeutic possibilities to interfere with 
integrin function (Shimaoka M., et al., 2003).  
 
In conclusion, the role of circulating immune system cells in AD-related brain damage is 
poorly understood, and future studies are needed to determine how specific populations of 
cells representing the innate and adaptive immunity systems promote the cognitive deficit 
and neuropathological changes in AD. In this sense, our study revealed novel insights on the 
role of circulating immune cells in AD highlighting the role of leukocyte recruitment. 
Considering the results obtained with natalizumab and efalizumab that proved the concept 
that blockade of leukocyte trafficking has therapeutic effects in humans we hypothesize that 
the anti-integrin therapies may be useful also to prevent and delay the progression of this 
neurodegenerative disease. 
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